Articles
-
All
-
Scientific Reviews
-
EDM
-
Product Guides
-
Blog
-
Most Recent
-
Oldest
-
SARS-CoV-2 contains four main structural proteins: spike (S), membrane (M), envelope (E), and nucleocapsid (N) proteins. All the proteins and subcellular structures of CoVs are promising targets for SARS-CoV-2 research.
-
The concept of ADC can be traced back to the early 1900s, It is a visionary magic bullet that could deliver a toxic drug to certain malignant cells without affecting other normal tissues. Now, it seems that a golden age of ADC drug development is coming.
-
It's has been proved that p53, as a tumor suppressor gene and immune guardian, may become a destroyer through its own mutation. Moreover, the mechanism of p53 was found to be related to ferroptosis. This article mainly explores the mechanism between p53 and ferroptosis in detail.
-
TME (Tumor microenvironment) is considered as a complex integrated system, composed of cellular components such as tumor cells and immune cells, as well as non-cellular components such as ECM and cytokines. According to the spatial distribution of immune cells in TME, "hot" and "cold" TME will be explained in this article.
-
Mammalian cells can also photosynthesize like plants! Photosynthesis can improve cell anabolism and exhibit good clinical effect in degenerative diseases (osteoarthritis).
-
The latest study of Cell magazine "Neural mechanism underlying depressive-like state associated with social status loss" considers social factors as a breakthrough point. It has been found that the downward transition of social status induces depression-like behavior in mice whereas improves the depressive state by restoring their social environment.
-
Necroptosis, also known as necroptosis, is a form of regulated necrotizing cell death mediated by RIP1 and RIP3 kinases. Necroptosis is a process that prevents the self-destruction of activated cells that are blocked by apoptosis. Necroptosis plays a tumor suppressor role in most cases. It may provide benefits in the researches of a variety of human diseases involving immune inflammation and cell death.
-
Structure of Lipid Droplets
2023-06-15
Huh? Lipid droplets? Organelles? In the past, biological data usually only show the traditional organelles, such as mitochondria, Golgi apparatus, endoplasmic reticulum, etc., lipid droplets are often not mentioned by people. Today, we will make a systematic explanation of lipid droplets, so that everyone has a clear understanding! -
HLA-E, A Novel Immune Checkpoint
2023-06-29
Immune checkpoints have immunosuppressive functions. It can be used in the research of tumor immunotherapy. In this article, we introduce a new paper entitled "Immune checkpoint HLA-E: CD94 - NKG2Amediates evasion of circulating tumor cells from NK cell surveillance "research paper. -
WHO's Q2 drug list has been updated. Let's take you through the list of the most noteworthy small molecule drugs that we should pay attention to.
-
FDA Approved Drug List!
2023-09-14
In the first half of 2023 (as of June 27), the FDA approved 26 new drugs, let's take you learn about it through the article. -
IHC is an indispensable technique for studying tissue morphology and in situ antigen expression, but usually only one or two antigens in tissues can be stained for analysis. It cannot judge the results more intuitively. Today, Little M will introduce you to the upgraded version mlHC.
-
A suitable model is crucial in drug screening experiments. Organs can mimic the three-dimensional functional structure of internal organs, have similar spatial organization to corresponding organs, maintain some key characteristics, and reproduce some physiological functions. They are widely used for modeling and personalized drug screening of diseases such as cancer, infectious diseases, and rare diseases.
-
FDA Annual Review | Record-breaking number of new drug approvals in 2023!
-
KRAS, a gene we've heard so much about, has quickly risen to fame after shedding its "undruggable" label. After reading numerous articles, it's easy to feel overwhelmed and wonder: What exactly should we know about this often-discussed but previously "undruggable" target KRAS?
-
Compound Screening Guide!
2024-03-15
How to use compound library? How to design an experiment if you buy a compound library? Want a specific experimental protocol? This article will introduce popular experimental techniques and provide new ideas for publishing high level literature. -
Wnt/β-catenin and tumor EMT
2024-03-18
Epithelial-Mesenchymal Transition (EMT) is closely related to the plasticity of tumor cells and is a necessary process for tumor metastasis. Wnt/β-catenin is one of the main actors involved in the EMT process. Today, we’re here to popularize the tumor EMT and Wnt/β-catenin pathway~ -
The 2024 AACR meeting concluded successfully in California, USA. Which antitumor drugs stole the show at this conference?
-
Katalin Karikó and Drew Weissman were awarded the Nobel Prize in Physiology or Medicine in 2023 for their groundbreaking work in nucleoside modification, which paved the way for the creation of successful mRNA vaccines to fight against COVID-19. Let's now delve into the complete process of mRNA vaccine development.
-
STZ Induced Diabetes Models
2024-06-13
Spotlight: How can STZ Help Diabetes Research? -
Exosomes, which won the Nobel Prize in 2013, are still a research hotspot in the national natural sciences, and their popularity has only increased over the past decade (in 2022, they still rank 5th in the national natural sciences hotspots!). Why have exosomes become the darling of scientific research? Let's take a look together~
-
How important is the compound library? It connects to drug screening on one end and leads to lead compound modifications on the other, serving as one of the sources of new drug development.
-
Antibodies!
2024-07-26
Today, We introduce antibodies for everyone! -
Science’s 2023 Breakthrough: GLP-1R Agonists
2024-08-13
GLP-1RAs, which achieved great success in 2023 and draws people’s attention back to obesity treatments and GLP-1 therapies worldwide, was chosen as the breakthrough of year 2023 by Science [2]. -
What Are Popular Anti-tumor Drug Targets?
2024-08-20
The rapid development of targeted anti-cancer drugs has spurred diverse research across various modalities. These include small molecules, monoclonal antibodies (mAbs), cell immunotherapies, antibody-drug conjugates (ADCs), and PROTACs (proteolysis targeting chimeras). -
Virtual Screening and New Uses for Old Drugs
2024-09-17
With the advancement of medical science, drug screening against various disease targets has become the fundamental strategy for drug development. Currently, computer-based virtual screening techniques are emerging in the field of new drug research due to their efficiency and low cost. Let's explore it today! -
2024 Nobel Prize Announcements! Curious about the details? Click to dive into the exciting developments!
-
A New Form of Cell Death: PANoptosis!
-
Unlocking the Power of Intermittent Fasting: The 16+8 Method
-
We are thrilled to share the latest advancements in AI technology as highlighted in this insightful article. From groundbreaking innovations to transformative applications, the future of AI is brighter than ever!
-
Advancing Chronic Kidney Disease Research with GJ103 and Lamin B1 Antibody!
-
When you hear "inflammation" and "DNA damage," you might immediately think of disease or injury. However, in brains, these two processes are key steps in forming long-term memories, particularly related to specialized cells in our brain called hippocampal neurons.
-
This article will tell you about the common methods of modeling liver disease in animal models.
-
This article will walk you through the remarkable impacts of anti-payload antibodies, delving into how these molecules are revolutionizing drug development and biological research!
-
This article introduces some common cardiovascular disease models, inducers, modeling protocols and successful modeling cases in the research.
-
Cell Migration vs. Invasion: Differences Revealed by Scratch Assays and Transwell Experiments
2025-05-30
In scientific research, cell migration and invasion are crucial for understanding many important biological processes. This article delves into commonly used detection methods: the scratch assay and Transwell migration/invasion assay. -
How should drug screening experiments be conducted? How can we ensure the accuracy of the lead compounds identified? This article will take you through how MCE's clients conduct drug screening experiments.
-
In this issue, we will conduct an in-depth interpretation from the dimensions of nanoparticle design, mechanism of action, in vivo and in vitro efficacy, and immune regulation, revealing how this research brings new hope for the treatment of invasive tumors through interdisciplinary innovation!
-
IHC, ICC, IF Techniques: A Practical Guide
2025-07-25
Confused About IHC/ICC/IF? Why Does Immunostaining Seem So Complicated? Read This Now! Master Immunostaining with Confidence! -
HTS Breakthroughs Powered by MCE Libraries
2025-08-13
Key High-Throughput Screening Breakthroughs of 2024 Featuring MCE -
Have you ever noticed that after staying up late, your appetite—especially for high-calorie foods—gets out of control? If this sounds familiar, today’s article might offer some good news.
-
Encountering challenges with the high costs and long timelines of drug screening? Have a defined target but remain uncertain how to efficiently identify active molecules? Unsure how to validate hits generated from virtual screening? The ‘Winning Combination’ of drug screening offers a powerful solution to address these critical obstacles.
-
A groundbreaking study in Nature Communications reveals the key mechanism behind Idiopathic Pulmonary Fibrosis and identifies an existing drug with the potential to counter it.
-
This detailed guide outlines the standardized experimental protocols for multiplex immunohistochemistry (mIHC), systematically summarizes common technical issues encountered during sample preparation, staining and imaging processes, and provides practical troubleshooting solutions to ensure reliable and reproducible results in biomedical research and clinical sample analysis.
-
Finding adipogenic induction media too expensive and tricky to prepare? This comprehensive guide to 3T3-L1 adipogenic differentiation simplifies the process, helping you achieve great results!
-
Microglia– the only immune cells within the brain parenchyma. With advancements in imaging technologies, people’s understanding of microglia has shifted from being viewed as 'resting' cells to 'highly active' cells, particularly due to their dynamic processes that seem to be probing surrounding tissues and monitoring neuronal activity. This has made microglia a focal point of research in the field of neuroscience.
-
Exosomes—natural nanoscale carriers—are revolutionizing targeted therapy. This article uncovers the science behind their precision in drug delivery.
-
Cracking the PROTAC Permeability Barrier: CD36-Mediated Endocytosis as a Potential Breakthrough
2025-12-03
This article provides an in-depth analysis of cutting-edge literature revealing CD36 as a key mediator of cellular uptake for PROTACs and bRO5 compounds. By structurally optimizing PROTAC molecules to enhance their affinity for CD36, membrane permeability can be markedly improved, leading to significantly enhanced antitumor efficacy. -
This paper elaborates on cytokines for culturing major immune cells, their regulatory roles, recombinant cytokines' merits and MCE’s related high-quality products.
-
In the hunt for the next ‘GLP-1,’ amylin therapeutics, which have shown strong weight-loss results in clinical trials, have become a major focus for both multinational pharma and the scientific community.
-
This article walks you through the experimental design and workflow of flow cytometry, delivering a clear, dynamic, and professional overview to elevate your research.
-
Molecular glue degraders have evolved from a serendipitous observation to one of the most dynamic and transformative fields in biomedical research.
-
GLP-1 and Obesity Research
2026-08-14
Obesity substantially increases the risk of chronic diseases such as T2D and cardiovascular disease. The breakout success of GLP-1 therapies has spotlighted GLP-1R and a wave of emerging obesity targets. -
Research Solution for Breast Cancer TME
2025-05-21
This review examines the complex interactions within the breast cancer tumor microenvironment, emphasizing how understanding these dynamics is essential for developing effective therapies and overcoming immune resistance. -
Research Progress of Type-2-Diabetes
2025-07-09
This review comprehensively analyzes the pathophysiological mechanisms underlying T2D, surveys current therapeutic strategies, and introduces commonly used disease modeling approaches to support translational research. -
This review discusses the fundamentals of lipid biology and lipid metabolism, examines dysregulated lipid metabolism in cancer, and summarizes therapeutic strategies targeting lipid metabolic pathways.
-
This review provides an overview of GLP-1 biology and physiological functions, summarizes the development and clinical applications of GLP-1 receptor agonists, and discusses next-generation GLP-1–based therapeutic strategies.
-
This review critically examines the role of the JAK-STAT pathway in immunity and autoimmune diseases, reviews current clinical applications of targeted therapies, and highlights emerging trends in autoimmune drug development.
-
This review presents an overview of antibody–drug conjugates from design principles and antitumor mechanisms to structural innovations, clinical progress, and future development prospects.
-
This review summarizes the mechanisms of DSS-induced colitis, commonly used modeling approaches, and key considerations related to DSS molecular weight.
-
This review explores mechanisms and strategies for modulating the gut microbiota to enhance cancer immunotherapy, providing insights to improve therapeutic efficacy.
-
Combating Immune Evasion in Cancer
2025-10-15
This review summarizes the mechanisms by which tumors evade immune surveillance and discusses therapeutic strategies to restore antitumor immunity. -
This review summarizes the mechanisms of drug resistance in triple-negative breast cancer and highlights emerging therapeutic strategies.
-
Bispecific Antibodies in Cancer Therapy
2025-10-29
This review highlights the mechanisms, technology platforms, and clinical progress of bispecific antibodies, and discusses emerging strategies to guide future development. -
This review provides insights into the pancreatic ductal adenocarcinoma tumor microenvironment, highlighting its cellular composition, stromal heterogeneity, and immune-targeting strategies.
-
Understanding In Vivo CAR-T Cell Therapy
2026-01-22
This review provides a comprehensive overview of in vivo CAR-T therapy, covering technical platforms, clinical translation, and key challenges such as gene delivery and immunogenicity. -
Explore next-generation obesity therapies from three perspectives: GLP-1-based multi-receptor agonists, oral GLP-1 strategies, and novel obesity targets.
-
Highlight single-cell metabolomics and stable isotope tracing (SIT) in uncovering metabolic heterogeneity and nutrient flux dynamics in tumors.
-
Explore ADC evolution, immune combination strategies, and clinical advances at the intersection of targeted therapy and immunotherapy.
-
Tumor Organoid-Immune Cell Co-Culture Models: Advances, Applications, and Future Directions
2026-05-07
Summarize technical strategies, application advances, and future directions of tumor organoid–immune co-culture systems. -
Review mechanisms, major challenges, and efficacy-enhancing strategies of TCR-T therapy in solid tumors, with implications for future research and clinical translation.
-
The Dual Role of Cellular Senescence in Cancer: Mechanisms, Microenvironment, and Therapeutics
2026-05-21
Explore the dual role of cellular senescence in cancer, including tumor suppression, SASP-driven tumor promotion, senescence heterogeneity and plasticity, and advances in senescence-targeted therapies. -
Review the mechanisms, mitochondrial regulation, disease relevance, and translational opportunities of the NLRP3–STING axis in neuroinflammation.
-
Breaking Immune Resistance in Colorectal Cancer: From Molecular Mechanisms to Precision Therapy
2026-06-25
Explore CRC molecular subtypes, immune landscapes, resistance mechanisms, and emerging precision strategies for improving outcomes across distinct subtypes. -
Explore the evolution from GLP-1 mono-agonists to multi-receptor therapeutics and the expanding role of incretin-based therapies in precision metabolic medicine.
-
Explore the mechanisms driving immune tolerance breakdown in autoimmune diseases and emerging tolerance-restoring strategies, with a focus on IL-2-based immune modulation.
-
Evolution of PCSK9 Inhibitors Modalities: From Monoclonal Antibodies to Oral Macrocyclic Peptides
2026-08-27
Review the biological basis of PCSK9, key therapeutic modalities, cardiovascular evidence, and future directions, including insights from the CORALreef clinical program. -
Explore the mechanisms of tumor immune evasion, dynamic checkpoint regulation, and the evolution of mechanism-driven combinations and patient stratification.
-
Explore how mitochondrial quality control, inflammatory signaling, and metabolic–epigenetic reprogramming regulate cellular senescence and the SASP, along with strategies to restore mitochondrial homeostasis.
-
Exosomes are nano-sized biovesicles released into surrounding body fluids after the fusion of multivesicular bodies with the plasma membrane. In this article, we will briefly introduce isolation, labeling and identification of exosomes. And the specific application of exosomes will also be mentioned.
-
EC0489, a SMDC for Cancer Therapy
2019-03-25
EC0489, a conjugate of folic acid and desacetyl vinblastine hydrazide, is a SMDC under development for the treatment of solid tumours. -
R916562, a dual Axl/VEGF-R2 inhibitor, could be a potential anti-angiogenic and anti-metastatic drug for cancer chemotherapy.
-
Role of PRMT7 Probe SGC3027 in Cancer
2019-03-27
SGC3027 is the first potent, selective and cell active chemical probe for PRMT7. SGC3027 is also a pro-drug, which converts to the active compound SGC8158 -
Alofanib, An Allosteric Inhibitor of FGFR2
2019-03-28
Alofanib is an allosteric inhibitor of FGFR2 and inhibits FGF-mediated proliferation with GI50s of 16-370 nM, showing pronounced antitumor activity. -
A Novel and Efficacious RAF Inhibitor RAF709
2019-03-30
RAF709, a novel and efficacious RAF inhibitor, activates the MAPK pathway and shows antitumor activity in tumor cells harboring BRAF or RAS mutations. -
CF53 is a highly potent, selective and orally active inhibitor of BET protein, with anti-tumor activity in acute leukemia and breast cancer cell lines.
-
AZD3229 is a Potent Pan-KIT Mutant Inhibitor
2019-04-04
AZD3229 is a potent, pan-KIT mutant inhibitor with potent single digit nM growth inhibition against a diverse panel of mutant KIT driven Ba/F3 cell lines. -
BR351 is a Brain Penetrant MMP Inhibitor
2019-04-05
BR351 is a brain penetrant MMP inhibitor, and a potential tool for the molecular imaging of activated MMPs with PET, with an IC50 in the nanomolar range. -
A Lead PROTAC BRD9 Chemical Degrader
2019-04-06
PROTAC BRD9 Degrader-1 is a lead PROTAC BRD9 chemical degrader and a selective probe useful for the study of BAF complex biology. -
SGC-GAK-1 is a potent, selective, and cell-active GAK inhibitor and shows potent anti-proliferative activity in LNCaP and 22Rv1 cells.
-
COH000 is an allosteric, covalent and irreversible inhibitor of SUMO-activating enzyme, with an IC50 of 0.2 μM for SUMOylation in vitro.
-
HS-1371 is a Small Molecule RIP3 Inhibitor
2019-04-09
HS-1371 is a novel kinase inhibitor of RIP3-mediated necroptosis, showing an inhibitory effect on S227 auto-phosphorylation of RIP3 at the basal level. -
Nevanimibe is a selective and potent ACAT1 inhibitor. An excellent drug candidate in the treatment of adrenocortical cancer.
-
MK-0429 is An Oral Integrin (αvβ3) Inhibitor
2019-04-11
MK-0429, an orally active αvβ3 inhibitor, is a potential therapeutic agent for the prevention of kidney fibrosis, melanoma and osteoporosis. -
AZ304, a Dual BRAF Inhibitor Against Cancer
2019-04-12
AZ304 is a potent BRAF inhibitor, blocks both wild type BRAF and V600E mutant BRAF activity, with IC50s in the nanomolar range. -
Erteberel is a Selective ERβ Agonist
2019-04-16
Erteberel (LY500307) is a synthetic, nonsteroidal estrogen which acts as a selective ERβ agonist and under development for the treatment of schizophrenia. -
MBQ-167 is a dual Rac/Cdc42 inhibitor in in metastatic cancer, with IC50s of 103 nM for Rac 1/2/3 and 78 nM for Cdc42 in MDA-MB-231 cells, respectively.
-
PRN1008 is a Reversible Covalent and Oral Active Inhibitor of Bruton’s Tyrosine Kinase (BTK)
2019-04-18
PRN1008 is a selective, reversible covalent and oral active inhibitor of Bruton’s Tyrosine Kinase (BTK), with an IC50 of 1.3 nM. -
Multiple Tyrosine Kinases Inhibitor TAS-115
2019-04-19
TAS-115 is a potent VEGFR and c-Met/HGFR-targeted kinase inhibitor with IC50s of 30 and 32 nM for rVEGFR2 and rMET, respectively. -
Y06036 is a potent and selective BET inhibitor for potential treatment of castration-resistant prostate cancer. With nanomolar inhibition.
-
JNJ-64619178 is a selective and pseudo-irreversible PRMT5 inhibitor with an IC50 of 0.14 nM. Has potent Activity In Lung Cancer.
-
(E)-AG 99 is an EGFR inhibitor and shows a growth-inhibition on not only serum-starved cells but also normally grown cells. Treatment for Bladder cancer.
-
TAK-828F is a potent, selective and orally active retinoic acid receptor-related orphan receptor γt (RORγt) inverse agonist. TAK-828F inhibits IL-17A cytokine expression and reduces symptoms of autoimmune encephalomyelitis mice.
-
Y06137 is a potent and selective BET inhibitor, which binds to the BRD4(1) bromodomain with a Kd of 81 nM. Antitumor activity.
-
Borussertib is a covalent-allosteric and first-in-class inhibitor of protein kinase Akt, with an IC50 of 0.8 nM and a Ki of 2.2 nM for Akt-wt.
-
NRX-252262 is a β-catenin:β-TrCP interaction enhancer, and its cognate E3 ligase, SCFβ-TrCP, induces mutant β-catenin degradation, with an EC50 of 3.8 nM
-
TAK-981 is a selective inhibitor of the SUMOylation enzymatic cascade, with potential immune-activating and antineoplastic activities
-
TD-428 is a Highly Specific BRD4 Degrader
2019-04-29
TD-428, a immunomodulatory drug analog, is a highly specific BRD4 degrader with a DC50 of 0.32 nM. TD-428 reduces c-Myc levels more efficiently than JQ1. -
SLLN-15 is an oral activ enhancer of autophagy that activates cytostatic macroautophagy/autophagy in triple-negative breast cancer (TNBC).
-
A1874 is a nutlin-based and BRD4-degrading PROTAC with a DC50 of 32 nM. Effective in inhibiting many cancer cell lines proliferation
-
BAY-8002 is a selective and orally active inhibitor of monocarboxylate transporter 1 (MCT1), with an IC50 of 85 nM. Has potential to treat lymphoma.
-
MRTX-1257 is a selective, irreversible, covalent and oral active KRAS G12C inhibitor, with an IC50 of 900 pM for KRAS dependent ERK phosphorylation.
-
USL311 is a selective CXCR4 antagonist, which prevents the binding of stromal-cell derived factor-1 (SDF-1 or CXCL12) to CXCR4. Anti-tumor activity.
-
TX1-85-1, a ATP-competitive ligand of Her3, covalent modification of Her3 to inhibit Her3 signaling
2019-06-01
TX1-85-1 is a Her3 (ErbB3) inhibitor with an IC50 of 23 nM. TX1-85-1 induces partial degradation of Her3 protein and attenuates Her3-dependent signaling. -
IWP-O1, a Highly Potent Porcupine Inhibitor, Functions by Preventing the Secretion of Wnt Proteins
2019-06-03
IWP-O1 is a Porcupine (Porcn) inhibitor, with an EC50 of 80 pM in L-Wnt-STF cells. IWP-O1 functions by preventing the secretion of Wnt proteins[ -
GSK3145095 is a RIP1 kinase inhibitor with an IC50 of 6.3 nM. Potently blocks the TNF response and RIP1-dependent inflammatory cytokine MIP-1β production.
-
PF-06465469 is a Covalent Inhibitor of ITK
2019-06-08
PF-06465469 is a potent and covalent inhibitor of ITK with an IC50 of 2 nM. PF-06465469 inhibits MEK1/2 or AKT phosphorylation. -
Olutasidenib is a highly potent, selective inhibitor of mutant IDH1 that could be used in the treatment of AML or myelodysplastic syndrome (MDS).
-
JMS-17-2 is a CX3CR1 Antagonist
2019-06-12
JMS-17-2 is a potent and selective CX3CR1 antagonist with an IC50 of 0.32 nM. Has potential to treat cancers such as breast cancer. -
BAY-11-7082 inhibits the proliferation and induces the apoptosis of U266 cells through inhibiting NF-κB pathway. BAY 11-7082 ameliorates experimental diabetic neuropathy by modulating neuroinflammation and improving antioxidant defence.
-
S18-000003 is a potent, selective and orally active inhibitor of retinoic acid receptor-related orphan receptor-gamma-t (RORγt). S18-000003 ameliorates psoriasis-like lesions in vivo. S18-000003 can be used for the research of skin inflammatory diseases.
-
PTC299 is a dual and orally active DHODH and VEGF inhibitor, has broad and potent activity against hematological cancer cells.
-
AMG 487 is an orally active and selective antagonist of CXC chemokine receptor 3 (CXCR3). AMG 487 has potential to treat metastatic cancer.
-
TPCA-1, a Direct Dual Inhibitor of STAT3 and NF-κB, Regresses Mutant EGFR-Associated NSCLC
2019-07-15
TPCA-1 is a potent and selective inhibitor of IKK-2 with IC50 of 17.9 nM. TPCA-1 is an effective inhibitor of STAT3 phosphorylation, DNA binding. -
FGTI-2734 is a dual farnesyl and geranylgeranyl transferase-1 inhibitor. FGTI-2734 prevents membrane localization of KRAS and mutant KRAS pancreatic tumors.
-
LSN 3213128 is a selective, nonclassical, orally bioavailable antifolate with anti-cancer activity. LSN 3213128 potently and specifically inhibits AICARFT.
-
BI-882370 is a potent RAF kinase inhibitor with IC50s of 0.4, 0.8, and 0.6 nM for oncogenic BRAFV600E-mutant, the WT BRAF and CRAF kinases , respectively.
-
MSX-122 is an orally active partial antagonist of CXCR4, inhibiting CXCR4/CXCL12 actions. MSX-122 has both anti-tumor and anti-metastasis activities.
-
ZT-12-037-01 is a ATP-competitive and specific STK19 inhibitor and inhibits oncogenic NRAS-driven melanocyte malignant transformation.
-
NXT629 is a potent, selective, and competitive PPAR-α antagonist and shows high selectivity over other nuclear hormone receptor.
-
PT2977 is an orally active and selective HIF-2α inhibitor with an IC50 of 9 nM. PT2977 is a potential treatment for ccRCC and VHL disease.
-
BI-2852 is a potent KRAS inhibitor with nanomolar affinity and reduces pERK and pAKT levels in a dose-dependent manner in a KRAS mutant cell line NCI-H358.
-
BI-4924 is a Selective PHGDH Inhibitor
2019-08-23
BI-4924 is a lipophilic and highly plasma protein bound selective phosphoglycerate dehydrogenase (PHGDH) inhibitor (IC50=3 nM) with excellent microsomal. -
BAY-293 is a potent inhibitor of Son of Sevenless 1 (SOS1) and blocks RAS activation via disruption of the KRAS-SOS1 interaction with an IC50 of 21 nM.
-
FT113 is a potent and orally active fatty acid synthase inhibitor, with an IC50 of 213 nM for full-length recombinant human FAS, with anti-tumor activity.
-
WZ811 is an Orally Active CXCR4 Antagonist
2019-09-07
WZ811 is an orally active, highly potent competitive antagonist of CXCR4, which inhibits chronic lymphocytic leukemia progression and tumorigenesis. -
RU-302 is a pan-TAM inhibitor that blocks the TAM Ig1 ectodomain and the Gas6 Lg domain interaction. RU-302 blocks Gas6-inducible Axl receptor activation.
-
BAY 61-3606 is an orally available, ATP-competitive, reversible and highly selective Syk inhibitor and sensitizes apoptosis by in breast cancer.
-
UPGL00004 is a allosteric glutaminase C inhibitor which strongly inhibits the proliferation of highly aggressive triple-negative breast cancer cell lines.
-
IDH889 is an orally available, brain penetrant, allosteric and mutant specific inhibitor of isocitrate dehydrogenase 1 (IDH1) R132 mutations.
-
BI-167107 is a high affinity, full agonist that binds to the β2 adrenergic receptor (β2AR) with a dissociation constant Kd of 84 pM.
-
IPR-803 is a potent inhibitor of the uPAR•uPA protein-protein interaction, and binds directly to uPAR with sub-micromolar affinity.
-
TVB-3166 is an orally-available, reversible, and selective FASN inhibitor and it induces apoptosis, and inhibits in-vivo xenograft tumor growth.
-
Vorolanib is an orally active, multikinase VEGF/PDGF receptor inhibitor with antitumor activity and is expected to disrupt tumor angiogenesis.
-
CCG-222740 is a potent and selective MRTF pathway inhibitor. It effectively reduces fibrosis in the skin and blocks melanoma metastasis.
-
ASLAN003 is an orally active and potent inhibitor of hDHODH with antitumor activity, and it has the potential to be a first-in-class drug candidate in AML.
-
IACS-8803 is a highly potent cyclic dinucleotide stimulator of interferon genes (STING) agonist with robust systemic antitumor efficacy.
-
DS18561882 is a highly potent, sozyme-selective methylenetetrahydrofolate dehydrogenase 2 (MTHFD2) inhibitor with a good oral pharmacokinetic profile.
-
AC-73 is a first specific, orally active the cluster of differentiation 147 (CD147) inhibitor and specifically disrupts CD147 dimerization.
-
GNE-618 is a Orally Active NAMPT Inhibitor
2019-11-28
GNE-618 is an orally active NAMPT inhibitor and reduces tumor growth. GNE-618 depletes NAD levels and induces tumor cell death. -
Telaglenastat is a first-in-class, reversible, orally bioavailable glutaminase 1 splice variants (KGA and GAC) inhibitor. It shows antitumor activity.
-
UK 356618 is a Selective MMP-3 Inhibitor
2019-12-25
UK 356618 is a selective and potent inhibitor of MMP-3. UK 356618 exhibits potent anti-inflammatory and anti-cancer activity. -
CH6953755 is a potent, orally active and selective YES1 kinase inhibitor leading to antitumor activity against YES1 Gene -amplified cancers.
-
CA-4948 is a Selective and Orally Bioavailable IRAK4 Kinase Inhibitor for Lymphoma Treatment
2020-01-05
CA-4948 is a potent, selective and orally bioavailable IRAK4 kinase inhibitor. CA-4948 can be used for the treatment of lymphoma. -
GPP78 is a potent Nampt inhibitor. GPP78 is cytotoxic to neuroblastoma cell line SH-SY5Y cells. GPP78 has anti-cancer and anti-tumor activity.
-
BAY-985 is an orally active and selective ATP-competitive dual inhibitor of TBK1 and IKKε with IC50s of 2/30 and 2 nM for TBK1 and IKKε, respectively.
-
ADH-503 is an orally active and allosteric CD11b agonist and leads to the repolarization of tumor-associated macrophages.
-
Balixafortide is a potent, selective peptidic CXCR4 antagonist with anti-cancer effects, and blocks β-arrestin recruitment and calcium flux.
-
CM10 is a potent and selective aldehyde dehydrogenase 1A family inhibitor and regulates metabolism and has anti-cancer activity.
-
CCT365623, an Orally Active LOX Inhibitor, Supresses EGFR (pY1068) and AKT Phosphorylation
2020-04-16
CCT365623 is an orally active LOX inhibitor, suppresses EGFR (pY1068) and AKT phosphorylation driven by EGF. CCT365623 has good pharmacokinetic properties. -
DC-5163 is a potent GAPDH inhibitor, can inhibit glycolysis pathway partially. DC-5163 selectively inhibits cancer cell proliferation and induces apoptosis.
-
RBN-2397 is an orally active accross species NAD+ competitive inhibitor of PARP7. RBN-2397 binds to PARP7 and restores interferon (Type I) signaling.
-
OT-82 is a selective inhibitor of NAMPT. Selectively toxic to cells of hematopoietic origin. OT-82 is a promising antineoplastic agent.
-
TNP-351, an Antifolate, is a Dihydrofolate Reductase (DHFR) Inhibitor. Antifolates serve medical science well in neoplastic and non-neoplastic diseases.
-
GSK143 is an orally active and highly selective spleen tyrosine kinase (SYK) inhibitor. GSK143 reduces inflammation in the intestinal muscularis in mice.
-
EW-7195 is a potent and selective ALK5 inhibitor, and efficiently inhibits TGF-β1-induced Smad signaling, EMT and breast tumour metastasis to the lung.
-
JX06 is a potent, selective and covalent inhibitor of PDK via covalently binding to a cysteine residue in an irreversible manner.
-
IPI-9119 is an orally active, selective and irreversible FASN inhibitor with potent anti-cancer activity. IPI-9119 induces cell cycle arrest, apoptosis.
-
CAY10404 is a potent and highly selective COX-2 inhibitor. CAY10404 is a potent inhibitor of PKB/Akt and MAPK signalling pathways.
-
MSA-2 is an orally available non-nucleotide STING agonist. MSA-2 shows antitumor activity and stimulates interferon-β secretion in tumors.
-
SP-8356, an orally active CD147inhibitor, exerts anti-breast cancer effects by inhibiting NF-κB signaling. Anti-atherosclerotic effects.
-
CB-1158, a potent and orally bioavailable inhibitor of arginase, blocks myeloid cell-mediated immune suppression in the tumor microenvironment.
-
SRX3207 is an orally active and first-in-class dual Syk/PI3K inhibitor. SRX3207 possesses effective anti-tumor activity in vitro and in vivo.
-
Verucopeptin inhibits v-ATPase activity by directly targeting the v-ATPase ATP6V1G subunit but not ATP1V1B2 or ATP6V1D. Also a potent HIF-1 inhibitor.
-
E7820, sulfonamide derivative, is a unique angiogenesis inhibitor suppressing an expression of integrin alpha2 subunit on endothelium.
-
Cyclo(-RGDfK) is a selective inhibitor of the αvβ3 integrin. Cyclo(-RGDfK) potently targets cancer cells through binding to the cell surface αvβ3 integrin.
-
Cilengitide is a compound targeting angiogenesis, the cornerstone of tumor growth and metastasis. ανβ3 and ανβ5 are the target of Cilengitide.
-
Tetrac inhibits the cellular actions of thyroid hormone initiated at the hormone receptor on plasma membrane integrin alphavbeta3.
-
BMS-P5 is an Orally Active PAD4 Inhibitor
2020-12-12
BMS-P5 is an orally active PAD4 inhibitor. BMS-P5 blocks MM-induced NET formation and delays progression of MM in a syngeneic mouse model -
ML132, a potent and selective caspase 1 inhibitor with a unique selectivity pattern, is responsible for the proteolytic activation of IL-1β and IL-18.
-
CTPI-2 is a SLC25A1 inhibitor. CTPI-2 inhibits glycolysis, PPARγ, and its downstream target the glucose transporter GLUT4. Antitumor activity.
-
BI99179 is a Selective Type I FASN Inhibitor
2021-01-28
FASN is a key enzyme for lipogenesis and highly expressed in lipogenic tissues. BI99179 is a Selective Type I FASN Inhibitor. -
Fasentin inhibits GLUT-1 and GLUT-4 transporters. Fasentin blocks glucose uptake in cancer cell lines and has anti-angiogenic activity.
-
ML390 is a Potent DHODH Inhibitor
2021-02-24
ML390 is a potent dihydroorotate dehydrogenase (DHODH) inhibitor and is an inducer of myeloid differentiation. -
ENMD-1198 is an orally active microtubule-targeting agent with antiproliferative and antiangiogenic activity.
-
CC-90001 is a potent, selective, and orally active inhibitor of JNK. CC-90001 can be used for the research of idiopathic pulmonary fibrosis (IPF).
-
TPP-1 is a potent inhibitor of the PD-1/PD-L1 interaction. TPP-1 binds specifically to PD-L1 with a high affinity (KD=95 nM).
-
FAPI-46 is a quinoline-based FAP-targeted radiotracer. FAPI-46 has higher tumor uptake and prolonged tumor accumulation.
-
SB-332235 is a potent, orally active nonpeptide CXCR2 antagonist. SB-332235 inhibits acute and chronic models of arthritis in the rabbit.
-
BMSpep-57 is a potent and competitive macrocyclic peptide inhibitor of PD-1/PD-L1 interaction. It induces high levels of IL-2.
-
ML339 is a Selective CXCR6 Antagonist
2021-05-12
ML339 is a small molecule antagonist would block Prostate cancer cell trafficking; hence mediate a metastatic event and disease progression. -
Sitravatinib (MGCD516) is an Orally Bioavailable RTK Inhibitor with PD-1 Blockade Activity
2021-06-03
Sitravatinib, a small molecule RTK inhibitor, shows potent anti-tumor activity in preclinical models of sarcoma. -
Vorasidenib is an orally available, brain penetrant second-generation dual mutant isocitrate dehydrogenases 1 and 2 (mIDH1/2) inhibitor.
-
Motesanib (AMG 706) is an orally active VEGFR inhibitor. Potently inhibits angiogenesis and induces regression in tumor xenografts.
-
EMD527040 is a highly selective αvβ6 antagonist with antifibrotic activities.
-
Lumiracoxib is a COX-2 inhibitor. Lumiracoxib acts as nonselective NSAID with anti-inflammatory, analgesic and antipyretic activities.
-
Inupadenant is an orally active, highly selective A2A receptor antagonist with potent anti-tumor activity.
-
UK122 is a potent and selective urokinase-type plasminogen activator (uPA) inhibitor with anti-cancer activity.
-
Ruxolitinib is a potent and selective JAK1/2 inhibitor and has 130-fold selectivity for JAK1/2 over JAK3. Ruxolitinib induces autophagy.
-
AZD4635 is a potent, selective and orally active antagonist of A2AR that reverses adenosine-mediated immune suppression.
-
Nintedanib a potent and orally active triple vascular kinase inhibitor for VEGFR1/2/3, FGFR1/2/3 and PDGFRα/β.
-
IMD-0354 is a Selective IKKβ Inhibitor
2021-11-09
IMD-0354 is a selective IKKβ inhibitor and potently inhibits NF-κB activity. IMD0354 has antitumor activity. -
Axitinib is a multi-targeted tyrosine kinase inhibitor and potently inhibitor VEGFR1, VEGFR2, VEGFR3 and PDGFRβ.
-
Lonidamine, an antitumor agent and an indazole derivative, interferes with energy-yielding processes in cancer cells.
-
CL097 is a TLR7/8 agonist. CL097 induces pro-nflammatory cytokines. CL097 induces NADPH oxidase priming and efficient diabetogenic cytotoxic T lymphocyte (CTL) function in NOD mice.
-
Zingerone is a natural orally active nontoxic methoxyphenol potent anti-inflammatory, antidiabetic, antioxidize, and anti-tumor properties.
-
Indoximod, an immunometabolic adjuvant, is an orally active IDO pathway inhibitor. Indoximod acts as a Trp mimetic in regulating mTOR.
-
Tanomastat is an orally active, non-peptidic biphenyl MMPs inhibitor, with antiangiogenic, anti-invasive and antimetastatic activities.
-
BM213 is a selective C5aR1 agonist. It’s a useful research tool to study C5aR1 function
-
Telatinib is an orally active inhibitor of VEGFR2, VEGFR3, PDGFα, and c-Kit.
-
Marimastat (BB2516) is a broad spectrum and orally bioavailable inhibitor of MMPs (Matrix metalloproteinases).
-
Gardiquimod is a TLR7/8 agonist and can inhibit HIV-1 infection.
-
Vatalanib is an inhibitor of VEGFR2/KDR. Vatalanib induces inhibition of the angiogenic response to VEGF and PDGF.
-
Toceranib is a selective and orally active inhibitor of RTK and has the potential for the research of canine mast cell tumors.
-
Tiragolumab is an immune checkpoint inhibitor binding to TIGIT. Tiragolumab is effective against multiple solid malignancies.
-
Henatinib is an orally active small-molecule multikinase inhibitor that has demonstrated broad and potent antitumor activities.
-
KGP94 is a selective inhibitor of cathepsin L. KGP94 has antitumor activity and improves survival of bone metastases bearing mice.
-
Pelecopan is a potent, selective, and orally active complement factor D inhibitor, possessing the potential to study paroxysmal nocturnal hemoglobinuria (PNH).
-
Certepetide is a Tumor-penetrating Enhancer via RGD Motif Interaction with Alphav-integrins
2022-09-01
Certepetide is a tumor-penetrating enhancer and has the potential for the research of metastatic pancreatic ductal adenocarcinoma. -
BSP16 is a potent, orally active stimulator of interferon genes (STING) agonist. BSP16 has potent anti-cancer activity.
-
Parsatuzumab (RG 7414) is a humanized monoclonal antibody, that acts as an immunomodulator, and binds to EGFL7.
-
Etrolizumab is a Gut-selective, Anti-β7 Integrin McAb for Inflammatory Bowel Disease (IBD) Research
2022-11-05
Etrolizumab is a gut-selective, anti-β7 integrin monoclonal antibody and has the potential for the research of inflammatory bowel disease. -
Serplulimab is a humanized monoclonal anti-PD-1 antibody and has the potential for the research of small cell lung cancer.
-
ABT-510, a peptide analog of thrombospondin-1 (TSP-1), can block angiogenesis in vitro and in vivo, and slow tumor growth.
-
STF-31 is a potent ans selective inhibitor of GLUT1 that inhibit glucose uptake in renal cell carcinoma (RCC) 4 cells.
-
Mogamulizumab is an Anti-CCR4 monoclonal antibody. It enhances antibody-dependent cellular cytotoxicity and is effective against leukemia.
-
Olutasidenib (FT-2102) is an orally active, brain penetrant inhibitor of mutant IDH1. Olutasidenib is used for AML or MDS Research.
-
Bapotulimab (BAY-1905254) is an ILDR2 IgG antibody that blocks the immunosuppressive effects of ILDR2 on T-cell activation.
-
Nanrilkefusp alfa is a selective and strong IL-15 agonist. It inhibits tumor metastasis and viability by activating natural killer (NK) cells.
-
Urabrelimab (SRF231) is an anti-CD47 monoclonal antibody, blocking the CD47-SIRPα interaction. It has the potential to research anticancer.
-
Efineptakin alfa (NT-17) is a Long-Acting Recombinant Human IL-7 for Glioblastoma Research
2023-02-07
Efineptakin alfa (NT-17) is a long-acting recombinant human IL-7. Efineptakin alfa can be used for glioblastoma research. -
Pegdinetanib (BMS-844203) is a selective VEGFR-2 inhibitor with antitumor activity.
-
Talotrexin (PT523), a classic antifolate, is an RFC (reduced folate carrier) specific inhibitor and selectively inhibits RFC transport.
-
Tifcemalimab, a Humanized anti-BTLA monoclonal antibody, blocks the interaction of HVEM-BTLA by binding to BTLA and activates lymphocytes.
-
Geptanolimab (CBT-501) is a programmed death-1 (PD-1) monoclonal antibody. Geptanolimab can be used in research forsolid tumor research.
-
Dazostinag is a STING Agonist and Can be used for Antibody-Drug Conjugates (ADCs) Synthesis
2023-03-13
Dazostinag is a STING agonist and a playload, to synthesis antibody-drug conjugates (ADCs). It has antitumor activity in vivo. -
Ruxolitinib is an orally-active JAK1/2 inhibitor. Ruxolitinib has the potential for the research of myeloproliferative neoplasm (MPN).
-
BBO-11818 is a potent, selective, orally bioavailable, and noncovalent pan-KRAS inhibitor targeting multiple clinically relevant KRAS mutants in both ON and OFF states.
Products
-
All
-
Inhibitors & Agonists
-
Isotope-Labeled Compounds
-
Fluorescent Dye
-
Peptides
-
Recombinant Proteins
-
Antibodies
-
Screening Libraries
-
Kits
-
Inhibitory Antibodies
-
Reference Standards
-
GMP Small Molecules
-
Biochemical Assay Reagents
-
Natural Products
| Cat. No. | Product Name | Information | Application | Publication |
|---|---|---|---|---|
| HY-P0035A | Insulin solution (human) |
|
105
|
|
| HY-P0035 | Insulin (human) |
|
105
|
|
| HY-L030 | Human Endogenous Metabolite Compound Library |
The composition of endogenous metabolite compounds is affected by the upstream influence of the proteome and genome as well as environmental factors, lifestyle factors, medication, and underlying disease. Therefore, metabolites have been described as proximal reporters of disease because their abundances in biological specimens are often directly related to pathogenic mechanisms. In more recent years, metabolomics approach has been adopted or suggested to be used in various research areas including drug discovery, neurosciences, agriculture, food and nutrition, and environmental sciences.
MCE owns a unique collection of 765 human endogenous metabolites, all of which are derived from human issues. This library is a powerful tool for metabonomics research and metabolism-related drug discovery.
|
|
91
|
| HY-L015 | PI3K/Akt/mTOR Compound Library |
The PI3K/Akt/mTOR pathway controls many cellular processes that are important for the formation and progression of cancer, including apoptosis, transcription, translation, metabolism, angiogenesis, and cell cycle progression. Every major node of this signaling network is activated in a wide range of human tumors. Mechanisms for the pathway activation include activation of receptor tyrosine kinases (RTKs) upstream of PI3K, mutation or amplification of PIK3CA encoding p110α catalytic subunit of PI3K, mutation or loss of PTEN tumor suppressor gene, and mutation or amplification of Akt1. Once the pathway is activated, signaling through Akt can stimulate a series of substrates including mTOR which is involved in protein synthesis. Thus, inhibition of this pathway is an attractive concept for cancer prevention and/or therapy. Currently some mTOR inhibitors are approved for several indications, and there are several novel PI3K/Akt/mTOR inhibitors in clinical trials.
MCE owns a unique collection of 1,149 compounds that can be used for PI3K/Akt/mTOR pathway research. PI3K/Akt/mTOR Compound Library also acts as a useful tool for anti-cancer drug discovery.
|
|
90
|
| HY-L055 | Medicine Food Homology Compound Library |
Medicine Food Homology (MFH) means that some food themselves are medicines and there is no absolute boundary between them. MFH theory combines the function of food and medicine together scientifically and MFH materials can be used both for food and medicine. Besides nutritional value, MFH materials also have the functions in the prevention and treatment of disease and many other healthcare effects. Food as medicines has many benefits because of their safety while taking drugs will bring inevitable side effect to people. In order to ensure the safe use of functional food, National Health Commission of People's Republic of China made specific provisions on MFH items. More than 100 kinds of widely used MFH materials have been released.
Based on MFH items released by National Health Commission, PRC, MCE carefully designs a unique collection of 1,824 Medicine Food Homology Compounds with high safety that can be used for high throughput and high content screening for drug discovery.
|
|
88
|
| HY-L067 | Antibiotics Library |
Antibiotics are types of antimicrobial products used for the treatment and prevention of bacterial infections. Antibiotics can kill or inhibit bacterial growth. Although the target of an antibiotic is bacteria, some antibiotics also attack fungi and protozoans. However, antibiotics rarely have an effect on viruses. The major mechanism underlying antibiotics is the inhibition or regulation of enzymes involved in cell wall biosynthesis, nucleic acid metabolism and repair, protein synthesis, or disruption of membrane structure. Many of these cellular functions targeted by antibiotics are most active in multiplying cells. Since there is often overlap in these functions between prokaryotic bacterial cells and eukaryotic mammalian cells, it is not surprising that some antibiotics have also been found to be useful as anticancer agents.
MCE supplies a unique collection of 748 antibiotics, including penicillins, cephalosporins, tetracyclines, macrolides, etc. MCE Antibiotics Library is a useful tool for anti-bacterial or anti-cancer drugs discovery.
|
|
85
|
| HY-L078 | Gut Microbial Metabolite Library |
Accumulating evidence has revealed that intestinal microbiota play an important role in human health and disease, including cardiovascular diseases, inflammatory bowel disease, diabetes, obesity, cancer, and depression, etc. Changes in the composition of gut microbiota associated with disease, referred to as dysbiosis, have been linked to pathologies. Indeed, the gut microbiome functions like an endocrine organ, generating bioactive metabolites which play important roles in human metabolism, health, and disease. Gut microbiome has become a novel therapeutic target for many diseases. Analysis and identification of gut microbial metabolite will contribute to the development of therapeutic methods.
In order to meet the need of gut microbiome research, MCE carefully selected a unique collection of 475 gut microbial metabolites. MCE gut microbial metabolite library is a powerful tool for gut microbiome research and gut microbiome -related drug discovery.
|
|
85
|
| HY-L091 | Lipid Metabolism Compound Library |
Lipids are a fundamental class of organic molecules implicated in a wide range of biological processes, and based on this can be broadly classified into five categories: fatty acids, triacylglycerols (TAGs), phospholipids, sterol lipids and sphingolipids. Lipids play a crucial role in different metabolic pathways and cellular functions. Lipid metabolism is an important physiological process that is related to nutrient adjustment, hormone regulation, and homeostasis. Lipid metabolism dysregulation is associated with many diseases such as obesity, liver disease, aging and inflammation.
MCE offers a unique collection of 1,026 compounds related to lipid metabolism, which target relevant targets in the process of lipid metabolism, such as ATGL, MAGL, FAAH, acetyl-Coa Carboxylase, FASN, etc. MCE lipid metabolism compound library is a useful tool for research lipid metabolism and drug discovery of diseases related to lipid metabolism.
|
|
85
|
| HY-L107 | Anti-Cancer Natural Product Library |
With features of enormous scaffold diversity and structural complexity, natural products (NPs) are the main sources of lead compounds and new drugs and play a highly significant role in the drug discovery and development process, especially for cancer and infectious diseases. A large number of natural products have been proven to have potential anti-tumor effects, mainly from plants, animals, Marine organisms and microorganisms. At present, derived than 60% of anti-tumor drugs come from natural sources, and they are widely used in breast, prostate and colon cancers.
MCE offers a unique collection of 2,020 natural products with validated anti-cancer activity. MCE anti-cancer natural product library is a useful tool for anti-tumor drugs screening and other related research.
|
|
85
|
| HY-L123 | Human Metabolite Library |
Human metabolism is an integral part of cellular function that reflects individual differences in health, disease, diet, and lifestyle. Many health conditions such as obesity, diabetes, hypertension, heart disease, and cancer are associated with abnormal metabolic states. In the pathological state of the human body, metabolic pathways are significantly altered, resulting in aberrant levels of intermediates or end-products that can be viewed as potential diagnostic biomarkers or even therapeutic targets. Therefore, detection, identification and quantification of human metabolites are very important for drug metabolism research in drug development.
MCE offers a unique collection of 6,767 human metabolites, including endogenous metabolites and exogenous metabolites, covering multiple structure types, such as lipids, amino acids, nucleic acids, carbohydrates, organic acids, biogenic amines, vitamins,. MCE Human Metabolites Library is a helpful tool for studying the relationship between diseases and metabolism.
|
|
85
|
| HY-L040 | Anti-diabetic Compound Library |
Diabetes mellitus, usually called diabetes, is a group of metabolic disorders characterized by a high blood sugar level over a prolonged period of time. The most common types are Type I and Type II. Type I diabetes (T1D), also called juvenile onset diabetes mellitus or insulin-dependent diabetes mellitus, is characterized by destruction of the β-cells of the pancreas and insulin is not produced, whereas type II diabetes (T2D), also called non-insulin-dependent diabetes mellitus, is characterized by a progressive impairment of insulin secretion and relative decreased sensitivity of target tissues to the action of this hormone. Type 2 diabetes accounts for the vast majority of all diabetes mellitus. Diabetes of all types can lead to complications in many parts of the body and can increase the overall risk of dying prematurely. Possible complications include kidney failure, leg amputation, vision loss and nerve damage.
The pathogenesis of diabetes is complicated, and development of the safe and effective drugs against diabetes is full of challenge. Increasing studies have confirmed that the pathogenesis of diabetes is related to various signaling pathways, such as insulin signaling pathway, AMPK pathway, PPAR regulation and chromatin modification pathways. These signaling pathways have thus become the major source of the promising novel drug targets to treat metabolic diseases and diabetes.
MCE Anti-diabetic Compound Library owns a unique collection of 1,172 compounds, which mainly target SGLT, PPAR, DPP-4, AMPK, Dipeptidyl Peptidase, Glucagon Receptor, etc. This library is a useful tool for discovery anti-diabetes drugs.
|
|
84
|
| HY-L046 | Anti-Cardiovascular Disease Compound Library |
Cardiovascular diseases (CVDs) are a group of disorders of the heart and blood vessels which include coronary heart disease, cerebrovascular disease, peripheral arterial disease, rheumatic heart disease, etc. CVDs are the number 1 cause of death globally. Smoking, unhealthy nutrition, aging population, lack of physical activity, arterial hypertension, or diabetes can promote cardiovascular disease like myocardial infarction or stroke. It is multifactorial and encompasses a multitude of mechanisms, such as eNOS uncoupling, reactive oxygen species formation, chronic inflammatory disorders and abnormal calcium homeostasis. Antioxidant, anti-inflammatory and anti-diabetes agents may reduce the cardiovascular disease risk.
MCE supplies a unique collection of 2,468 compounds with confirmed anti-cardiovascular activity. These compounds mainly target metabolic enzyme, membrane transporter, ion channel, inflammation related signaling pathways. MCE Anti-Cardiovascular Disease Compound Library can be used for cardiovascular diseases related research and high throughput and high content screening for new drugs.
|
|
84
|
| HY-L083 | Anti-Cancer Metabolism Compound Library |
Mutations in oncogenes and tumor suppressor genes can modify multiple signaling pathways and in turn cell metabolism, which facilitates tumorigenesis. The paramount hallmark of tumor metabolism is “aerobic glycolysis” or the Warburg effect, coined by Otto Warburg in 1926, in which cancer cells produce most of energy from glycolysis pathway regardless of whether in aerobic or anaerobic condition. Usually, cancer cells are highly glycolytic (glucose addiction) and take up more glucose than do normal cells from outside. The increased uptake of glucose is facilitated by the overexpression of several isoforms of membrane glucose transporters (GLUTs). Likewise, the metabolic pathways of glutamine, amino acid and fat metabolism are also altered. Recent trends in anti-cancer drug discovery suggests that targeting the altered metabolic pathways of cancer cells result in energy crisis inside the cancer cells and can selectively inhibit cancer cell proliferation by delaying or suppressing tumor growth.
MCE provides a unique collection of 3,806 compounds which cover various tumor metabolism-related signaling pathways. These compounds can be used for anti-cancer metabolism targets identification, validation as well anti-cancer drug discovery.
|
|
84
|
| HY-L094 | Food-Sourced Compound Library |
The health benefits deriving from the consumption of certain foods have been common knowledge. All foods are made up of chemical substances. Chemicals in foods are largely harmless and often desirable. At present, numerous researchers have been focused on the beneficial role played by certain food components in the close relationship between food intake and health status. For example, polyphenols, a common class of compounds among foods, are well-known antioxidants, which may play a role in the prevention of several diseases including type 2 diabetes, cardiovascular diseases, and some types of cancer.
MCE supplies a unique collection of 2,064 compounds from variety of foods. All compounds are with specific food source(s). MCE Food-Sourced Compound Library is the useful tool to discover molecules with pharmaceutical activity from foods.
|
|
84
|
| HY-L146 | Metabolic Enzyme Compound Library |
Metabolism is the set of life-sustaining chemical reactions in organisms that maintain cell homeostasis. Metabolic pathways are enzyme-mediated biochemical reactions that lead to biosynthesis (anabolism) or breakdown (catabolism) of molecules including glucose metabolism, lipid metabolism and amino acid or protein metabolism within a cell or tissue. As catalysts, enzymes are crucial to metabolism as they allow a reaction to proceed more rapidly and tregulate the rate of a metabolic reaction. Due to the importance of metabolic balance in the organism, the abnormal function of metabolic enzymes often leads to the occurrence of a variety of metabolic diseases, such as diabetes, obesity, cardiovascular disease, etc.
MCE designs a unique collection of 4,407 metabolic enzymes related small molecules, which is an important tool for studying the metabolic activities of organisms and developing drugs for metabolic diseases.
|
|
84
|
| HY-L188 | Anti-Brain Cancer Compound Library |
Although brain cancer only accounts for 2% of all tumors, it has a poor prognosis, high mortality and high recurrence rate. Brain cancer can be divided into primary brain cancer and secondary brain cancer. According to the location of the cancer, brain cancer can also be divided into: brain glioma, pituitary adenoma, schwannoma, craniopharyngioma, meningioma and so on. Glioma is the most common primary brain tumor, accounting for about 1/3 of all brain tumors. At present, brain cancer lacks precision targeted therapeutic drugs, and there is still a great clinical demand that has not been met. With the continuous development of high-throughput screening technology, it may be able to help develop effective anti-brain cancer drugs by screening compounds targeting PKC, PD-1, c-Met, PARP, etc targets.
MCE designs a unique collection of 2,134 small molecules with definite or potential anti-brain cancer activity, which is an important tool for studying the pathological mechanism of brain cancer and developing drugs for brain cancer.
|
|
84
|
| HY-L064 | Glutamine Metabolism Compound Library |
Glutamine is an important metabolic fuel that helps rapidly proliferating cells meet the increased demand for ATP, biosynthetic precursors, and reducing agents. Glutamine Metabolism pathway involves the initial deamination of glutamine by glutaminase(GLS), yielding glutamate and ammonia. Glutamate is converted to the TCA cycle intermediate α-ketoglutarate (α-KG) by either glutamate dehydrogenase (GDH) or by the alanine or aspartate transaminases (TAs), to produce both ATP and anabolic carbons for the synthesis of amino acids, nucleotides and lipids. During periods of hypoxia or mitochondrial dysfunction, α-KG can be converted to citrate in a reductive carboxylation reaction catalyzed by IDH2. The newly formed citrate exits the mitochondria where it is used to synthesize fatty acids and amino acids and produce the reducing agent, NADPH.
Cancer cells display an altered metabolic circuitry that is directly regulated by oncogenic mutations and loss of tumor suppressors. Mounting evidence indicates that altered glutamine metabolism in cancer cells has critical roles in supporting macromolecule biosynthesis, regulating signaling pathways, and maintaining redox homeostasis, all of which contribute to cancer cell proliferation and survival. Thus, intervention in glutamine metabolic processes could provide novel approaches to improve cancer treatment.
MCE owns a unique collection of 1,827 compounds targeting the mainly proteins and enzymes involved in glutamine metabolism pathway. Glutamine Metabolism compound library is a useful tool for intervention in glutamine metabolic processes.
|
|
83
|
| HY-L074 | Anti-Breast Cancer Compound Library |
Breast cancer is the most frequent cancer among women, impacting 2.1 million women each year, and also causes the greatest number of cancer-related deaths among women. Surgery is usually the first type of treatment for breast cancer, which is usually followed by chemotherapy or radiotherapy or, in some cases, hormone or targeted therapies, especially for metastatic breast cancer (MBC).
Breast cancer is a heterogeneous disease, which is categorized into 3 major subtypes based on the presence or absence of molecular markers for estrogen or progesterone receptors and human epidermal growth factor 2 (ERBB2; formerly HER2): hormone receptor positive/ERBB2 negative (70% of patients), ERBB2 positive (15%-20%), and triple-negative (tumors lacking all 3 standard molecular markers; 15%). Different intrinsic subtypes exhibit different tumor behavior with different prognoses, and may require specific targeted therapies to maximize treatment effectiveness. Otherwise, some signaling pathways also play important roles in the development of breast cancer, such as NF-κB Signaling Pathway, TGF-beta Signaling Pathway, PI3K/AKT/mTOR signaling pathway and Notch Signaling Pathway. These signaling pathways offer ideal targets for development of new targeted therapies for breast cancer.
MCE supplies a unique collection of 3,404 compounds with identified and potential anti-breast cancer activity. MCE Anti-Breast Cancer Compound Library is a useful tool for anti-breast cancer drugs screening.
|
|
83
|
| HY-L087 | Anti-Obesity Compound Library |
Obesity is widely recognized as the largest and fastest growing public health problem and is associated with numerous chronic disorders including osteoarthritis, obstructive sleep apnea, gallstones, fatty liver disease, reproductive and gastrointestinal cancers, dyslipidemia, hypertension, type 2 diabetes, heart failure, coronary artery disease, stroke, etc. Although obesity has long been associated with serious health issues, it has only recently been regarded as a disease in the sense of being a specific target for medical therapy. Obesity may be viewed as the dysregulation of two physiological functions, appetite regulation and energy metabolism, which combine to create disordered energy balance. Consequently, developing obesity treatments that target novel pathways is a growing focus for both biopharmaceutical industries.
MCE Anti-Obesity Compound Library owns a unique collection of 3,741 compounds, which mainly target signaling pathway of controlling appetite, fatty acid metabolism and energy expenditure, etc. This library is a useful tool for discovery anti-obesity drugs.
|
|
83
|
| HY-L103 | Anti-Colorectal Cancer Compound Library |
Colorectal cancer (CRC), also known as bowel cancer, colon cancer, or rectal cancer, arises as adenocarcinoma from glandular epithelial cells of the large intestine comprised of the colon and rectum. The majority of cases of CRC are sporadic and result from risk factors, such as a sedentary lifestyle, obesity, processed diets, alcohol consumption and smoking. CRC is also a common preventable cancer.
Studies showed several cellular signaling pathways dysregulated in CRC, leading to the onset of malignant phenotypes. Therefore, it is necessary to analyze the signaling pathways involved in the occurrence and development of colorectal cancer to study the progression and drug treatment of colorectal cancer. Among them, Wnt/β-catenin, p53, TGF-β/SMAD, NF-κB, Notch, VEGF and other target genes and signaling pathways are the focus of research.
MCE offers a unique collection of 2,653 compounds with identified and potential anti-colorectal cancer activity. MCE anti-colorectal cancer compound library is a useful tool for anti-colorectal cancer drugs screening and other related research.
|
|
83
|
| HY-L105S | Peptide Compound Library |
Peptides, composed of amino acids, serve as crucial building blocks for proteins and have gained significant attention in drug development over the past decade. The advancements in production, modification, and analytical technologies have led to a surge in the potential applications of peptides in medicine. Peptides offer a number of advantages over small molecule drugs, including: greater target specificity and efficacy, more predictable metabolic profiles, easier delivery to where they are needed in the body, and fewer side effects. Peptides are increasingly appearing in all branches of medicine as components of innovative drugs, imaging agents, diagnostic agents, and other complex drugs such as peptide-drug conjugates. To date, more than 80 peptide drugs have been approved to treat a variety of diseases, including microbial infections, obesity, anti-diabetes, and cancer, as well as to develop cell targeting platforms and improve cell penetration properties.
MCE designs a unique collection of 867 peptide compounds. HY-L105S is a peptide compound library that can be provided with solution form based on HY-L105, and can be applied to peptides-based drug development.
|
|
83
|
| HY-L126 | Nuclear Receptor Compound Library |
Nuclear receptors (NR) are proteins found in cells that sense androgen and thyroid hormones and certain other molecules. They are ligand-activated transcription factors that participate in many aspects of human physiology and pathology, and regulate the expression of various important genes.
Nuclear receptors have become one of the main targets in the development of new drug strategies, providing a unique type of receptors for studying a variety of human diseases, such as breast cancers, skin disorders and diabetes. 13% of U.S. Food and Drug Administration (FDA) approved drugs target nuclear receptors.
MCE supplies a unique collection of 1,092 nuclear receptor inhibitors and activators, all of which have the identified inhibitory or activated effect on nuclear receptor. MCE Nuclear Receptor Library is a useful tool for drugs research related to cancer, skin disease and diabetes.
|
|
83
|
| HY-L133 | Cuproptosis Compound Library |
Copper is an important co-factor of all biological enzymes, but if the concentration exceeds the threshold of maintaining the homeostasis mechanism, copper will lead to cytotoxicity. This death mechanism has been named "Cuproptosis".
The mechanism of cuproptosis distinct from all other known mechanisms of regulated cell death, including apoptosis, pyroptosis, necroptosis, and ferroptosis.
Copper combine with the lipoylated components of the tricarboxylic acid cycle (TCA), leading to lipoylated protein aggregation and subsequent loss of iron-sulfur cluster proteins, ultimately resulting in protein toxicity stress and cell death. Studies have shown that the necessary factors for cuproptosis include the presence of glutathione, mitochondrial metabolism of galactose and pyruvate, and glutamine metabolism.
Targeted regulation of cuproptosis is a potential choice to treat cancer, rheumatoid arthritis, and other diseases. For example, up-regulation of LIPT1 may inhibit the occurrence and development of tumors by destroying TCA in mitochondria and then inducing cuproptosis.
MCE supplies a unique collection of 446 cuproptosis-related compounds, all of which act on the targets or signaling pathways related to cuproptosis and may have in inhibitory or activated effect on cuproptosis. MCE Cuproptosis Library is a useful tool for drug research related to cancer, rheumatoid arthritis, and other diseases.
|
|
83
|
| HY-L135 | Cancer Stem Cells Compound Library |
With the progress of modern cancer therapy, the life of cancer patients has been extended. However, after initial treatment and recovery, the development of secondary tumors often leads to cancer recurrence. Cancer stem cells are a small number of cells that tumor growth and reproduction depend on.
Cancer stem cells have strong self-renewal ability, which is the direct cause of tumor occurrence. In addition, cancer stem cells also have the ability to differentiate into different cell types, playing a crucial role in tumor metastasis and development. Chemotherapy and radiotherapy induced DNA damage and apoptosis are common cancer treatments. However, cancer stem cells can effectively protect cancer cells from apoptosis by activating DNA repair ability. Cancer stem cells are regarded as the key "seed" of tumor occurrence, development, metastasis and recurrence. Since its first discovery in leukemia in 1994, cancer stem cells have been considered a promising therapeutic target for cancer treatment.
MCE supplies a unique collection of 3,540 compounds targeting key proteins in cancer stem cells. MCE Cancer Stem Cells Compound Library is a useful tool for cancer stem cells related research and anti-cancer drug development.
|
|
83
|
| HY-L169 | Anti-Drug-Resistant Compound Library |
Resistance refers to the decrease in the effectiveness of drugs in treating diseases or symptoms. Due to the increasing global antibiotic resistance, it may threaten our ability to treat common infectious diseases. Drug resistance is also the main cause of chemotherapy failure in malignant tumors. In approximately 50% of cases, drug resistance exists even before chemotherapy begins. There are many mechanisms of anticancer drug resistance, including increased protein expression that leads to drug removal, mutations in drug binding sites, recovery of tumor protein production, and pre-existing genetic heterogeneity in tumor cell populations. In addition, the issue of drug resistance seems to have affected the development of new anticancer drugs. Drug resistance may be caused by various conditions, such as mutations, epigenetic modifications, and upregulation of drug efflux protein expression. Overcoming multidrug resistance in cancer treatment is becoming increasingly important.
MCE designs a unique collection of 706 anti-drug-resistant compounds. It is a good tool to be used for research on cancer and other diseases.
|
|
83
|
| HY-L173 | Anti-Ovarian Cancer Compound Library |
Ovarian cancer is the most common cause of death in female genital malignancies, with the highest mortality rate in female genital malignancies. It is characterized by difficulty in detection in the early stage of the disease, high recurrence rate and poor prognosis. In fact, ovarian cancer includes many pathologic types. It is usually divided into epithelial ovarian cancer, malignant germ cell tumors and sex cord stromal tumors, of which epithelial ovarian cancer is the most dominant form. Clinical treatment of ovarian cancer prioritizes surgery combined with paclitaxel chemotherapy. However, due to the spread and drug resistance of tumor cells, the recurrence of ovarian cancer is high. In this case, combined with traditional methods, the development of new therapeutic agents can help to improve the treatment effect of ovarian cancer.
MCE designs a unique collection of 2,967 compounds with definite or potential anti-ovarian cancer activity, which mainly targeting the main targets of ovarian cancer such as PARP, ATM/ATR, VEGFR and HIF/HIF Prolyl-Hydroxylase, etc. It is an essential tool for development and research of anti-ovarian compounds.
|
|
83
|
| HY-L192 | Dietary Supplement Library |
Dietary supplement, also known as nutritional supplement or food supplement, include dietary components such as vitamins, minerals, and amino acids. The unique value of dietary supplement is particularly significant in the post-pandemic era. Compared to traditional medication, dietary supplement is often more readily accepted by the public due to their higher safety profile and the natural origin. By orally supplementing essential nutrients and bioactive substances, dietary supplement can help to enhance the body's health level and reduce the risk of diseases. For certain chronic conditions, proper dietary supplement can also serve as a powerful adjunct to conventional medical treatment, enhancing the effectiveness of medication.
MCE has included 69 dietary supplements, whose ingredients are all derived from the official lists published by authoritative organizations such as the FDA, EFSA, NMPA, etc. These compounds can be utilized in the development of health food products and for the mechanistic research of certain chronic diseases.
|
|
83
|
| HY-L199 | Non-Alcoholic Fatty Liver Disease (NAFLD) Compound Library |
Non-alcoholic fatty liver disease (NAFLD) is one of the most common liver diseases worldwide and is the primary liver manifestation of metabolic syndrome. The growth of NAFLD has coincided with the obesity epidemic. NAFLD is composed of excess lipid accumulation in the liver, causing steatotoxicity, and shows a wide range of histopathological abnormalities. NAFLD may progress from simple steatosis to Non-alcoholic steatohepatitis (NASH) with or without fibrosis (NASH), and eventually to cirrhosis and hepatocellular carcinoma. To date, very few drugs have been approved for marketing specifically for the treatment of NAFLD, so increased efforts to develop NAFLD drugs are necessary.
MCE designs a unique collection of 5,024 small molecules with definite or potential anti-NAFLD activity, which is an important tool for studying the pathological mechanism of NAFLD and developing drugs for NAFLD.
|
|
83
|
| HY-L201 | Cell Proliferation Compound Library |
Cell proliferation, the increase in cell numbers resulting from cell division, is a complex and tightly regulated process. Cell proliferation is regulated by coordinated entry into the cell cycle, and changes in proliferation are closely linked to disease development. Evolutionary dynamics links tumor growth and progression with cell proliferation, cell death, and mutation rates. In addition, cell proliferation is central to degenerative diseases, the development of which is often accompanied by accelerated multiplication of cancer cells. Therefore, assays of cell proliferation levels are frequently used for laboratory research purposes and increasingly for clinical assessment of tumor aggressiveness and potentially to guide care. It has been shown that multiple key targets are collectively involved in regulating the process of cell proliferation, such as CDK, E2F, pRB, β-Catenin, and others.
MCE collects 3,628 compounds that target and regulate key targets of cell proliferation, which can be used in studies of cell proliferation mechanisms and drug discovery.
|
|
83
|
| HY-L204 | Lactic Acid Metabolic Compound Library |
Lactic acid metabolism is one of the key metabolic pathways within living organisms. It plays a crucial role not only in cellular energy conversion but is also closely related to a variety of physiological and pathological processes. The production and clearance of lactic acid are important indicators of cellular metabolic balance, and its abnormal regulation may lead to conditions such as lactic acidosis, muscle fatigue, and hereditary metabolic diseases. Moreover, lactic acid is closely related to the malignancy of tumors and is considered a biomarker for malignant tumors and poor prognosis. Lactic acid can serve as a metabolic substrate to support the metabolic needs of tumor cells under hypoxic conditions, and it can also cause acidification of the tumor microenvironment, suppress immune cell function to promote immune evasion, and induce drug resistance in tumor cells. Currently, targeting lactic acid-lactylation and its related metabolic pathways has become a new research avenue for cancer treatment. In-depth exploration of the molecular mechanisms of lactic acid metabolism can help in screening lead compounds that regulate the lactic acid metabolism.
MCE contains 582 small molecule compounds targeting enzymes involved in lactic acid metabolism. This library is of significant value for researching the role of lactate metabolism in the mechanisms of diseases.
|
|
83
|
| HY-L208 | Bile Acids Library |
Bile acids are a class of amphiphilic molecules derived from the metabolic breakdown of cholesterol, primarily synthesized in the liver, and play a crucial role in the intestines. Based on their structural characteristics, bile acids are mainly divided into two categories: free bile acids (including Cholic acid, Deoxycholic acid, Chenodeoxycholic acid) and conjugated bile acids (including Glycocholic acid, Glycochenodeoxycholic acid, Taurocholic acid, etc.). Bile acids play a significant role in the pathophysiological research of liver and gastrointestinal diseases and are closely associated with the occurrence of metabolic diseases such as obesity, type II diabetes, non-alcoholic fatty liver disease, and atherosclerosis. Bile acids maintain metabolic balance within the body by regulating sugar metabolism, lipid metabolism, and amino acid metabolism, and they influence the activity of metabolism-related enzymes and transporters. In addition, Bile acids can also be used to construct a bile acid metabolism research platform, which helps to delve into the metabolic pathways and dynamic changes of bile acids in living organisms and aids in identifying new biomarkers for certain diseases.
MCE included 62 bile acids, including Cholic acid, Deoxycholic acid, Glycocholic acid, etc., which are effective tools for the study of liver and gallbladder diseases.
|
|
83
|
| HY-L213 | Anti-Cancer Approved Drug Library |
The anti-cancer drug library meticulously collects all drugs approved by FDA and other major national drug regulatory authorities for cancer treatment. These drugs cover a variety of cancer types, including but not limited to lung cancer, breast cancer, colorectal cancer, leukemia, and other common cancers. The library includes a wide range of drugs, from classic chemotherapeutic agents to cutting-edge targeted therapies and immunotherapies. It contains various types of drug compounds with different mechanisms of action. There are cytotoxic drugs that directly kill cancer cells, as well as drugs that work by modulating the tumor microenvironment, inhibiting tumor angiogenesis, and activating the immune system. This diversity provides researchers with a broad range of perspectives and options for intervention strategies.
This library can be used for basic research on cancer treatment, exploring new targets and new mechanisms of drug action; Conducting drug reuse research to look for potential therapeutic effects of existing drugs on other cancer types or diseases; Or conducting research into combination drugs to optimize cancer treatment.
MCE has collected 265 small-molecule compounds with cancer indications, which are good tools for drug repurposing.
|
|
83
|
| HY-L214 | Liposome Library |
Liposomes are spherical or multilayered spherical vesicles formed by the self-assembly of diacyl chain phospholipids (lipid bilayers) in aqueous solutions, which can be made from natural or synthetic phospholipids and exhibit good biocompatibility and low toxicity. They can serve as delivery carriers for various bioactive substances (such as drugs, proteins, nucleic acids, etc.) and are widely used in biomedical and chemical research. The main advantages of liposomes include 1) Protective effect: Their bilayer structure can protect encapsulated molecules from enzymatic degradation, oxidation, and other influences, extending stability and activity; 2) Active targeting: Surface modifications enable active targeting, enhancing the concentration of drugs or molecules in specific tissues or cells; 3) Customizability: The composition and structure of liposomes can be adjusted according to needs, such as altering phospholipid types or adding targeting ligands. These properties make liposomes highly valuable in developing novel drug delivery systems, serving as nucleic acid carriers for gene transfection, studying cellular uptake mechanisms and drug release kinetics, as well as developing functional food additives to improve the bioavailability of nutritional components.
MCE contains 227 liposome compounds, which is a good tool for drug delivery-related studies.
|
|
83
|
| HY-L219 | Antimicrobial Peptides Library |
Antimicrobial Peptides (AMPs), also known as antimicrobial peptides or antibiotic peptides, are a class of polypeptides encoded by specific genes in various biological cells and induced by external stimuli. They exhibit broad-spectrum bioactivity against bacteria, fungi, viruses, protozoa, and even tumor cells. AMPs serve as crucial effector molecules in the host's innate immune system.Due to their wide antimicrobial spectrum, low toxicity to normal cells of higher animals, high safety profile, low tendency to induce resistance, and additional benefits such as immune enhancement and antioxidant effects, antimicrobial peptides hold significant promise in new drug development.
MCE offers 58 types of antimicrobial peptides, which can be applied in high-throughput screening for research in anti-infection therapies, immunotherapy, anticancer drug development, and agricultural disease control.
|
|
83
|
| HY-L227 | Amino Acid Metabolite Compound Library |
Amino acids are the fundamental components that sustain life activities, playing roles in ATP generation, promoting nucleotide synthesis, and maintaining cellular redox balance. Moreover, dysregulation of amino acid consumption is a significant potential regulatory mechanism leading to impaired anti-tumor immunity in immune cells. The normal functioning of immune cells relies on amino acid metabolic pathways to obtain energy and materials, and upon activation, they reprogram their metabolism to support growth, proliferation, and effector functions. Additionally, metabolic disorders of specific amino acids (such as branched-chain amino acids, glutamine, and arginine) can exacerbate mitochondrial dysfunction and oxidative stress, thereby promoting myocardial fibrosis and cardiac cell damage. Therefore, conducting research related to amino acid metabolism holds promise for discovering potential drugs for diseases related to cancer, immunity, and metabolism.
MCE can provide 195 kinds of metabolites of amino acid metabolic pathways, which can be used for drug screening in various diseases such as cancer, immune disorders, metabolic diseases, mitochondrial-targeted diseases
|
|
83
|
| HY-L228 | Lipid Metabolite Compound Library |
Lipids are important energy storage substances in the human body. They are involved in the regulation of cell structure and function, as well as signaling pathways and gene expression. Abnormal lipid levels in tissues or their dysregulation can lead to various diseases. These include obesity, type 2 diabetes, non-alcoholic fatty liver disease, neurodegenerative diseases, infections, and cancer. Therefore, maintaining normal levels of lipid metabolism is critical to overall health.
One of the key features of cancer is aberrant lipid metabolism. This includes alterations in lipid uptake, lipid desaturation, neolipogenesis, lipid droplets, and fatty acid oxidation in cancer cells. These changes all contribute to cellular survival in an ever-changing microenvironment. They do this by modulating feed-forward oncogenic signals and key oncogenic functions. Additionally, they affect oxidative stress, other types of stress, immune responses, and intercellular communication. Alterations in lipid metabolism have a strong impact on the properties of cancer stem cells. This includes aspects such as self-renewal, differentiation, invasion, metastasis, drug sensitivity, and resistance. Furthermore, these alterations also modulate T cell responses.
MCE can offer 146 metabolites of lipid metabolism pathways, which can be used for drug screening in cancer, immune-based diseases, metabolic diseases, and other diseases.
|
|
83
|
| HY-L234 | Nucleotide Metabolite Compound Library |
Nucleotide metabolism is central to cancer aggressiveness, underpinning uncontrolled proliferation, chemotherapy resistance, immune evasion, and metastasis. It is transcriptionally regulated by oncogenes (e.g., MYC) and tumor suppressors (e.g., pRb). Nucleotide imbalance and nucleoside degradation further regulate cell state transitions, especially following replication stress. Additionally, secretion of nucleotides/nucleosides into the tumor microenvironment modulates immune responses and influences treatment efficacy. Therefore, nucleotide metabolites have roles in disease response and indication in cancer research, and can be utilized to develop cancer-related mechanisms and drugs.
MCE can provide 83 metabolites produced by nucleotide metabolic pathways, which can be used for disease mechanism research and drug research.
|
|
83
|
| HY-L235 | 20 Amino Acids Library |
Amino acids are indispensable building blocks for life activities and are widely involved in key biological processes such as cell signal transduction, energy metabolism, gene expression regulation, and neurotransmitter synthesis. As components of proteins, 20 kinds of amino acids make up over one million kinds of proteins in the human body. These amino acids can be classified into nine types of "essential amino acids" that the human body cannot synthesize on its own and must obtain from food, as well as eleven types of "non-essential amino acids" that the human body can synthesize on its own.
MCE offers 18 kinds of amino acids provided which can be applied in research fields such as the study of amino acid metabolic processes, metabolite identification, food/cosmetic ingredient research, and the development of nutritional supplements.
|
|
83
|
| HY-L249 | Lactylation Compound Library |
Protein lactylation, an emerging post-translational modification identified in recent years, plays a critical role in linking cellular metabolic reprogramming, epigenetic regulation, and signaling networks. Based on a systematic framework encompassing lactate metabolism, lactylation, and downstream signaling pathways, this compound library comprehensively targets multiple regulatory layers, including histone modification enzymes (such as p300 and HDACs), key glycolytic enzymes (such as PKM2, LDHA, and GAPDH), transcriptional regulators (such as STAT3, HMGB1, and p53), as well as central signaling pathway nodes including HIF-1α, NF-κB, and PI3K-AKT-mTOR. This integrated design enables a comprehensive representation of the regulatory roles of lactylation across the “metabolism–epigenetics–signaling” axis.
MCE has assembled a collection of 6,182 known bioactive compounds and potential functional molecules, making this library suitable for a wide range of applications, including high-throughput drug screening, inhibitor identification, and mechanistic studies. It can be used to systematically evaluate the functional roles of lactylation in biological processes such as tumor metabolism, immune regulation, and inflammatory responses, and to efficiently identify small-molecule candidates with regulatory potential, thereby facilitating the development of innovative therapeutics targeting the interplay between metabolism and epigenetic regulation.
|
|
83
|
| HY-L250 | Lactic Acid Metabolite Compound Library |
In the progression of various diseases, metabolic reprogramming has emerged as a key hallmark. Lactate, as an important metabolic signaling molecule, is widely involved in tumorigenesis, immune regulation, and inflammatory responses. Particularly within the tumor microenvironment, the abnormal accumulation of lactate not only affects cellular energy metabolism but also promotes disease progression by modulating immune cell functions and mediating protein lactylation, thereby participating in epigenetic regulation and signaling networks. Therefore, systematic investigation of lactate metabolic pathways and their associated metabolites is of great significance for understanding disease mechanisms and developing novel therapeutic strategies.
The MCE lactic acid metabolite compound library contains 61 compounds and is constructed around key metabolic pathways involving lactate production, transport, and utilization. This library systematically includes core intermediates from glycolysis, the tricarboxylic acid (TCA) cycle, and the lactate cycle. Focusing on disease-associated metabolic reprogramming, it is suitable for research in oncology, inflammation, and metabolic disorders. The library can be used to elucidate the roles of lactate in tumor microenvironment regulation, immune evasion, and epigenetic modifications (such as protein lactylation). In addition, it provides high-quality small-molecule resources for drug screening, facilitating the discovery of potential modulators targeting key enzymes (such as LDH) or transporters (such as MCTs) involved in lactate metabolism.
|
|
83
|
| HY-L252 | Carbohydrate Metabolite Compound Library |
Carbohydrate metabolism serves as a central hub for energy supply and biosynthesis in living organisms and plays a critical role in the onset and progression of various diseases. In recent years, studies have shown that tumor cells reprogram their energy metabolism through aerobic glycolysis (the Warburg effect) to support rapid proliferation. Immune cells also rely on specific carbohydrate metabolic pathways to regulate their activation and differentiation states, while disorders such as diabetes and metabolic syndrome arise directly from dysregulation of carbohydrate metabolism. In addition, enzymes and key metabolic nodes involved in carbohydrate metabolism have become important targets for drug discovery, and therapeutic strategies targeting glycolysis, the pentose phosphate pathway, and energy metabolism are continuously advancing the treatment of cancer and metabolic diseases. Therefore, systematic analysis of carbohydrate metabolic networks and their associated metabolites is of great significance for elucidating disease mechanisms and developing novel therapeutic approaches.
The MCE Carbohydrate Metabolism Metabolite Library is constructed based on classical carbohydrate metabolic pathways and contains 76 metabolites. It systematically integrates key metabolic networks, including glycolysis, the pentose phosphate pathway, the tricarboxylic acid (TCA) cycle, monosaccharide metabolism, and sugar acid interconversions. The library comprehensively covers core metabolic nodes from glucose uptake and utilization to energy production and biosynthesis, while also incorporating important upstream and downstream intermediates. It enables accurate representation of intracellular metabolic flux dynamics and is well suited for applications such as metabolic flux analysis, target validation, and mechanistic studies. Furthermore, it provides robust support for multi-omics integration and the development of precision intervention strategies.
|
|
83
|
| HY-L253 | Fungal-Sourced Compound Library |
For thousands of years, natural products have always been an important source for drug discovery. Fungi, due to their unique and diverse secondary metabolic capabilities, have become a valuable resource for natural active molecules. Since the discovery of penicillin, natural products derived from fungi have demonstrated significant application value in areas such as anti-infection, anti-tumor, immune regulation, and metabolic disease research. A large number of clinical drugs, such as antibiotics, immunosuppressants, and lipid-lowering drugs, are derived from fungal metabolites or their structurally optimized derivatives.
MCE fungal-derived compound library contains 91 structurally diverse and bioactive fungal natural products and their derivatives. It can be widely applied in various research fields such as antibacterial, anti-tumor, anti-inflammatory, immune regulation, epigenetics, and cell signaling pathways, providing high-quality tools for natural product drug development and high-throughput screening.
|
|
83
|
| HY-L260 | KRAS Targeted Compound Library |
KRAS (Kirsten Rat Sarcoma Viral Oncogene Homolog) is one of the most important oncogenic driver genes in oncology, with high mutation frequencies in pancreatic cancer, non‑small cell lung cancer, and colorectal cancer. For a long time, KRAS was considered "undruggable" due to the lack of suitable small‑molecule binding pockets on its protein surface. In recent years, with the discovery of the switch‑II pocket and the successful approval of KRAS G12C inhibitors, KRAS‑targeted research has achieved groundbreaking progress, which has also spurred a wave of development targeting non‑G12C mutants such as G12D and G12V, as well as upstream and downstream regulatory factors including SOS1 and SHP2.
MCE KRAS Targeted Compound Library contains 82 small‑molecule compounds targeting the KRAS, serving as high‑quality research tools for mechanistic studies of KRAS‑mutant tumors, combination therapy development, resistance mechanism exploration, and high‑throughput drug screening, thereby providing robust support for KRAS‑targeted drug discovery.
|
|
83
|
| HY-L263 | Energy Metabolites Library |
Energy metabolism is the most fundamental biochemical process in living organisms, encompassing glycolysis, the TCA cycle, oxidative phosphorylation, the pentose phosphate pathway, and fatty acid oxidation. These core pathways directly regulate cell survival, proliferation, differentiation, and apoptosis. Dysregulation of energy metabolism is closely linked to major diseases including cancer, diabetes, obesity, cardiovascular diseases, neurodegenerative disorders, and ischemia‑reperfusion injury. Targeting these metabolic pathways has become a frontier in drug discovery and mechanistic research.
The MCE Energy Metabolite Compound Library features 89 structurally defined small‑molecule compounds. It covers energy substrates, pathway intermediates, coenzymes and redox carriers, nucleotide derivatives, and microenvironmental modulators. This library is applicable to research areas including tumor metabolism, insulin resistance, mitochondrial dysfunction, oxidative stress, neuroprotection, and cardiometabolic diseases, providing a high‑quality tool for mechanistic studies, biomarker discovery, and high‑throughput drug screening.
|
|
83
|
| HY-10585B | Valproic acid sodium (2:1) |
Valproic acid (VPA) sodium (2:1) is an orally active HDAC inhibitor, with IC50 in the range of 0.5 and 2 mM, also inhibits HDAC1 (IC50, 400 μM), and induces proteasomal degradation of HDAC2. Valproic acid sodium (2:1) activates Notch1 signaling and inhibits proliferation in small cell lung cancer (SCLC) cells. Valproic acid sodium (2:1) is used in the treatment of epilepsy, bipolar disorder, metabolic disease, HIV infection and prevention of migraine headaches.
|
|
70
|
| HY-10585A | Valproic acid sodium |
Valproic acid (Sodium Valproate) sodium is an orally active HDAC inhibitor, with IC50 in the range of 0.5 and 2 mM, also inhibits HDAC1 (IC50, 400 μM), and induces proteasomal degradation of HDAC2. Valproic acid sodium activates Notch1 signaling and inhibits proliferation in small cell lung cancer (SCLC) cells. Valproic acid sodium is used in the treatment of epilepsy, bipolar disorder, metabolic disease, HIV infection and prevention of migraine headaches.
|
|
70
|
| HY-10585 | Valproic acid |
Valproic acid (VPA) is an orally active HDAC inhibitor, with IC50 in the range of 0.5 and 2 mM. Valproic acid inhibits HDAC1 (IC50, 400 μM), and induces proteasomal degradation of HDAC2. Valproic acid activates Notch1 signaling and inhibits proliferation in small cell lung cancer (SCLC) cells. Valproic acid is used in the epilepsy, bipolar disorder, metabolic disease, HIV infection and prevention of migraine headaches.
|
Infection
Neurological, Eye or Ear Disease
Metabolic or Endocrine Disease
Respiratory Disease
Small Cell Lung Cancer
|
70
|
| HY-B0445A | NAD sodium |
NAD sodium is an orally effective cofactor and homeostatic regulator. NAD sodium can be reduced to β-nicotinamide adenine dinucleotide (NADH) during coupling with reactions that oxidize organic substrates. NAD sodium can be converted to β-nicotinamide adenine dinucleotide (NADH) and passes to the inside of mitochondria, which indirectly generates ATP. NAD sodium can be used for the research of non-alcoholic fatty liver disease, obesity, and glucose intolerance.
|
|
53
|
| HY-10191 | Linsitinib |
Linsitinib (OSI-906) is a potent, selective and orally bioavailable dual inhibitor of the IGF-1 receptor and insulin receptor (IR) with IC50s of 35 and 75 nM, respectively.
|
|
52
|
| HY-114118B | Semaglutide acetate |
Semaglutide acetate is a long-acting, selective, competitive GLP-1R agonist that can penetrate the blood-brain barrier. After activating GLP-1R, Semaglutide acetate promotes insulin secretion, inhibits gastric emptying and appetite, and at the same time enhances autophagy, inhibits oxidative stress and apoptosis. Semaglutide acetate also regulates mitochondrial function and lipid metabolism (such as reducing de novo lipogenesis in the liver). Semaglutide acetate has activities such as lowering blood sugar, reducing weight, neuroprotection (such as improving motor function in Parkinson's disease models, reducing α-synuclein aggregation) and improving hepatic steatosis. Semaglutide acetate can be used for the study of neurodegenerative diseases and liver diseases such as type 2 diabetes, obesity, Parkinson's disease, metabolic associated fatty liver disease (MASLD), and cancer.
|
|
50
|
| HY-114118A | Semaglutide TFA |
Semaglutide TFA is a long-acting, selective, competitive GLP-1R agonist that can penetrate the blood-brain barrier. After activating GLP-1R, Semaglutide TFA promotes insulin secretion, inhibits gastric emptying and appetite, and at the same time enhances autophagy, inhibits oxidative stress and apoptosis. Semaglutide TFA also regulates mitochondrial function and lipid metabolism (such as reducing de novo lipogenesis in the liver). Semaglutide TFA has activities such as lowering blood sugar, reducing weight, neuroprotection (such as improving motor function in Parkinson's disease models, reducing α-synuclein aggregation) and improving hepatic steatosis. Semaglutide TFA can be used for the study of neurodegenerative diseases and liver diseases such as type 2 diabetes, obesity, Parkinson's disease, metabolic associated fatty liver disease (MASLD), and cancer.
|
|
50
|
| HY-114118 | Semaglutide |
Semaglutide is a long-acting, selective, competitive GLP-1R agonist that can penetrate the blood-brain barrier. After activating GLP-1R, Semaglutide promotes insulin secretion, inhibits gastric emptying and appetite, and at the same time enhances autophagy, inhibits oxidative stress and apoptosis. Semaglutide also regulates mitochondrial function and lipid metabolism (such as reducing de novo lipogenesis in the liver). Semaglutide has activities such as lowering blood sugar, reducing weight, neuroprotection (such as improving motor function in Parkinson's disease models, reducing α-synuclein aggregation) and improving hepatic steatosis. Semaglutide can be used for the study of neurodegenerative diseases and liver diseases such as type 2 diabetes, obesity, Parkinson's disease, metabolic associated fatty liver disease (MASLD), and cancer.
|
|
50
|
| HY-15656 | Ceritinib |
Metabolic or Endocrine Disease
Respiratory Disease
Prostate Cancer
Leukemia/Lymphoma/Myeloma
Pancreatic Cancer
Non-Small Cell Lung Cancer
|
43
|
|
| HY-18569A | Sodium 2-(1H-indol-3-yl)acetate |
3-Indoleacetic acid sodium is is an IAA hormone and growth regulator that can promote plant nutritional growth through processes such as cell expansion, differentiation, morphogenesis, and organogenesis.
|
|
25
|
| HY-18569 | 3-Indoleacetic acid |
3-Indoleacetic acid is is an IAA hormone and growth regulator that can promote plant nutritional growth through processes such as cell expansion, differentiation, morphogenesis, and organogenesis.
|
|
25
|
| HY-W000450 | 5-Aminolevulinic acid |
5-Aminolevulinic acid (5-ALA; δ-Aminolevulinic acid; 5-Amino-4-oxopentanoic acid) is an orally active heme precursor. 5-Aminolevulinic acid promotes aerobic energy metabolism and increases ATP levels by enhancing the activity of cytochrome c oxidase. 5-Aminolevulinic acid enhances LPS-induced proinflammatory cytokine production and gene activation, and restores the phagocytic activity and ROS generation capacity of neutrophils. 5-Aminolevulinic acid selectively accumulates protoporphyrin IX in tumor cells; as a photosensitizer and radiosensitizer, it induces ROS burst upon light or X-ray irradiation to inhibit tumor growth. 5-Aminolevulinic acid can be applied to the research of septic shock, melanoma, and cancer radiotherapy.
|
|
21
|
| HY-N0140 | Ursolic acid |
Ursolic acid (Prunol) is a natural pentacyclic triterpenoid carboxylic acid, exerts anti-tumor effects and is an effective compound for cancer prevention and therapy.
|
|
21
|
| HY-N0305 | 5-Aminolevulinic acid hydrochloride |
5-Aminolevulinic acid (5-ALA; δ-Aminolevulinic acid; 5-Amino-4-oxopentanoic acid) hydrochloride is an orally active heme precursor. 5-Aminolevulinic acid hydrochloride promotes aerobic energy metabolism and increases ATP levels by enhancing the activity of cytochrome c oxidase. 5-Aminolevulinic acid hydrochloride enhances LPS-induced proinflammatory cytokine production and gene activation, and restores the phagocytic activity and ROS generation capacity of neutrophils. 5-Aminolevulinic acid hydrochloride selectively accumulates protoporphyrin IX in tumor cells; as a photosensitizer and radiosensitizer, it induces ROS burst upon light or X-ray irradiation to inhibit tumor growth. 5-Aminolevulinic acid hydrochloride can be applied to the research of septic shock, melanoma, and cancer radiotherapy.
|
Metabolic or Endocrine Disease
Colorectal Cancer
Melanoma
Digestive System Inflammation
Glioblastoma
Alzheimer's Disease
|
21
|
| HY-P1156 | Insulin(cattle) |
|
17
|
|
| HY-106224A | Orexin A (human, rat, mouse) TFA |
Orexin A (human, rat, mouse) (Hypocretin-1 (human, rat, mouse)) TFA, a 33 amino acid excitatory neuropeptide, orchestrates diverse central and peripheral processes. Orexin A (human, rat, mouse) TFA binds and activates two types of G protein-coupled receptors, the orexin-1 receptor (OX1R) and the orexin-2 receptor (OX2R). Orexin A (human, rat, mouse) TFA has a role in the regulation of feeding behavior. Orexin A (human, rat, mouse) TFA is an effective anti-nociceptive and anti-hyperalgesic agent in mice and rats.
|
|
13
|
| HY-106224 | Orexin A (human, rat, mouse) |
Orexin A (human, rat, mouse) (Hypocretin-1 (human, rat, mouse)), a 33 amino acid excitatory neuropeptide, orchestrates diverse central and peripheral processes. Orexin A (human, rat, mouse) binds and activates two types of G protein-coupled receptors, the orexin-1 receptor (OX1R) and the orexin-2 receptor (OX2R). Orexin A (human, rat, mouse) has a role in the regulation of feeding behavior. Orexin A (human, rat, mouse) is an effective anti-nociceptive and anti-hyperalgesic agent in mice and rats.
|
|
13
|
| HY-19870C | Setmelanotide monoacetate |
Setmelanotide monoacetate (RM-493 monoacetate) is a blood-brain barrier-permeable, selective MC4R agonist with a Ki value of 2.1 nM for hMC4R. Setmelanotide monoacetate activates the CaMKK2/AMPK signaling pathway. Setmelanotide monoacetate mediates body weight homeostasis, feeding regulation and energy expenditure modulation; it reduces food intake, induces weight loss, decreases obesity severity, increases daytime activity and energy expenditure, lowers levels of leptin, triglycerides, fasting insulin and diastolic blood pressure, improves insulin sensitivity, glucose tolerance and fatty liver condition, and reverses respiratory depression. Setmelanotide monoacetate is applicable to research related to obesity, hyperinsulinemia, fatty liver and respiratory depression.
|
|
8
|
| HY-N0391A | L-Citrulline DL-malate |
L-Citrulline (DL-malate) is an organic compound commonly used as a nutritional supplement. It boosts the body's production of nitrogen oxides, improves circulation and athletic performance, and reduces muscle fatigue. In addition, L-Citrulline DL-malate also plays an important role in some industrial fields, for example, it is used in the field of agriculture to enhance plant immunity.
|
|
7
|
| HY-N0681 | D-Pantothenic acid hemicalcium salt |
D-Pantothenic acid hemicalcium salt is an orally active vitamin that reduces patulin in apple juice. D-Pantothenic acid hemicalcium salt removes ROS. D-Pantothenic acid hemicalcium salt has antibacterial and immunomodulatory activities. D-Pantothenic acid hemicalcium salt also has the effect of improving osteoporosis and obesity.
|
Metabolic or Endocrine Disease
Mycobacterium Tuberculosis Infection
Experimental Autoimmune Encephalomyelitis
Experimental Autoimmune Encephalomyelitis
|
7
|
| HY-W051723 | (R)-3-Hydroxybutanoic acid |
(R)-3-Hydroxybutanoic acid is a metabolite, and converted from acetoacetic acid catalyzed by 3-hydroxybutyrate dehydrogenase. (R)-3-Hydroxybutanoic acid has applications as a nutrition source and as a precursor for vitamins, antibiotics and pheromones.
|
|
7
|
| HY-W015851 | (R)-3-Hydroxybutanoic acid sodium |
(R)-3-Hydroxybutanoic acid ((R)-3-Hydroxybutyric acid) sodium is a metabolite converted from acetoacetic acid catalyzed by 3-hydroxybutyrate dehydrogenase. (R)-3-Hydroxybutanoic acid sodium can function as a nutrition source, and as a precursor for vitamins, antibiotics and pheromones.
|
|
7
|
| HY-P70704 | Leptin Protein, Mouse |
Leptin Protein, Mouse is a hormone secreted by fat cells that helps to regulate energy balance by inhibiting feeding and increase thermogenesis.
Species: Mouse; Source: E. coli |
|
7
|
| HY-N9933 | Tauro-β-muricholic acid |
Tauro-β-muricholic acid (TβMCA) is an orally active trihydroxylated bile acid and a competitive, reversible FXR antagonist (IC50=40 μM). Tauro-β-muricholic acid inhibits bile acid-induced hepatocyte apoptosis by maintaining mitochondrial membrane potential, while simultaneously inhibiting intestinal FXR signaling, affecting bile acid synthesis, hepatic lipid metabolism, and insulin sensitivity. Accumulation of tauro-β-muricholic acid disrupts metabolic homeostasis, promoting cancer stem cell proliferation and tumor progression. The mechanisms of tauro-β-muricholic acid involve two aspects: first, inhibiting the translocation of the pro-apoptotic protein Bax to mitochondria and maintaining mitochondrial membrane potential (MMP); and second, blocking the FXR signaling pathway to regulate bile acid metabolism, reduce serum ceramide production, and downregulate the hepatic SREBP1C/CIDEA pathway. Tauro-β-muricholic acid possesses anti-hepatocyte apoptosis, bile acid homeostasis regulation, and liver fat accumulation reduction properties, and also functions as a biomarker, making it useful in the study of diseases such as bile acid metabolism disorders, non-alcoholic fatty liver disease, colorectal cancer, and liver fibrosis.
Source: rat |
|
6
|
| HY-N0587 | Demethylzeylasteral |
Demethylzeylasteral is an orally active triterpenoid compound isolated from Tripterygium wilfordii, which has functions such as anti-inflammatory, anti-tumor, anti fertility, estrogen metabolism regulation, immune suppression, and immune system regulation .
|
Colorectal Cancer
Prostate Cancer
Liver Cancer
Leukemia/Lymphoma/Myeloma
Pancreatic Cancer
Ovarian Cancer
Depression
Pain
Digestive System Inflammation
Cardiovascular Disease
Triple-Negative Breast Cancer
Obesity
Lung Fibrosis
|
6
|
| HY-W250303A | Malic acid disodium hydrate |
Malic acid disodium hydrate is an organic compound that is commonly used as a food additive, buffering agent, and nutritional supplement. It contains sodium and malic acid. Malic acid disodium hydrate has a variety of properties that make it suitable for these applications, including the ability to enhance food flavor, improve texture, and regulate acidity. In addition, due to its potential health benefits, including improved energy production, reduced fatigue, and enhanced athletic performance, Malic acid disodium hydrate can be used as a dietary supplement.
|
|
5
|
| HY-W250303 | Malic acid disodium salt |
Sodium DL-Malate is an organic compound commonly used as a food additive, buffer and nutritional supplement. It contains sodium and malic acid. Malic acid disodium salt has several properties suitable for these applications, including the ability to enhance food flavor, improve texture and regulate acidity. Additionally, it can be used as a dietary supplement due to its potential health benefits, including improved energy production, reduced fatigue, and enhanced athletic performance.
|
|
5
|
| HY-137808 | Succinyl-Coenzyme A sodium |
Succinyl CoA (Succinyl-coenzyme A) sodium is a pivotal intermediate metabolite in the tricarboxylic acid cycle and a key coenzyme A metabolite. Succinyl CoA sodium is biosynthesized from α-ketoglutarate or propionyl-CoA. Succinyl CoA sodium acts as a critical precursor and substrate for heme biosynthesis and gluconeogenesis. Succinyl CoA sodium insufficiency caused by cobalamin deficiency is directly linked to growth retardation, impaired heme synthesis, tissue glycine accumulation and neurological abnormalities. Succinyl CoA sodium can be used in research on metabolic, neurological, and hematological abnormalities (such as porphyria) caused by nutritional vitamin B12 deficiency (leading to a lack of Succinyl-Coenzyme A synthesis).
|
|
5
|
| HY-N2821 | (+)-Afzelechin |
(+)-Afzelechin, isolated from rhizomes of Bergenia ligulata, is an alpha-glucosidase activity inhibitor with an ID50 (50% inhibition dose) value of 0.13 mM. (+)-Afzelechin can delay the absorption of carbohydrates in food to suppress postprandial hyperglycemia and hyperinsulinemia.
|
|
4
|
| HY-112173 | Prolylleucine |
Prolylleucine (Z-Pro-D-Leu) is a dipeptide containing branched-chain amino acids. Prolylleucine (Z-Pro-D-Leu) can affect the circadian rhythms and behaviour of animals.
|
|
4
|
| HY-B1071A | Lasalocid sodium |
Lasalocid sodium (Lasalocid sodium-A) is an antibacterial and anticoccidial agent that can be used as feed additives. Lasalocid sodium exhibits antitumor activity. Lasalocid sodium is orally active.
Source: Streptomyces lasaliensis |
Cancer
Digestive System Disease
Bacterial Infection
Parasitic Infection
Digestive System Inflammation
|
4
|
| HY-139109 | IR-783 |
IR-783 (ADS 780WS) is a heptamethine cyanine dye. IR-783 induces Mitochondrial membrane potential loss, ATP depletion, mitochondrial permeability transition pore opening, Cytochrome c release and Apoptosis in breast cancer cells. IR-783 promotes the translocation of Drp1 from the cytosol to mitochondria. IR-783 increases the expression of mitochondrial fission proteins such as MFF and Fission-1. IR-783 possesses imaging, cancer-targeting and anticancer properties. IR-783 exerts anticancer effects against breast cancer. IR-783 can be used in breast cancer-related research.
|
|
4
|
| HY-B1071 | Lasalocid |
Lasalocid (Lasalocid-A) is an antibacterial and anticoccidial agent that can be used as feed additives. Lasalocid exhibits antitumor activity. Lasalocid is orally active.
Source: Streptomyces lasaliensis |
|
4
|
| HY-113081 | 1-Methyladenosine |
1-Methyladenosine is an RNA modification that can serve as a tumor marker, with elevated levels in the body associated with cancer development. Following 1-methyladenosine methylation, upregulation of PPARδ expression regulates cholesterol metabolism and activates Hedgehog signaling pathway, driving liver tumorigenesis.
|
|
4
|
| HY-N5034 | Phosphorylethanolamine |
Phosphorylethanolamine (Monoaminoethyl phosphate) is a membrane phospholipid and an important precursor of Phosphatidylcholine (HY-N18891). It is found in most animal tissues and various human extracranial tumors, playing a critical role in membrane integrity, cell division, mitochondrial respiratory function, and more. Studies have shown that changes in the abundance of Phosphorylethanolamine are associated with Alzheimer's disease and Parkinson's disease. Lowering the ratio of Phosphorylethanolamine to Phosphatidylcholine in the liver can improve insulin signaling. Phosphorylethanolamine holds promise for research in the fields of cancer, neurodegenerative disorders, and metabolic diseases.
|
|
4
|
| HY-150012 | N-Lactoyl-phenylalanine |
N-Lactoyl-phenylalanine, a N-lactoyl-amino acid, is a blood-derived signaling metabolite that can be induced by exercise. N-Lactoyl-phenylalanine can reduce obesity and improve glucose tolerance.
|
|
4
|
| HY-Y0520 | Itaconic acid |
Itaconic acid, a precursor of polymers, chemicals, and fuels, can be synthesized by many fungi. Itaconic acid also is a macrophage-specific metabolite. Itaconic acid mediates crosstalk between macrophage metabolism and peritoneal tumors. Itaconic acid has anti-inflammatory, anti-microbial and immunomodulatory effect.
|
|
4
|
| HY-N5027 | Oxyberberine |
Oxyberberine (Oxyberberin; Berlambine) is an orally effective heme oxygenase HO-1 agonist that can activate antioxidant mechanisms by regulating the PI3K/Akt/AMPK signaling pathway. Oxyberberine induces HO-1 expression, increases SOD and GSH-Px activity, inhibits NF-κB-mediated inflammatory responses, and improves insulin sensitivity and glucose metabolism. Oxyberberine has anti-diabetic, neuroprotective, anti-inflammatory and antioxidant effects, and can be used to study type 2 diabetes, traumatic brain injury (TBI) and inflammatory bowel disease.
|
Infection
Neurological, Eye or Ear Disease
Inflammation or Immune System Disease
Glucose Metabolism
Obesity
|
3
|
| HY-N10473 | Pulcherriminic acid |
Pulcherriminic acid is a cyclic dipeptide antimicrobial agent with high affinity for Fe3+, found mainly in Bacillus and yeast. Pulcherriminic acid chelates iron ions through a non-enzymatic reaction to form the extracellular red pigment pulcherrimin, which competes for iron nutrition and thus achieves an antibacterial effect. Pulcherriminic acid has great applications in food, agriculture and medical industries.
Source: Bacillus and yeast |
|
3
|
| HY-N0658 | L-Threonine |
L-Threonine is a natural amino acid, can be produced by microbial fermentation, and is used in food, medicine, or feed.
|
|
3
|
| HY-164992 | Trastuzumab vedotin |
Trastuzumab vedotin (MRG002; Trastuzumab MMAE) is an antibody-drug conjugate and cytotoxin targeting HER2, with a Kd of 7.50E-11 M for human HER2. After binding to HER2, Trastuzumab vedotin undergoes internalization and lysosomal trafficking, delivering a cytotoxic payload to HER2-expressing cells and inducing tumor regression in in vivo xenograft models with HER2-expressing tumors. The anti-tumor activity of Trastuzumab vedotin is enhanced when used in combination with anti-PD-1 antibodies, and it exhibits preclinical anti-tumor activity in drug-resistant breast cancer, gastric cancer, and urothelial carcinoma PDX models. Trastuzumab vedotin has low antibody-dependent cellular cytotoxicity activity and can be used in studies related to HER2-positive breast cancer, HER2-positive gastric cancer, and unresectable locally advanced or metastatic HER2-positive urothelial carcinoma.
|
|
3
|
| HY-P10138 | human GIP(3-30), amide |
Human GIP(3-30), amide is a high affinity antagonist of the human GIP receptor in vitro. Human GIP(3-30), amide has potential anti-obesity and anti-diabetic effects.
|
|
3
|
| HY-P3462A | Cagrilintide acetate |
Cagrilintide acetate is a non-selective AMYR/CTR agonist and long-acting acylated amylase analogue. Cagrilintide acetate causes a reduction in food intake and significant weight loss in a dose-dependent manner. Cagrilintide acetate can be used in obesity studies.
|
|
3
|
| HY-P0276 | GIP, human |
GIP, human, a peptide hormone consisting of 42 amino acids, is a stimulator of glucose-dependent insulin secretion and a weak inhibitor of gastric acid secretion. GIP, human acts as an incretin hormone released from intestinal K cells in response to nutrient ingestion.
|
|
3
|
| HY-P7232 | Leptin Protein, Human |
Leptin is a cytokine-like sugar secretory protein secreted by adipocytes that helps regulate energy balance by inhibiting food intake and increasing thermogenesis. Leptin can activate the JAK2-STAT3 and PI3K-AKT/mTOR pathways to regulate energy metabolism, prolong the QT interval via MAPK in the myocardium, and play a protective role in the gastric mucosa by inducing NO/CGRP release via the vagus nerve. Circulating CRP protein binds to leptin and blocks signal transduction, leading to obesity resistance. Leptin Protein, Human is a recombinant human Leptin protein expressed by E. coli without a tag.
Species: Human; Source: E. coli |
|
3
|
| HY-P1723A | Spexin TFA |
Spexin (Neuropeptide Q) TFA is a selective agonist of galanin receptors GAL2 and GAL3, and is a conserved peptide that functions as a neurotransmitter/neuromodulator and endocrine factor. Spexin TFA can function through both central and peripheral actions. Spexin TFA upregulates Beclin 1 to inhibit ferroptosis induced by excessive autophagy, reduces the uptake of long-chain fatty acids by adipocytes, and regulates energy metabolism by increasing lipid oxidation (e.g., reducing the respiratory exchange ratio in rodents). Spexin TFA improves cardiac function in the Doxorubicin hydrochloride (HY-15142)-induced cardiotoxicity model, protects mitochondrial membrane potential, and reduces iron accumulation and lipid peroxidation. Spexin TFA can be used to study obesity and its related metabolic disorders, cardiovascular diseases (e.g., cardioprotection), and side effects of tumor chemotherapy.
|
|
2
|
| HY-13673 | Goserelin |
Goserelin (ICI 118630), a decapeptide analogue of gonadotropin-releasing hormone (GnRH/LHRH), functions as a GnRH agonist. Goserelin can be used for the research of breast cancer, epithelial ovarian cancer and prostate cancer.
|
Metabolic or Endocrine Disease
Luminal Breast Cancer
Triple-Negative Breast Cancer
Metastatic Breast Cancer
|
2
|
| HY-P0254A | Kisspeptin-10, human TFA |
Kisspeptin-10, human TFA is a potent vasoconstrictor and inhibitor of angiogenesis. Kisspeptin-10, human TFA acts as a tumor metastasis suppressor via its receptor GPR54. Kisspeptin-10-GPR54 system plays an important role in embryonic kidney development. Kisspeptin-10/GPR54 signaling induces osteoblast differentiation via NFATc4-mediated BMP2 expression.
|
|
2
|
| HY-N0325 | DL-Methionine |
DL-Methionine is an essential amino acid containing sulfur with oxidative stress defense effects. DL-Methionine can be used for animal natural feed. DL-Methionine also kills H. rostochiensis on potato plants.
|
|
2
|
| HY-N7255 | Cycloartenol |
Cycloartenol, a phytosterol compound, is one of the key precusor substances for biosynthesis of numerous sterol compounds. Cycloartenol inhibits the migration of glioma cells and suppresses the phosphorylation of the p38 MAP kinase. Cycloartenol has a variety of pharmacological activities such as anti-inflammatory, anti-tumor, antioxidant, antibiosis and anti-alzheimer's disease. Cycloartenol also plays an important role in the process of plant growth and development.
|
|
2
|
| HY-P1723 | Spexin |
Spexin (Neuropeptide Q) is a selective agonist of galanin receptors GAL2 and GAL3, and is a conserved peptide that functions as a neurotransmitter/neuromodulator and endocrine factor. Spexin can function through both central and peripheral actions. Spexin upregulates Beclin 1 to inhibit ferroptosis induced by excessive autophagy, reduces the uptake of long-chain fatty acids by adipocytes, and regulates energy metabolism by increasing lipid oxidation (e.g., reducing the respiratory exchange ratio in rodents). Spexin improves cardiac function in the Doxorubicin hydrochloride (HY-15142)-induced cardiotoxicity model, protects mitochondrial membrane potential, and reduces iron accumulation and lipid peroxidation. Spexin can be used to study obesity and its related metabolic disorders, cardiovascular diseases (e.g., cardioprotection), and side effects of tumor chemotherapy.
|
|
2
|
| HY-B1278A | DL-α-Tocopherol acetate |
DL-α-Tocopherol acetate is a vitamin E derivative which is often included in the formulations of enteral nutrition.
|
|
2
|
| HY-32349 | Ercalcidiol |
Ercalcidiol is a metabolite of vitamin D2, is regarded as an indicator of vitamin D nutritional status.
|
|
2
|
| HY-P0254 | Kisspeptin-10, human |
Kisspeptin-10, human is a potent vasoconstrictor and inhibitor of angiogenesis. Kisspeptin-10, human acts as a tumor metastasis suppressor via its receptor GPR54. Kisspeptin-10-GPR54 system plays an important role in embryonic kidney development. Kisspeptin-10/GPR54 signaling induces osteoblast differentiation via NFATc4-mediated BMP2 expression.
|
|
2
|
| HY-A0183 | Phosphatidylserine |
Phosphatidylserine (Phospholipids) is a well-conserved anti-inflammatory and immunosuppressive signal. Phosphatidylserine is involved in membrane translocation and the activation of protein kinase C, participating in Akt signaling through its interaction with PIP3. The local exposure of Phosphatidylserine can interact with complement and other proteins, promoting microglial phagocytosis during critical periods of synaptic refinement. Phosphatidylserine can promote blood coagulation in the extracellular environment and acts as a "eat me" signal to clear out apoptotic cells. Phosphatidylserine can suppress inflammation in tissues by inducing TGF-β secretion and inhibiting immune responses.
Source: Most organisms |
|
2
|
| HY-Y1103A | Iron(II) sulfate heptahydrate, for cell culture, 99% |
Iron(II) sulfate heptahydrate, for cell culture, 99% (Ferrous sulfate heptahydrate, for cell culture, 99%) is an orally active iron salt. Iron(II) sulfate heptahydrate, for cell culture, 99% replaces iron found in hemoglobin and myoglobin, allowing for the transportation of oxygen via hemoglobin. Iron(II) sulfate heptahydrate, for cell culture, 99% is mainly used for the prevention of iron-deficiency anemia. Iron(II) sulfate heptahydrate, for cell culture, 99% also has anti-tumor effects on chronic myeloid leukemia and breast cancer.
|
|
2
|
| HY-Y1103 | Iron(II) sulfate heptahydrate, 99% |
Iron(II) sulfate heptahydrate, 99% (Ferrous sulfate heptahydrate, 99%) is an orally active iron salt. Iron(II) sulfate heptahydrate, 99% replaces iron found in hemoglobin and myoglobin, allowing for the transportation of oxygen via hemoglobin. Iron(II) sulfate heptahydrate, 99% is mainly used for the prevention of iron-deficiency anemia. Iron(II) sulfate heptahydrate, 99% also has anti-tumor effects on chronic myeloid leukemia and breast cancer.
|
|
2
|
| HY-P7233 | Leptin Protein, Rat |
Leptin Protein, Rat is a hormone secreted by fat cells that helps to regulate energy balance by inhibiting feeding and increase thermogenesis.
Species: Rat; Source: E. coli |
|
2
|
| HY-N6612A | D-Glucuronic acid sodium salt monohydrate |
D-Glucuronic acid sodium salt monohydrate is a major component of many anti-inflammatory proteoglycans, which can promote embryonic development and inhibit cell aggregation. After being metabolized into ethyl glucuronide (HY-113093), D-Glucuronic acid sodium salt monohydrate activates Toll-like receptor 4 (TLR4), causing pain. D-Glucuronic acid sodium salt monohydrate and its derivative glucurono-lactone can serve as liver detoxifiers, and its derivatives also possess anti-tumor activity.
|
|
1
|
| HY-10585S3 | Valproic acid-d4 sodium |
Valproic acid-d4 (sodium) is the deuterium labeled Valproic acid. Valproic acid (VPA; 2-Propylpentanoic Acid) is an HDAC inhibitor, with IC50 in the range of 0.5 and 2 mM, also inhibits HDAC1 (IC50, 400 μM), and induces proteasomal degradation of HDAC2. Valproic acid activates Notch1 signaling and inhibits proliferation in small cell lung cancer (SCLC) cells. Valproic acid sodium salt is used in the treatment of epilepsy, bipolar disorder and prevention of migraine headaches.
|
|
1
|
| HY-W127601 | Lard oil |
Lard oil is an orally active biochemical reagent. Lard oil upregulates PERK, eIF2a, CHOP, OPN, TLR2, TLR4, TNF-α, and downregulates GRP78 and IRE1a. Lard oil induces responses such as body fat accumulation, elevated serum insulin levels, increased HOMA-IR, hepatic ectopic lipid deposition, hepatic endoplasmic reticulum stress, and hepatic inflammation. Lard oil can be used in studies related to diet-induced obesity, insulin resistance, and non-alcoholic fatty liver disease.
|
Biochemical Assay Reagents
PERK
Eukaryotic Initiation Factor (eIF)
Toll-like Receptor (TLR)
TNF Receptor
IRE1
|
1
|
| HY-10585S | Valproic acid-d4 |
Valproic acid-d4 is the deuterium labeled Valproic acid. Valproic acid (VPA; 2-Propylpentanoic Acid) is an HDAC inhibitor, with IC50 in the range of 0.5 and 2 mM, also inhibits HDAC1 (IC50, 400 μM), and induces proteasomal degradation of HDAC2. Valproic acid activates Notch1 signaling and inhibits proliferation in small cell lung cancer (SCLC) cells. Valproic acid sodium salt is used in the treatment of epilepsy, bipolar disorder and prevention of migraine headaches.
|
|
1
|
| HY-163001 | Microcolin H |
Microcolin H is a marine lipopeptide and phosphatidylinositol transfer protein ligand that targets PITPα/β. Microcolin H increases the conversion of LC3I to LC3II and reduces p62 levels in cancer cells, leading to autophagy cell death (Autophagy). Microcolin H effectively inhibits tumor development and has anti-proliferative activity in nude mouse subcutaneous tumor models.
Source: Moorea producens |
|
1
|
| HY-B1340 | Carbadox |
Carbadox is a quinoxaline-di-N-oxide antibiotic compound which is widely fed to nursery-age pigs to control enteric diseases and improve feed efficiency.
|
|
1
|
| HY-N0479 | Licarin B |
|
1
|
|
| HY-113440 | 5-Methoxytryptophol |
5-Methoxytryptophol is a 5-methoxyindole alcohol structurally homologous to Melatonin (HY-B0075). It is secreted by the mammalian pineal gland and exhibits an inverse circadian rhythm. 5-Methoxytryptophol regulates bone metabolism by activating the ERK1/2 pathway. It reduces the levels of pro-inflammatory cytokines TNF-α and IL-1β, as well as proteolytic enzymes MMP-1 and MMP-2, in serum and dental pulp tissues, thereby ameliorating acute pulpitis. 5-Methoxytryptophol induces rapid sleep in mice, while high doses cause respiratory depression and death. 5-Methoxytryptophol. 5-Methoxytryptophol can be used in studies related to acute pulpitis, hypnosis, and bone metabolism.
|
|
1
|
| HY-B2243B | Anhydrous sodium dihydrogen phosphate, for molecular biology |
Anhydrous sodium dihydrogen phosphate, for molecular biology is an inorganic salt compound that can be used as a buffer and nutritional supplement. Anhydrous sodium dihydrogen phosphate, for molecular biology can be used in molecular biology experiments.
|
|
1
|
| HY-P2543 | Neuropeptide Y (3-36) (human, rat) |
Neuropeptide Y (3-36) (human, rat) is a neuropeptide Y fragment derived from humans or rats. Neuropeptide Y is an extremely abundant neurotransmitter in central and peripheral neurons, and it participates in the regulation of psychomotor activity, circadian rhythm, feeding behavior and cardiovascular function. Neuropeptide Y (3-36) (human, rat) can serve as a substrate to be sequentially degraded from its N-terminus by AfuS28, and it requires binding to AfuS28 and SedB to be decomposed into amino acids, dipeptides and tripeptides[1].
|
|
1
|
| HY-P1149A | Epitalon TFA |
Epitalon TFA is an anti-aging agent and a telomerase activator. Epitalon TFA has an inhibitory effect of the on the development of spontaneous tumors in mice, has geroprotective actions and intranasal administration increases neuronal activity. Epitalon TFA can be used for cancer, old age and Retinitis Pigmentosa.
|
|
1
|
| HY-N0658S6 | L-Threonine-13C4 |
L-Threonine-13C4 is the 13C labeled L-Threonine. L-Threonine is a natural amino acid, can be produced by microbial fermentation, and is used in food, medicine, or feed.
|
|
1
|
| HY-W105750 | 6-Hydroxyhexanoic acid |
6-Hydroxyhexanoic acid (6-HHA) is a bacterial effector molecule with metabolic and immunomodulatory activities. 6-Hydroxyhexanoic acid activates the JAK1-STAT1 signaling pathway, promotes phenotypic conversion of M2 macrophages to M1 macrophages, and exerts anti-tumor effects by regulating macrophage polarization. 6-Hydroxyhexanoic acid inhibits lipolysis in adipocytes mediated by Gαi family GPCR, and reduces high-fat diet-induced weight gain and obesity. 6-Hydroxyhexanoic acid can be used in studies related to pancreatic ductal adenocarcinoma, obesity, and insulin resistance.
|
|
1
|
| HY-P1149 | Epitalon |
Epitalon is an anti-aging agent and a telomerase activator. Epitalon has an inhibitory effect of the on the development of spontaneous tumors in mice, has geroprotective actions and intranasal administration increases neuronal activity. Epitalon can be used for cancer, old age and Retinitis Pigmentosa.
|
|
1
|
| HY-77490A | 1,3-Butanediol |
1,3-Butanediol, an orally active ethanol dimer providing a source of calories for human nutrition. 1,3-Butanediol administeration can stimulate the biosynthesis of the ketone body, β-hydroxybutyrate (βHB). 1,3-Butanediol has cerebral protective and hypoglycaemic effect.
|
|
1
|
| HY-Y0488A | Formic acid ammonium |
Formic acid ammonium is the ammonium salt form of formic acid, which is an endogenous metabolite. Formic acid ammonium activates the nitric oxide/cyclic guanosine monophosphate (NO/cGMP) signaling pathway in endothelial cells and inhibits calcium ion influx in vascular smooth muscle cells, resulting in vasomotor relaxation. Formic acid ammonium inhibits cytochrome C oxidase (CcO) and disrupts the electron transport chain, leading to ATP depletion. Formic acid ammonium can be used as a feed additive, which can lower the feed pH value, inhibit the growth of microorganisms (such as Escherichia coli, Salmonella), and extend the shelf life of the feed.
|
|
1
|
| HY-B2243D | Anhydrous sodium dihydrogen phosphate, for cell culture |
Anhydrous sodium dihydrogen phosphate, for cell culture is an inorganic salt compound that can be used as a buffer and nutritional supplement. Anhydrous sodium dihydrogen phosphate, for cell culture can be used in cell culture.
|
|
1
|
| HY-W014233 | L-Histidinol dihydrochloride |
L-Histidinol dihydrochloride is an orally active histidyl-tRNA synthetase inhibitor. L-Histidinol dihydrochloride interferes with the initiation stage of protein synthesis, thus affecting cell proliferation and metabolism. L-Histidinol dihydrochloride has the effect of modulating the sensitivity of tumor cells to chemotherapeutic agents. L-Histidinol dihydrochloride reduces the toxicity of certain chemotherapeutic agents to normal tissues and enhance the sensitivity of tumor cells to chemotherapeutic agents.
|
|
1
|
| HY-N6612 | D-Glucuronic acid |
D-Glucuronic acid is a major component of many anti-inflammatory proteoglycans, which can promote embryonic development and inhibit cell aggregation. After being metabolized into ethyl glucuronide (HY-113093), D-Glucuronic acid activates Toll-like receptor 4 (TLR4), causing pain. D-Glucuronic acid and its derivative glucurono-lactone can serve as liver detoxifiers, and its derivatives also possess anti-tumor activity.
|
|
1
|
| HY-W250122 | Glutamic acid sodium salt |
Glutamic acid sodium salt (Monosodium glutamate) is an orally active food flavor enhancer. Glutamic acid sodium salt causes ROS generation, mitochondrial dysfunction, and Apoptosis. Glutamic acid sodium salt upregulates CHOP, Grp78, and Bcl-2. Glutamic acid sodium salt impairs cognition, induces depressive-like behavior, induces hyperalgesia, and induces obesity and insulin resistance. Glutamic acid sodium salt can be used to study neurotoxicity (e.g., brain damage, cognitive impairment), metabolic disorders (e.g., obesity, insulin resistance), hepatotoxicity, and renal toxicity, as well as pain-related disorders.
|
Biochemical Assay Reagents
Reactive Oxygen Species (ROS)
Mitochondrial Metabolism
Apoptosis
HSP
Bcl-2 Family
Neurological, Eye or Ear Disease
Inflammation or Immune System Disease
Metabolic or Endocrine Disease
|
1
|
| HY-N10574 | Queuine |
Queuine is a selective substrate for tRNA guanine transglycosylase (TGT) and can be incorporated into eukaryotic tRNA. Queuine promotes tRNA modification, affecting mitochondrial function and Warburg metabolic phenotype. If Queuine is deficient, aerobic glycolysis can be enhanced, oxidative phosphorylation can be inhibited, and Warburg metabolism can be promoted, accompanied by increased ammonia and lactate production and increased lactate dehydrogenase activity. Queuine can be used for autoimmune diseases (such as experimental models of multiple sclerosis) and cancer metabolic regulation, and its deficiency is associated with low tRNA modification in tumor cells.
Source: eubacteria |
|
1
|
| HY-W071746 | Linolelaidic acid |
Linolelaidic acid (Linoelaidic acid) is an omega-6 trans fatty acid (TFA) that is an essential nutrient with oral activity. Linolelaidic acid can be added to enteral nutrition (oral), parenteral nutrition (intravenous), and infant formula. Linolelaidic acid has anti-inflammatory and anti-parasitic ((Parasite)) activities, and can induce Apoptosis. Linolelaidic acid is useful for research in infections.
|
|
1
|
| HY-W015273A | trans-3-Indoleacrylic acid |
Trans-3-Indoleacrylic acid is a tryptophan metabolite, which promotes tumor development through inhibition of RSL3 (HY-100218A) induced ferroptosis via AHR-ALDH1A3-FSP1-CoQ10 axis, and facilitates colorectal carcinogenesis
|
|
1
|
| HY-P70704A | Leptin Protein, Mouse (His) |
Leptin is a key regulator of energy balance and body weight and binds to LEPR receptors in multiple tissues.It controls appetite in the hypothalamus and affects bone mass, hormone regulation, and reproductive function.Leptin Protein, Mouse (His) is the recombinant mouse-derived Leptin protein, expressed by E.coli , with N-6*His labeled tag.
Species: Mouse; Source: E. coli |
|
1
|
| HY-P11274 | Zenagamtide |
Zenagamtide (Amycretin; NN 9487) is an orally active, blood-brain barrier permeable triple agonist that targets GLP-1, amylin (Amylin Receptor) and calcitonin receptor (Calcitonin Receptor). Zenagamtide is a single peptide consisting of 68 amino acids that can target brain regions regulating food intake, significantly suppress appetite and reduce energy intake. Therefore, Zenagamtide improves body weight, waist circumference, glycated hemoglobin and lipid profile, and also alleviates the histological features of metabolic dysfunction-associated steatotic liver disease (MASLD) and enhances insulin sensitivity. Zenagamtide may cause transient increases in heart rate and fluctuations in serum calcium levels, but it is an important compound for the study of overweight, obesity, insulin resistance and related metabolic diseases.
|
|
/
|
| HY-P1120A | WKYMVm TFA |
WKYMVm (TFA) is a selective formylpeptide receptor 2 (FPR2) agonist. WKYMVm has a powerful anti-inflammatory effect that can reduce lung injury and spinal cord injury. WKYMVm ameliorates obesity by regulating lipid metabolism and leptin signaling. WKYMVm is involved in the regulation of immune cells by activating FPRs, and WKYMVm can promote the chemotactic migration of immune cells and inhibit the apoptosis of phagocytes. In addition, WKYMVm may play a favorable or unfavorable role in tumors, depending on the type of tumor.
|
Cancer
Neurological, Eye or Ear Disease
Inflammation or Immune System Disease
Metabolic or Endocrine Disease
|
/
|
| HY-18719S | Endoxifen-d5 (Z-isomer) |
Endoxifen-d5 (Z-isomer) is the deuterated-labeled Endoxifen (Z-isomer methanesulfonate) (HY-18719H). Endoxifen-d5 Z-isomer is an orally active selective PKCβ1 inhibitor with an IC50 of 360 nM against human PKCβ1. It also acts as an estrogen receptor modulator and antiestrogen. Endoxifen-d5 Z-isomer binds to and blocks ERα, ERβ and PKCβ1, inhibits estrogen and PI3K/AKT/mTORC1 signaling pathways, suppresses the expression of genes associated with cell cycle, cell proliferation and extracellular matrix remodeling, and induces apoptosis, reactive oxygen species (ROS) production and hypoxic features. Endoxifen-d5 Z-isomer inhibits tumor growth in breast tumor and glioblastoma models, reduces bone turnover and blood lipid levels, and does not require metabolism via CYP2D6. It can be used in research related to ER+ breast cancer, invasive breast cancer, glioblastoma multiforme, type I bipolar disorder, desmoid tumor, gynecological malignancies, melanoma and hormone receptor-positive solid tumors
|
|
/
|
| HY-179219S | RTx-303 |
RTx-303 is an orally active, selective DNA polymerase θ (Polθ) inhibitor (IC50 = 5.1 nM). RTx-303 exhibits significantly high cellular potency and strongly potentiates PARPi in BRCA1/2 mutant cells and patient-derived xenograft models. RTx-303 can be used for the study of BRCA2-mutated breast cancer.
|
|
/
|
| HY-13738S | Raloxifene-d4 |
Raloxifene-d4 is the deuterium labeled Raloxifene. Raloxifene (Keoxifene) is a benzothiophene-derived selective estrogen receptor modulator (SERM). Raloxifene has estrogen-agonistic effects on bone and lipids and estrogen-antagonistic effects on the breast and uterus. Raloxifene is used for breast cancer and osteoporosis research.
|
|
/
|
| HY-10585AS | Valproic acid-d7 sodium |
Valproic acid-d7 (sodium) is the deuterium labeled Valproic acid (sodium salt). Valproic acid sodium salt (Sodium Valproate) is an HDAC inhibitor, with IC50 in the range of 0.5 and 2 mM, also inhibits HDAC1 (IC50, 400 μM), and induces proteasomal degradation of HDAC2. Valproic acid sodium salt activates Notch1 signaling and inhibits proliferation in small cell lung cancer (SCLC) cells. Valproic acid sodium salt is used in the treatment of epilepsy, bipolar disorder and prevention of migraine headaches.
|
|
/
|
| HY-13738S2 | Raloxifene-d4 hydrochloride |
Raloxifene-d4 (hydrochloride) is the deuterium labeled Raloxifene. Raloxifene (Keoxifene) is a benzothiophene-derived selective estrogen receptor modulator (SERM). Raloxifene has estrogen-agonistic effects on bone and lipids and estrogen-antagonistic effects on the breast and uterus. Raloxifene is used for breast cancer and osteoporosis research.
|
|
/
|
| HY-W051723S2 | (R)-3-Hydroxybutanoic acid-d |
(R)-3-Hydroxybutanoic acid-d ((R)-(-)-3-Hydroxybutanoic acid-d) is the deuterium labeled (R)-3-Hydroxybutanoic acid (HY-W051723). (R)-3-Hydroxybutanoic acid is a metabolite, and converted from acetoacetic acid catalyzed by 3-hydroxybutyrate dehydrogenase. (R)-3-Hydroxybutanoic acid has applications as a nutrition source and as a precursor for vitamins, antibiotics and pheromones.
|
|
/
|
| HY-N10606 | Uvagrandol |
Uvagrandol potently inhibits α-glucosidase and porcine lipase (IC50: 15.2 μM, 11.2 μM respectively). Uvagrandol can be used in the research of Type 2 diabetes and obesity.
|
|
/
|
| HY-P991317 | BTH1704 |
|
/
|
|
| HY-B1340S | Carbadox-d3 |
Carbadox-d3 is the deuterium labeled Carbadox. Carbadox is a quinoxaline-di-N-oxide antibiotic compound which is widely fed to nursery-age pigs to control enteric diseases and improve feed efficiency.
|
|
/
|
| HY-P3134 | CPN-267 |
CPN-267 (compound 7b) is a selective neuromedin U receptor 1 (NMUR1) agonist with the EC50 of 0.25 nM. CPN-267 suppresses body weight gain in mice and can be used for study of obesity.
|
|
/
|
| HY-W127851 | CLA |
CLA, or conjugated linoleic acid, is a polyunsaturated fatty acid that occurs naturally in a variety of animal products, such as meat and dairy. It has several potential benefits for human health, including the ability to reduce body fat mass, improve insulin sensitivity, and reduce inflammation. CLA has been extensively studied for its effects on weight loss and muscle growth, as well as its potential role in preventing chronic diseases such as heart disease and cancer. Additionally, it can be taken as a dietary supplement in capsule form.
|
|
/
|
| HY-172439S | Simedeutirom |
Simedeutirom is the agonist for thyroid hormone beta receptor (THRβ) and can be used for researchs of metabolic diseases, such as obesity and diabetes mellitus.
|
|
/
|
| HY-P11105 | Short neuropeptide F |
Short neuropeptide F is an insect neurohormone involved in regulating insect locomotor activity and circadian rhythm.
|
|
/
|
| HY-W145699 | D-myo-Inositol 4-monophosphate |
D-myo-Inositol 4-mono-phosphate, also known as IMP, is a phosphorylated form of inositol that is commonly found in various metabolic pathways, especially in the biosynthesis of phospholipids and cell signaling molecules. D-myo-Inositol 4-mono-phosphate has unique chemical properties that make it an important intermediate in the production of second messengers, such as inositol triphosphate (IP3) and diacylglycerol (DAG), which signal in cells plays a key role in. D-myo-Inositol 4-mono-phosphate is also used in dietary supplements and pharmaceuticals because of its potential health benefits, including improved insulin sensitivity and cognitive function.
|
|
/
|
| HY-P991292 | AB-3A4 |
AB-3A4 is a human IgG1 monoclonal antibody (mAb) targeting KAAG1. AB-3A4 can be used in the study of ovarian cancer, triple-negative breast cancer, and prostate cancer. Recommended isotype control: Human IgG1 kappa, Isotype Control (HY-P99001).
Species: Human |
|
/
|
| HY-N8293 | Eupalinolide I |
Eupalinolide I inhibits the viability of breast cancer cells. Eupalinolide I can be isolated from Eupatorium lindleyanum.
|
|
/
|
| HY-P10445 | TAT-PiET |
TAT-PiET is a cell-penetrating peptide targeting the extra-terminal (ET) domain of BRD4. TAT-PiET can reduce BRD4 and JMJD6 levels and inhibit cell proliferation. TAT-PiET also resists the endocrine resistance of ERα-positive breast cancer cells. TAT-PiET can be used for the research of cancer, such as breast cancer.
|
|
/
|
| HY-P991245 | Anti-ERBB3/HER3 (SGP1) |
Anti-ERBB3/HER3 (SGP1) is a human monoclonal antibody (mAb) targeting ERBB3/HER3. Anti-ERBB3/HER3 (SGP1) inhibits Neuregulin stimulated growth of cultured breast cancer cells. Anti-ERBB3/HER3 (SGP1) can be used in breast cancer research.
Species: Human |
|
/
|
| HY-P99458 | Balugrastim |
Balugrastim (CG 10639) is a novel long-acting recombinant granulocyte colony-stimulating factor (G-CSF) obtained by means of a genetic fusion between recombinant human serum albumin and granulocyte colony-stimulating factor. Balugrastim can be used for the research of breast cancer.
|
|
/
|
| HY-15947G | Ravoxertinib (GMP) |
Ravoxertinib GMP is Ravoxertinib (HY-15947) produced by using GMP guidelines. GMP small molecules works appropriately as an auxiliary reagent for cell therapy manufacture. Ravoxertinib (GDC-0994) is an orally active ERK1/2 inhibitor. Ravoxertinib inhibits the ERK1/2 MAPK signaling pathway and reduces the expression levels of c-Myc, HK2 and LDHA. Ravoxertinib decreases mammosphere formation, and exerts additive and/or superadditive cytotoxicity when combined with Ipatasertib (HY-15186) in 3D tumor sphere models. Ravoxertinib can be used in research related to various cancers including breast cancer, melanoma, head and neck cancer, non-small cell lung cancer, ovarian cancer and Merkel cell carcinoma.
|
|
/
|
| HY-128753S3 | D-Lyxose-13C-2 |
D-Lyxose-13C-2 is the 13C labeled D-Lyxose. D-Lyxose is an endogenous metabolite. D-Lyxose is a rare pentose sugar with significant potential for drug synthesis. D-Lyxose can be used as a starting material for anti-tumor drugs such as alpha galactose ceramide immunostimulants. D-Lyxose can be used as a precursor for L-nucleoside analogs for the development of antiviral drugs. D-Lyxose can be used as a synthetic intermediate for other rare sugars such as L-ribose.
|
|
/
|
| HY-P3135 | CPN-116 |
|
/
|
|
| HY-N0479S | Licarin B-d4 |
|
/
|
|
| HY-19822S2 | Elacestrant-d10 |
Elacestrant-d10 is the deuterium labeled of Elacestrant (HY-19822). Elacestrant is an orally available and selective estrogen receptor degrader (SERD) with IC50s of 48 and 870 nM for ERα and ERβ, respectively. Elacestrant also inhibits growth of ER+ breast cancer cell lines in vitro and in vivo.
|
|
/
|
| HY-D3182 | AldRed 588-A |
AldeRed 588-A is a fluorescent labeling reagent and a substrate for aldehyde dehydrogenase (ALDH). AldeRed 588-A is metabolized by functionally active ALDH enzymes, thereby specifically labeling viable ALDHbright cell populations with red-shifted fluorescence. AldeRed 588-A supports one-step isolation and sorting of ALDH-expressing cells (including normal stem cells and cancer stem cells), and can be used in combination with green fluorophores for multicolor experimental applications. AldeRed 588-A is widely applicable to research related to various cancers such as bladder cancer, breast cancer, and head and neck cancer.
|
|
/
|
| HY-32349S2 | Ercalcidiol-d9 |
Ercalcidiol-d9 (25-Hydroxy Vitamin D2-d9) is the deuterium labeled Ercalcidiol (HY-32349). Ercalcidiol is a metabolite of vitamin D2, is regarded as an indicator of vitamin D nutritional status.
|
|
/
|
| HY-B1278AS | DL-α-Tocopherol acetate-13C4,d6 |
DL-α-Tocopherol acetate-13C4,d6 is the deuterium and 13C labeled DL-α-Tocopherol acetate. DL-α-Tocopherol acetate is a vitamin E derivative which is often included in the formulations of enteral nutrition.
|
|
/
|
| HY-D2309 | IRDye700Dx (Maleimide) |
IRDye700Dx Maleimide is a Photosensitizer. When conjugated with HER2 Affibody and activated by near-infrared light, IRDye700Dx Maleimide induces death in HER2-positive breast cancer cells without causing damage to HER2-negative breast cancer cells.
|
|
/
|
| HY-N0390G | L-Glutamine (GMP) |
L-Glutamine GMP is L-Glutamine (HY-N0390) produced by using GMP guidelines. GMP small molecules works appropriately as an auxiliary reagent for cell therapy manufacture. L-Glutamine is an orally active nutritional agent and cellular metabolism regulator. L-Glutamine is taken up in a Na+-dependent manner and targets multiple key molecules including glutaminase, mTORC1, NF-κB, STAT-3 and HIF-1α. L-Glutamine enhances glutaminolytic catabolism, drives the conversion of glutamate to α-ketoglutarate, thereby regulating gene expression, integrating metabolic signals, mediating glutamine flux and maintaining redox homeostasis. L-Glutamine also promotes cell proliferation, osteogenic differentiation and fracture healing, exerts neuroprotective and cardioprotective effects, and inhibits osteoarthritis. L-Glutamine can be applied to research related to osteoporosis, osteoarthritis, ischemic stroke and acute cantharidin-induced cardiotoxicity.
|
|
/
|
| HY-N19725 | Calonysterone |
Calonysterone is an orally effective IL-6 inhibitor. Calonysterone reduces the level of the proinflammatory cytokine IL-6. Calonysterone prevents diet-induced obesity. Calonysterone normalizes abnormal plasma adiponectin and leptin concentrations. Calonysterone increases the percentage of total DNA methylation. Calonysterone enhances antioxidant activity. Calonysterone is applicable to obesity-related research.
|
|
/
|
| HY-42680S1 | D-Tagatose-13C-1 |
D-Tagatose-13C-1 is the 13C labeled D-Tagatose (HY-42680). D-Tagatose (D-(-)-Tagatose) is a natural low-calorie rare sugar. D-Tagatose inhibits the activities of sucrase, maltase and intestinal disaccharidases, reduces the digestion of sucrose and starch, and blocks the absorption of sucrose, maltose and glucose. D-Tagatose promotes glucokinase activity and inhibits glycogen phosphorylase activity via tagatose-1-phosphate, regulates the synthesis and decomposition of hepatic glycogen, reduces postprandial and fasting blood glucose levels, and improves hyperinsulinemia. D-Tagatose regulates lipid profiles, stimulates GLP-1 secretion, and exhibits prebiotic effects. D-Tagatose is a bulking sweetener. D-Tagatose can be used in research related to diabetes, hyperlipidemia, dental caries, atherosclerosis and type 2 diabetes.
|
|
/
|
| HY-128753S6 | D-Lyxose-d |
D-Lyxose-d is the deuterium labeled D-Lyxose. D-Lyxose is an endogenous metabolite. D-Lyxose is a rare pentose sugar with significant potential for drug synthesis. D-Lyxose can be used as a starting material for anti-tumor drugs such as alpha galactose ceramide immunostimulants. D-Lyxose can be used as a precursor for L-nucleoside analogs for the development of antiviral drugs. D-Lyxose can be used as a synthetic intermediate for other rare sugars such as L-ribose.
|
|
/
|
| HY-B0283S | Acipimox-d4 |
Acipimox-d4 is the deuterium labeled Acipimox. Acipimox (K-9321), a nicotinic acid analogue, is an antilipolytic compound. Acipimox acutely inhibits lipolysis and suppresses systemic levels of free fatty acids (FFAs) and improves insulin sensitivity.
|
|
/
|
| HY-15150G | Bemcentinib (GMP) |
Bemcentinib (R428) GMP is Bemcentinib (HY-15150) in GMP grade. GMP-grade small molecules can be used as auxiliary reagents in cell therapy.Bemcentinib (R428) is a selective and orally active Axl inhibitor with an IC50 of 14 nM. Bemcentinib retards cancer cell migration and invasion. Bemcentinib exhibits >100-fold selectivity for Axl versus Abl and 50- and >100-fold selectivity over TAM family kinases Mer and Tyro3, respectively, in cells. Bemcentinib blocks tumor spread and prolongs survival in models of metastatic breast cancer.
|
|
/
|
| HY-D3185 | AlDeSense AM |
AlDeSense AM is a cell-permeable ALDH1A1-selective fluorescent reporter. AlDeSense AM is oxidized by ALDH1A1, which eliminates photoinduced electron transfer quenching and enhances the fluorescent signal. AlDeSense AM can be used to detect cells with cancer stem cell properties, as well as to monitor the plasticity of cancer stem cells in cell culture systems and animal models. AlDeSense AM is applicable to the study of cancers associated with cancer stem cells, including chronic myeloid leukemia, melanoma, and breast cancer.
|
|
/
|
| HY-N2840S | Allitol-13C |
Allitol (Allodulcitol)-13C is the 13C labeled Allitol (HY-N2840). Allitol is an orally active rare sugar alcohol found in Itea virginica L, Tylopilus plumbeoviolaceus. Allitol has anti-obesity and hypoglycaemic activities. Allitol reduces carcass and total body fat mass, increases cecal weight, surface area, and short-chain fatty acid production, and upregulates cecal microbial enzymes linked to butyrate metabolism. Allitol can be used for the researches of obesity and diabetes.
|
|
/
|
| HY-N1823 | Pygenic acid A |
Pygenic acid A is a natural compound that can be found in Prunella vulgaris. Pygenic acid A induces apoptosis in metastatic breast cancer cells. Pygenic acid A can be used for the research of diabetes, inflammatory diseases, and cancers.
|
|
/
|
| HY-P1325 | BWX 46 |
BWX 46 (((Cys31, Nva 34)-Neuropeptide Y (27-36))2) is a selective Y5 receptor agonist with an IC50 value of 0.85 nM. BWX 46 can inhibit the synthesis of cAMP in Y5 cells.
|
|
/
|
| HY-14472S1 | Tesofensine-13C,d3 |
Tesofensine-13C,d3 (NS-2330-13C,d3) is the deuterium and 13C-labeled Tesofensine (HY-14472). Tesofensine (NS-2330) is a triple monoamine reuptake inhibitor inducing a potent inhibition of the re-uptake process in the synaptic cleft of the neurotransmitters dopamine (DA; IC50=6.5 nM), norepinephrine (NE;IC50=1.7 nM), and serotonin (5-HT;IC50=11 nM), and with potentials as an anti-obesity agent. Tesofensine is a CNS acting anti-obesity agent.
|
|
/
|
| HY-W778057 | Ethyl 3,4-Dihydroxybenzoate-13C3 |
Ethyl 3,4-Dihydroxybenzoate-13C3 (Protocatechuic acid ethyl ester-13C3) is the 13C-labeled Ethyl 3,4-dihydroxybenzoate (HY-W016409). Ethyl 3,4-dihydroxybenzoate (Protocatechuic acid ethyl ester) is an orally effective, blood-brain barrier-permeable, competitive prolyl hydroxylase (PHD) inhibitor that inhibits the hydroxylation modification of hypoxia-inducible factor (HIF) by PHD. Ethyl 3,4-dihydroxybenzoate stabilizes HIF-1α by inhibiting PHD, activates downstream pathways to induce autophagy and apoptosis of tumor cells, and regulates inflammatory responses, inhibits the NF-κB pathway, improves vascular permeability, and promotes osteoblast differentiation. Ethyl 3,4-dihydroxybenzoate has anti-tumor, anti-hypoxic injury, and bone metabolism regulation effects. It can also be used in the research of cardiovascular protection (such as reducing myocardial ischemic damage), bone tissue engineering (promoting osteogenesis/inhibiting osteoclast differentiation), and prevention and treatment of high-altitude cerebral edema.
|
|
/
|
| HY-B1812S3 | Veratrole-d6 |
Veratrole-d6 is the deuterium labeled Veratrole. Veratrole (1,2-Dimethoxybenzene) is a key compound that widely exists in plants and attracts pollinators. The release of Veratrole has a circadian rhythm and plays an important role in plant reproduction, species differentiation, and interactions with pollinators. In addition, Veratrole can be demethylated by cytochrome P-450 in Streptomyces setonii.
|
|
/
|
| HY-P992313 | AS3288802 |
|
/
|
|
| HY-P5065 | Galanin-Like Peptide (rat) |
Galanin-Like Peptide (rat) is a 60 amino acid neuropeptide. Galanin-Like Peptide (rat) plays an important role in the regulation of feeding, body weight and energy metabolism.
|
|
/
|
| HY-N6678S | (Rac)-Zearalanone-d6 |
(Rac)-Zearalanone-d6 is the d6-labeled (Rac)-Zearalanone (HY-N6678A). (Rac)-Zearalanone is an ATP-competitive HSP90 inhibitor with an EC50 of 2.3 μM. (Rac)-Zearalanone interferes with the binding of ATP to HSP90, impairs the chaperone function of HSP90, and promotes the degradation of client proteins. (Rac)-Zearalanone reduces intracellular accumulation of Raf-1, induces cleavage of caspase-3, and promotes Her2 degradation in a dose-dependent manner by disrupting the Her2-HSP90 interaction. (Rac)-Zearalanone can be used in the research of small cell lung cancer and breast cancer.
|
|
/
|
| HY-W778286 | Enterolactone-13C3 |
Enterolactone-13C3 is the 13C-labeled Enterolactone (HY-108692). Enterolactone is a bioactive phenolic metabolite known as a mammalian lignan derived from dietary lignans. Enterolactone has estrogenic properties and anti-breast cancer activity. Enterolactone is a radiosensitizer for human breast cancer cell lines through impaired DNA repair and increased apoptosis.
|
|
/
|
| HY-D3187 | HMRef-αMan |
HMRef-αMan is a substrate-based green fluorescent probe (Ex/Em=465 nm/515 nm) targeting MAN2C1 (α-mannosidase). HMRef-αMan can be specifically cleaved by MAN2C1 to generate a highly fluorescent product, which thus gets activated to produce green fluorescence in malignant breast tissues, benign lesions and living cancer cells. The signal intensity of HMRef-αMan is directly correlated with MAN2C1 activity, and it can effectively detect tiny breast cancer lesions with a diameter of less than 1 mm. When used in combination with the red-emitting γ-glutamyl transpeptidase (GGT) probe gGlu-2OMe SiR600 (HY-D3188), HMRef-αMan enables precise optical differentiation of breast tissue types via a dual-color imaging strategy. HMRef-αMan has been widely used in the research of breast diseases such as breast cancer, fibroadenoma, phyllodes tumor and various types of papilloma.
|
|
/
|
| HY-10585AG | Valproic acid sodium (GMP) |
Valproic acid (Sodium Valproate) sodium is an orally active HDAC inhibitor, with IC50 in the range of 0.5 and 2 mM, also inhibits HDAC1 (IC50, 400 μM), and induces proteasomal degradation of HDAC2. Valproic acid sodium activates Notch1 signaling and inhibits proliferation in small cell lung cancer (SCLC) cells. Valproic acid sodium is used in the treatment of epilepsy, bipolar disorder, metabolic disease, HIV infection and prevention of migraine headaches.
|
|
/
|
| HY-P10790 | Breast cancer targeting peptide 18–4 |
Breast cancer targeting peptide 18–4 is a KRT1 receptor-targeting peptide, with a Kd of 0.98 μM. The amino acid sequence of Breast cancer targeting peptide 18–4 is WxEAAYQrFL, and it is an analogue of P160 peptide (HY-P10789). When covalently conjugated with the anticancer peptide MccJ25, Breast cancer targeting peptide 18–4 significantly increases the cellular uptake of MccJ25 in breast cancer cells and enhances its anticancer activity. The covalent conjugate exhibits IC50 values of 14.2, 20, and 25 μM against MCF-7, MDA-MB-435, and MDA-MB-435-MDR cells, respectively.
|
|
/
|
| HY-P11197 | ACT1 |
ACT1 is a peptide that targets endogenous Cx43 by stabilizing its activity at gap junctions. ACT1 stabilizes gap junction intercellular communication in breast cancer cells. ACT1 enhances the activity of Tamoxifen (HY-13757A) and Lapatinib (HY-50898) in breast cancer. ACT1 can be used for breast cancer research.
|
|
/
|
| HY-W102387 | D-Galactose pentaacetate |
D-Galactose pentaacetate inhibits leucine-induced insulin release. D-Galactose pentaacetate can be used for the research of persistent hyperinsulinemia in childhood or insulinoma.
|
|
/
|
| HY-P990262 | Anti-Mouse CD8 Antibody (HB-129) |
Anti-Mouse CD8 Antibody (HB-129) is a mouse-derived IgG2a κ type antibody inhibitor, targeting to mouse CD8. Anti-Mouse CD8 Antibody (HB-129) can deplete CD8+ T cells. Anti-Mouse CD8 Antibody (HB-129) can be used for the researches of cancer, inflammation, immunology and metabolic disease, such as P815 tumor, experimental autoimmune thyroiditis (EAT) and graft versus host disease (GVHD).
Species: Mouse |
|
/
|
| HY-P3720 | YEQLRNSRA |
YEQLRNSRA is a MycC Peptide. MycC Peptide is encoded by c-myc proto-oncogene, the c-myc oncogene has been implicated in malignant progression in a variety of human tumors. MycC Peptide regulates fundamental cellular processes like growth control, metabolism, proliferation, differentiation, and apoptosis.
|
|
/
|
| HY-P3677 | Neuropeptide Y (2-36) (porcine) |
Neuropeptide Y (2-36) (porcine) is a porcine-derived neuropeptide with 97.14% homology to rat/human origin. Neuropeptide Y (2-36) (porcine) is also a rat neuropeptide receptor agonist, with EC50 values of 1.2, 1.6 and 3.4 nM for receptor of Y5, Y2 and Y1 respectively. Neuropeptide Y (2-36) (porcine) can be used in studies related to obesity and eating disorders.
|
|
/
|
| HY-187257S | [U-15N]-IGF-1 |
[U-15N]-IGF-1 is the 15N-labeled IGF-1. Abnormal expression of insulin-like growth factor 1 (IGF-1) is associated with various conditions, including growth hormone deficiency, diabetes, and the development of certain tumors. This isotope can be used in NMR studies to investigate disease mechanisms and in mass spectrometry analysis.
|
|
/
|
| HY-187258S | [U-13C,15N]-IGF-1 |
[U-13C,15N]-IGF-1 is the 13C- and 15N-labeled IGF-1. Abnormal expression of insulin-like growth factor 1 (IGF-1) is associated with various conditions, including growth hormone deficiency, diabetes, and the development of certain tumors. This isotope can be used in NMR studies to investigate disease mechanisms and in mass spectrometry analysis.
|
|
/
|
| HY-128753S7 | D-Lyxose-d-1 |
D-Lyxose-d-1 is the deuterium labeled D-Lyxose. D-Lyxose is an endogenous metabolite. D-Lyxose is a rare pentose sugar with significant potential for drug synthesis. D-Lyxose can be used as a starting material for anti-tumor drugs such as alpha galactose ceramide immunostimulants. D-Lyxose can be used as a precursor for L-nucleoside analogs for the development of antiviral drugs. D-Lyxose can be used as a synthetic intermediate for other rare sugars such as L-ribose.
|
|
/
|
| HY-14472S | Tesofensine-d5 |
Tesofensine-d5 (NS-2330-d5) is the deuterium labeled Tesofensine (HY-14472). Tesofensine (NS-2330) is a triple monoamine reuptake inhibitor inducing a potent inhibition of the re-uptake process in the synaptic cleft of the neurotransmitters dopamine (DA; IC50=6.5 nM), norepinephrine (NE;IC50=1.7 nM), and serotonin (5-HT;IC50=11 nM), and with potentials as an anti-obesity agent. Tesofensine is a CNS acting anti-obesity agent.
|
|
/
|
| HY-128753S5 | D-Lyxose-13C-4 |
D-Lyxose-13C-4 is the 13C labeled D-Lyxose. D-Lyxose is an endogenous metabolite. D-Lyxose is a rare pentose sugar with significant potential for drug synthesis. D-Lyxose can be used as a starting material for anti-tumor drugs such as alpha galactose ceramide immunostimulants. D-Lyxose can be used as a precursor for L-nucleoside analogs for the development of antiviral drugs. D-Lyxose can be used as a synthetic intermediate for other rare sugars such as L-ribose.
|
|
/
|
| HY-P10290 | Neuropeptide Y (human) free acid |
Neuropeptide Y (human) free acid is the deamidated form of Neuropeptide Y (human, rat, mouse) (HY-P0198). The amidation of Neuropeptide Y C-terminal tyrosine is critical for its function. Non-amidated Neuropeptide Y fails to elicit G protein signaling.
|
|
/
|
| HY-P11019 | IS4 |
IS4 is a selective CXCR4 competitive antagonist, with an IC50 of 0.65 nM in THP-1 cells and 38.75 nM in Jurkat cells. IS4 is stable in serum and non-cytotoxic. IS4 competitively binds to CXCR4 with CXCL12, thereby inhibiting CXCL12-induced intracellular Ca2+ release and cancer cell migration. IS4 can be used in the research on the prevention of metastasis of breast cancer, prostate cancer, leukemia, and other diseases.
|
|
/
|
| HY-P1300 | [(pF)Phe4]Nociceptin(1-13)NH2 |
[(pF)Phe4]Nociceptin(1-13)NH2 is a highly potent and selective NOP receptor (OP4) agonist, with a pKi of 10.68 and a pEC50 of 9.31. [(pF)Phe4]Nociceptin(1-13)NH2 displays high selectivity over δ, κ, and μ opioid receptors (>3000 fold).
|
|
/
|
| HY-182832 | Skim Milk powder |
Skim Milk powder (Dry skim milk) is an orally effective, dairy-derived non-fat milk solid powder. Skim Milk powder serves as a nutrient source in microbial culture media and can also be used for blocking procedures in WB assays. Skim Milk powder protects zebrafish sperm from oxidative stress, DNA damage, membrane disruption and morphological abnormalities during cryopreservation, and improves their survival rate. After undergoing high Maillard reaction during moist-heat storage, Skim Milk powder exhibits negative metabolic activities such as inhibiting GLP-1/GIP and promoting intestinal inflammation. Skim Milk powder can be used in studies related to intestinal inflammation, diabetes and obesity.
|
|
/
|
| HY-P992096 | Pemtumomab Antibody |
|
/
|
|
| HY-P10041 | Obestatin(11-23)mouse, rat |
Obestatin(11-23)mouse, rat is a polypeptide involved in regulating energy balance and inhibiting eating. Obestatin(11-23)mouse, rat causes reduced food intake, body weight, and jejunal contractions in rodents.
|
|
/
|
| HY-P10491 | MAGE A4 (230-239) |
MAGE A4 (230-239) is a peptide sequence derived from the MAGE-A4 protein. MAGE A4 (230-239) is an immunogenic epitope that can activate T cells and trigger the killing of tumor cells expressing MAGE-A4. MAGE A4 (230-239) is used in the development of next-generation T cell-based immunotherapies.
|
|
/
|
| HY-32349S3 | Ercalcidiol-13C3 |
Ercalcidiol-13C3 (25-Hydroxy Vitamin D2-13C3) is the 13C-labeled Ercalcidiol (HY-32349). Ercalcidiol is a metabolite of vitamin D2, is regarded as an indicator of vitamin D nutritional status.
|
|
/
|
| HY-P11944 | Peptide 22 |
Peptide 22 is a polypeptide that binds to EGFR. Peptide 22 competes with endogenous EGF for EGFR binding sites and is taken up by triple-negative breast cancer cells in a dose-dependent manner. Peptide 22 can be used in studies related to triple-negative breast cancer.
|
|
/
|
| HY-124547S | 2,4-D methyl ester-d3 |
2,4-D methyl ester-d3 is the deuterium labeled 2,4-D methyl ester (HY-124547). 2,4-D methyl ester is a bioactive compound with the activity of promoting the accumulation of nutritional and medicinal components. 2,4-D methyl ester can be used to enhance the production of bioactive components in Cordyceps militaris. 2,4-D methyl ester showed an inductive effect on bioactive components at specific concentrations. The application of 2,4-D methyl ester provides an effective strategy to improve the fruit quality of Cordyceps militaris. 2,4-D methyl ester, as a biostimulant, can induce dose-dependent responses in different components.
|
|
/
|
| HY-151890 | NIR-βgal-2 |
NIR-βgal-2 is a β-galactosidase-activated near-infrared fluorescent probe with superior sensitivity. NIR-βgal-2 can be used for visualizing β-galactosidase in breast cancer.
|
|
/
|
| HY-B0222S | 1-Docosanol-d45 |
1-Docosanol-d45 is the deuterium labeled 1-Docosanol. 1-Docosanol is a saturated fatty alcohol used traditionally as an emollient, emulsifier, and thickener in cosmetics, and nutritional supplement. 1-Docosanol is an inhibitor of lipid-enveloped viruses including herpes simplex.
|
|
/
|
| HY-B1812R | Veratrole (Standard) |
Veratrole (Standard) is the analytical standard of Veratrole. This product is intended for research and analytical applications. Veratrole (1,2-Dimethoxybenzene) is a key compound that widely exists in plants and attracts pollinators. The release of Veratrole has a circadian rhythm and plays an important role in plant reproduction, species differentiation, and interactions with pollinators. In addition, Veratrole can be demethylated by cytochrome P-450 in Streptomyces setonii.
|
|
/
|
| HY-W002116S | Methyl syringate-d6 |
Methyl syringate-d6 is the deuterium labeled Methyl syringate. Methyl syringate is a selective TRPA1 agonist. Methyl syringate regulates food intake and gastric emptying through a TRPA1-mediated pathway. Methyl syringate is an efficient phenolic mediator for bacterial and fungal laccases. Methyl syringate is a chemical marker of Asphodel monofloral honey. Methyl syringate contributes to the antibacterial activity of honey. Methyl syringate inhibits aflatoxin production. Methyl syringate can contribute to weight suppression. Methyl syringate can be studies for cancer prevention (e.g. lung cancer), suppression of hypoxia-induced inflammatory response and tumorigenesis.
|
|
/
|
| HY-W064342S | L-Histidinol-d3 |
L-Histidinol-d3 ((S)-2-Amino-3-(1H-imidazol-5-yl)propan-1-ol-d3) is the deuterium labeled L-Histidinol (HY-W014233). L-Histidinol is an orally active histidyl-tRNA synthetase inhibitor. L-Histidinol interferes with the initiation stage of protein synthesis, thus affecting cell proliferation and metabolism. L-Histidinol has the effect of modulating the sensitivity of tumor cells to chemotherapeutic agents. L-Histidinol reduces the toxicity of certain chemotherapeutic agents to normal tissues and enhance the sensitivity of tumor cells to chemotherapeutic agents.
|
|
/
|
| HY-P992056 | Anti-Human/Mouse LY6E Antibody (9B12) |
Anti-Human/Mouse LY6E Antibody (9B12) is a high-affinity, multi-target antibody that binds specifically to LY6E. Anti-Human/Mouse LY6E Antibody (9B12) binds specifically to cell-surface LY6E and enters lysosomes via lipid raft-dependent endocytosis, thereby effectively inhibiting the growth of various LY6E-expressing solid tumors (such as breast cancer and lung cancer) in both in vitro and in vivo models. Anti-Human/Mouse LY6E Antibody (9B12) exerts a dual mechanism of action: on one hand, it blocks the interaction between PILRα and CD8α, specifically reduces the survival rate of peripheral CD8+ T cells and induces their activation, breaking the state of cellular quiescence; on the other hand, it recognizes and immunoprecipitates IDE under both non-denaturing and denaturing conditions, which is applicable to studies on the subcellular localization and protein interactions of IDE. The regulatory effect of Anti-Human/Mouse LY6E Antibody (9B12) on CD8+ T cells strictly depends on the presence of PILRα, and it does not affect CD4+ T cells or T cell development in the thymus, exhibiting high specificity.
Species: Human/Mouse |
|
/
|
| HY-N17567 | Morusalnol A |
|
/
|
|
| HY-P5765 | Galanin (1-13)-spantide I |
Galanin (1-13)-spantide I is a chimeric peptide composed of the N-terminal fragment of galanin (amino acids 1-13) and spantide, a known substance P receptor antagonist. Galanin (1-13)-spantide I has a high affinity for spinal galanin receptor (Kd=1.16 nM). Galanin (1-13)-spantide I can be used to study the effects of galanin on feeding behavior.
|
|
/
|
| HY-D3188 | gGlu-2OMe SiR600 |
gGlu-2OMe SiR600 is a γ-glutamyl transpeptidase (GGT) responsive fluorescent probe. gGlu-2OMe SiR600 can be converted into a highly fluorescent molecule via reaction with GGT, and its initial fluorescence is quenched through a photoinduced electron transfer (PeT) mechanism. gGlu-2OMe SiR600 exhibits fluorescence activation in malignant breast cancer and benign breast fibroadenoma tissues, enabling lesion visualization. gGlu-2OMe SiR600 can be used for research related to breast cancer and fibroadenoma.
|
|
/
|
| HY-N13223A | White Kidney Bean Extract (30:1) |
|
/
|
|
| HY-P11245 | NN1213 |
NN1213, a long-acting human amylin peptide analog, is a selective Amylin receptor agonist with EC50 values of 0.177 and 0.262 nM for hAMY3R and rAMY3R, respectively. NN1213 significantly reduces food intake and fat mass. NN1213 can reduce body weightin diet-induced obese rats. NN1213 can be used for the research of obesity.
|
|
/
|
| HY-P10295 | p53 (232-240) |
p53 (232-240) is a peptide segment of the 232-240 amino acid sequence of the human tumor suppressor protein p53. p53 (232-240) enhances its binding affinity to the Major histocompatibility complex (MHC), thereby enhancing the immunogenicity of this peptide to enhance the immune system's response to tumor antigens. p53 (232-240) can be used in the development of cancer vaccines and in the study of tumor cell recognition and clearance by the immune system.
|
|
/
|
| HY-N3800 | Eichlerialactone |
Eichlerialactone is a sesquiterpene compound isolated from Chisocheton penduliflorus. Eichlerialactone is weakly cytotoxic to breast cancer cells.
|
|
/
|
| HY-131306B | 2-Hexadecenoic acid |
2-Hexadecenoic acid is a natural unsaturated fatty acid. It is ubiquitously present in various animal and plant tissues, especially adipose tissue and certain vegetable oils, such as macadamia nut oil. 2-Hexadecenoic acid has unique chemical properties that make it an important component of cell membranes and storage lipids, and participates in various metabolic processes such as lipid metabolism and inflammation. It's also been linked to potential health benefits, including improved insulin sensitivity and a lower risk of heart disease.
|
|
/
|
| HY-P991378 | MORAb-066 |
MORAb-066 is a human monoclonal antibody (mAb) targeting CD142/F3/TF. MORAb-066 can be used in Breast cancer, Colorectal cancer, Non-small cell lung cancer and Pancreatic cancer research.
Species: Human |
|
/
|
| HY-P992158 | VBI-009 |
VBI-009 is a CD47 and B7-H3 (CD276) bispecific antibody. VBI-009 blocks CD47-SIRPα 'don't eat me' signals and restricts activity to CD47+/B7-H3+ cells. VBI-009 induces antibody-dependent cellular phagocytosis (ADCP) and antibody-dependent cellular cytotoxicity (ADCC) in CD47+/B7-H3+ tumor cells. VBI-009 inhibits tumor growth in CD47+/B7-H3+ lung cancer xenograft models. VBI-009 can be used for the research of lung cancer.
Species: Human |
|
/
|
| HY-P990873 | Anti-BRCA1 Antibody (BR64) |
Anti-BRCA1 Antibody (BR64) is a kind of mouse IgG1 κ chimeric antibody, targeting to human BRCA1. Anti-BRCA1 Antibody (BR64) reacts with BRCA1 (Breast cancer susceptibility gene 1) involved in tumor suppression, transcription, genomic stability, DNA repair and recombination. Anti-BRCA1 Antibody (BR64) can be used for the detections of immunofluorescence, western blot, and immunoprecipitation in cancer, such as breast and ovarian cancer.
Species: Human |
|
/
|
| HY-113334R | Turanose (Standard) |
Turanose (Standard) is the analytical standard of Turanose. This product is intended for research and analytical applications. Turanose is an isomer of Sucrose that naturally exists in honey. Turanose has anti-inflammatory and regulates adipogenesis effect. Turanose has potential for obesity and related chronic diseases research[1][2].
|
|
/
|
| HY-14281S | Trilostane-d3 |
Trilostane-d3 is the deuterium-labeled Trilostane (HY-14281). Trilostane-d3 (Win 24540) is a competitive and orally active 3-β-hydroxysteroiddehydrogenase (3β-HSD) inhibitor. Trilostane-d3 is a synthetic nonhormonal steroid. Trilostane-d3 can be used for the research of breast cancer and prostate cancer.
|
|
/
|
| HY-113161S | L-Octanoylcarnitine-d3 |
L-Octanoylcarnitine-d3 is the deuterium-labeled L-Octanoylcarnitine (HY-113161). L-Octanoylcarnitine-d3 is a plasma metabolite and a physiologically active form of octanoylcarnitine. L-Octanoylcarnitine-d3 can be used for the research of breast cancer.
|
|
/
|
| HY-P992441 | PHST001 |
PHST001 is a humanized anti-CD24 antibody. PHST001 binds cell-surface CD24, blocks CD24-Siglec10 interaction, and engages Fc receptors to promote macrophage-mediated tumor cell phagocytosis. PHST001 inhibits growth of breast cancer and ovarian cancer, and reduces metastatic lesions in mouse xenograft models. PHST001 can be used for the research of triple negative breast cancer, HER2+ breast cancer, metastatic tumors, and ovarian cancer.
Species: Human |
|
/
|
| HY-N0658S4 | L-Threonine-15N,d5 |
L-Threonine-15N,d5 is the deuterium and 15N-labeled L-Threonine. L-Threonine is a natural amino acid, can be produced by microbial fermentation, and is used in food, medicine, or feed.
|
|
/
|
| HY-B1812S2 | Veratrole-d10 |
Veratrole-d10 is the deuterium labeled Veratrole. Veratrole (1,2-Dimethoxybenzene) is a key compound that widely exists in plants and attracts pollinators. The release of Veratrole has a circadian rhythm and plays an important role in plant reproduction, species differentiation, and interactions with pollinators. In addition, Veratrole can be demethylated by cytochrome P-450 in Streptomyces setonii.
|
|
/
|
| HY-D3431 | CFSE-Tz |
CFSE-Tz is a fluorescent bioorthogonal probe constructed based on the IEDDA reaction, which is mainly used for visual tracing of amino acid uptake in living cells. The tetrazine group within the CFSE-Tz molecule quenches CFSE fluorescence via photoinduced electron transfer; after the probe specifically undergoes a bioorthogonal reaction with trans-cyclooctene-modified amino acids, the quenching effect is eliminated, and a green fluorescent signal is released, thereby dynamically monitoring the intracellular amino acid uptake process. CFSE-Tz can be applied to in vitro single-cell fluorescence imaging and studies related to amino acid metabolism in tumor cells (Ex = 495 nm, Em = 519 nm)[1][2]. |
|
/
|
| HY-P10417 | RTDLDSLRTYTL |
RTDLDSLRTYTL is an Alpha (v) beta (6) integrin (avb6) inhibitor with high affinity and specificity. RTDLDSLRTYTL binds to avb6 integrin, a peptide sequence that activates cytotoxicity and cytokine production in T cells, such as interferon-gamma. RTDLDSLRTYTL is designed through a chimeric T cell antigen receptor (CAR) so that T cells can be redirected to specifically recognize and attack tumor cells. RTDLDSLRTYTL can be used in the research of cancer immunotherapy and targeted drug development.
|
|
/
|
| HY-P10792A | HYNIC-H6F |
HYNIC-H6F is a SPECT imaging probe with binding specificity for human epidermal growth factor receptor 2 (HER2) domain II (IC50 = 11 nM). HYNIC-H6F accumulates in HER2-positive breast cancer xenografts via receptor-mediated uptake, while shows low uptake in HER2-negative breast cancer xenografts. HYNIC-H6F enables non-invasive detection of HER2-positive breast cancer in mouse models and allows evaluation of HER2 expression levels without blocking interference. HYNIC-H6F can be used in breast cancer-related research.
|
|
/
|
| HY-N2692 | 6,8-Diprenylgenistein |
6,8-Diprenylgenistein is an isoflavone compound isolated from Cudrania tricuspidata. 6,8-Diprenylgenistein has antimicrobial and anti-obesity activity. 6,8-Diprenylgenistein inhibits the proliferation, migration and tubular formation of HLMEC induced by recombinant human vascular endothelial growth factor-A. 6,8-Diprenylgenistein can be used to study new therapeutic drugs for the prevention and treatment of oral cancer metastasis .
|
|
/
|
| HY-128753S4 | D-Lyxose-13C-3 |
D-Lyxose-13C-3 is the 13C labeled D-Lyxose. D-Lyxose is an endogenous metabolite. D-Lyxose is a rare pentose sugar with significant potential for drug synthesis. D-Lyxose can be used as a starting material for anti-tumor drugs such as alpha galactose ceramide immunostimulants. D-Lyxose can be used as a precursor for L-nucleoside analogs for the development of antiviral drugs. D-Lyxose can be used as a synthetic intermediate for other rare sugars such as L-ribose.
|
|
/
|
| HY-P3676 | Neuropeptide Y (3-36) (porcine) |
Neuropeptide Y (3-36) (porcine) is an agonist of neuropeptide Y (NPY) receptor subtype Y2, and stimulates feeding in rats. Neuropeptide Y (3-36) (porcine) is a highly Y2 selective ligand compared with nselective Y1/Y2 receptor ligand, Neuropeptide Y 1-36.
|
|
/
|
| HY-135217 | Apiole |
|
/
|
|
| HY-P5063 | Galanin-Like Peptide (human) |
Galanin-Like Peptide (human) is a 60 amino acid neuropeptide. Galanin-Like Peptide (human) plays an important role in the regulation of feeding, body weight and energy metabolism.
|
|
/
|
| HY-P11285 | LAGIPRA peptide |
LAGIPRA peptide is a long-acting GIP1R agonist. LAGIPRA peptide enhances insulin sensitivity by augmenting glucose disposal and reduces branched-chain amino acids (BCAAs) and ketoacids. LAGIPRA peptide has the potential for the research of type 2 diabetes.
|
|
/
|
| HY-A0072S | Zilpaterol-d7 |
Zilpaterol-d7 is a deuterium Zilpaterol. Zilpaterol is a β-adrenergic agonist that have been widely used to feed cattle.
|
|
/
|
| HY-P2166 | MMP3 inhibitor 3 |
MMP3 inhibitor 3 is an inhibitor of MMP3. MMP3 inhibitor 3 can used to study breast cancer.
|
|
/
|
| HY-42680S | D-Tagatose-13C |
D-Tagatose-13C is the 13C labeled D-Tagatose (HY-42680). D-Tagatose (D-(-)-Tagatose) is a natural low-calorie rare sugar. D-Tagatose inhibits the activities of sucrase, maltase and intestinal disaccharidases, reduces the digestion of sucrose and starch, and blocks the absorption of sucrose, maltose and glucose. D-Tagatose promotes glucokinase activity and inhibits glycogen phosphorylase activity via tagatose-1-phosphate, regulates the synthesis and decomposition of hepatic glycogen, reduces postprandial and fasting blood glucose levels, and improves hyperinsulinemia. D-Tagatose regulates lipid profiles, stimulates GLP-1 secretion, and exhibits prebiotic effects. D-Tagatose is a bulking sweetener. D-Tagatose can be used in research related to diabetes, hyperlipidemia, dental caries, atherosclerosis and type 2 diabetes.
|
|
/
|
| HY-W087006 | p-Hydroxyphenylacetone |
p-Hydroxyphenylacetone, a Raspberry ketone (HY-N1426) derivative, is an androgen receptor (AR) antagonist with an IC50 of 420 μM in MDA-kb2 human breast cancer cells. p-Hydroxyphenylacetone can be used for breast cancer research.
|
|
/
|
| HY-N0565AG | Doxycycline (hydrochloride) (GMP) |
Doxycycline hydrochloride GMP is Doxycycline (hydrochloride) (HY-N0565A) produced by using GMP guidelines. GMP small molecules works appropriately as an auxiliary reagent for cell therapy manufacture. Doxycycline hydrochloride is an orally active highly lipophilic, tissue-permeable MMP inhibitor with broad-spectrum antibacterial activity. Doxycycline hydrochloride is also a semi-synthetic antibiotic with chelating properties, which blocks bacterial protein synthesis and inhibits extracellular matrix degradation through interactions with zinc and calcium atoms. Doxycycline hydrochloride also inhibits mitochondrial biogenesis, translation, and the expression of respiratory chain proteins. Doxycycline hydrochloride induces apoptosis, inhibits autophagy and EMT, downregulates stem cell markers, and activates the PI3K-AKT pathway, thereby effectively inhibiting the viability and proliferation of cancer cells such as breast cancer cells. Doxycycline hydrochloride also promotes the survival and self-renewal of embryonic stem cells and neural stem cells, and reduces the frequency of medium changes in culture. Doxycycline hydrochloride has been applied in studies related to breast cancer, prostate cancer, bladder cancer, and other cancers.
|
Infection
Neurological, Eye or Ear Disease
Inflammation or Immune System Disease
Breast Cancer
Prostate Cancer
Bladder Cancer
|
/
|
| HY-P991583 | GP369 |
GP369 is a humanized FGFR2-IIIb-specific antibody. GP369 significantly inhibits the proliferation of tumor cells. GP369 can significantly inhibit phosphorylation of FGFR2 and downstream signaling pathways. GP369 can be used for research on cancer such as gastric cancer and breast cancer.
Species: Human |
|
/
|
| HY-P0237 | KKI-5 |
KKI-5 is a specific inhibitor of tissue kallikrein. KKI-5 can attenuate breast cancer cell invasion.
|
|
/
|
| HY-N3426 | Kazinol B |
|
/
|
|
| HY-N13198 | 4-(4-Hydroxyphenyl)-2-butanone 4'-O-β-D-(2-O-galloyl-6-O-cinnamoyl)glucopyranoside |
4-(4-Hydroxyphenyl)-2-butanone 4'-O-β-D-(2-O-galloyl-6-O-cinnamoyl)glucopyranoside is a pancreatic lipase inhibitor, with an IC50 value of 2.91 μM. 4-(4-Hydroxyphenyl)-2-butanone 4'-O-β-D-(2-O-galloyl-6-O-cinnamoyl)glucopyranoside can effectively reduce lipid absorption and regulate obesity-related metabolic disorders, making it useful for research on obesity.
|
|
/
|
| HY-N1180 | Tanshinlactone |
Tanshinlactone is a compound found in Salvia miltiorrhiza with anti-coronavirus (CoV) and anti-tumor activities. Tanshinlactone induces methuocytic cell death (methuosis) by activating the NRF2 pathway, and selectively kills ER+, HER2+/EGFR+ breast cancer cells. Tanshinlactone is applicable to research related to breast cancer and coronavirus infections.
|
|
/
|
| HY-A0096R | Iloprost (Standard) |
Iloprost (Standard) is the analytical standard of Iloprost. This product is intended for research and analytical applications. Iloprost (ZK 36374; Ciloprost) is a prostacyclin (PGI2) analogue, involves in embryo development and inflammation improvement, and inhibits tumor metastasis. Iloprost can be used for peripheral vascular research.
|
|
/
|
| HY-105375 | FR 901537 |
FR 901537 is a potent and competitive aromatase inhibitor. FR 901537, a novel naphthol derivative, has the potential for breast cancer research.
Source: Bacillus sp. |
|
/
|
| HY-42680R | D-Tagatose (Standard) |
D-Tagatose (Standard) is the analytical standard of D-Tagatose (HY-42680). This product is intended for research and analytical applications. D-Tagatose (D-(-)-Tagatose) is a natural low-calorie rare sugar. D-Tagatose inhibits the activities of sucrase, maltase and intestinal disaccharidases, reduces the digestion of sucrose and starch, and blocks the absorption of sucrose, maltose and glucose. D-Tagatose promotes glucokinase activity and inhibits glycogen phosphorylase activity via tagatose-1-phosphate, regulates the synthesis and decomposition of hepatic glycogen, reduces postprandial and fasting blood glucose levels, and improves hyperinsulinemia. D-Tagatose regulates lipid profiles, stimulates GLP-1 secretion, and exhibits prebiotic effects. D-Tagatose is a bulking sweetener. D-Tagatose can be used in research related to diabetes, hyperlipidemia, dental caries, atherosclerosis and type 2 diabetes.
|
|
/
|
| HY-W002116R | Methyl syringate (Standard) |
Methyl syringate is a selective TRPA1 agonist. Methyl syringate regulates food intake and gastric emptying through a TRPA1-mediated pathway. Methyl syringate is an efficient phenolic mediator for bacterial and fungal laccases. Methyl syringate is a chemical marker of Asphodel monofloral honey. Methyl syringate contributes to the antibacterial activity of honey. Methyl syringate inhibits aflatoxin production. Methyl syringate can contribute to weight suppression. Methyl syringate can be studies for cancer prevention (e.g. lung cancer), suppression of hypoxia-induced inflammatory response and tumorigenesis.
|
|
/
|
| HY-N19911 | Pubetallin |
|
/
|
|
| HY-120657S | 9-PAHSA-d4 |
9-PAHSA-d4 is the deuterium labeled 9-PAHSA. 9-PAHSA is an orally active endogenous GPR120 agonist (EC50=18 μM). 9-PAHSA significantly inhibits LPS-induced inflammatory responses by blocking the NF-κB pathway. 9-PAHSA induces adipocyte browning, enhances glucose uptake and reduces lipid accumulation, while improving mitochondrial function and the survival rate of steatotic hepatocytes. In terms of neuroprotection, 9-PAHSA regulates the expression of REST and BDNF in the prefrontal cortex of diabetic mice, and effectively prevents spatial working memory deficits and abnormal social behaviors. 9-PAHSA does not directly regulate insulin secretion or improve systemic insulin sensitivity, and possesses specific anti-inflammatory, metabolic regulatory and neuroprotective properties. 9-PAHSA can be used in the research of diabetes-related cognitive impairment, obesity and non-alcoholic fatty liver disease.
|
|
/
|
| HY-N15841 | C25 Ceramide (d18:1/25:0) |
C25 Ceramide (d18:1/25:0) is an endogenous ultra-long-chain ceramide that antagonizes the detrimental effects of long-chain ceramides on insulin sensitivity. C25 Ceramide (d18:1/25:0) is specifically enriched in oxidative skeletal muscle fibers, where it serves dual roles in providing structural support to cell membranes and regulating cellular signaling. By participating in the regulation of lipid homeostasis within muscle fibers, C25 Ceramide (d18:1/25:0) helps maintain normal insulin signaling. C25 Ceramide (d18:1/25:0) is primarily utilized in research concerning metabolic diseases—particularly in mechanistic studies investigating the muscle fiber type-specific aspects of insulin resistance.
Source: Tan sheep |
|
/
|
| HY-B1812S4 | Veratrole-d2-1 |
Veratrole-d2-1 is the deuterium labeled Veratrole (HY-B1812). Veratrole (1,2-Dimethoxybenzene) is a key compound that widely exists in plants and attracts pollinators. The release of Veratrole has a circadian rhythm and plays an important role in plant reproduction, species differentiation, and interactions with pollinators. In addition, Veratrole can be demethylated by cytochrome P-450 in Streptomyces setonii.
|
|
/
|
| HY-149469 | 3,7,2',4'-Tetramethoxy-5-hydroxyflavone |
|
/
|
|
| HY-15401A | WAY 163909 (hydrochloride) |
WAY 163909 hydrochloride is an orally active, blood-brain barrier permeable 5-HT2C receptor-selective agonist. WAY 163909 hydrochloride exhibits an EC50 of 8 nM and a Ki of 10.5 nM for h5-HT2C. Instead of triggering apoptosis, WAY 163909 hydrochloride induces anorectic, antipsychotic-like, antidepressant-like, anti-aggressive and anti-compulsive effects. WAY 163909 hydrochloride alleviates ketamine-induced hypothermia, but impairs sexual function at high doses. With rapid antidepressant-like properties, WAY 163909 hydrochloride can be used in research related to obesity, schizophrenia, depression, obsessive-compulsive disorder, and anesthesia-induced hypothermia.
|
|
/
|
| HY-P991410 | 5T4_0108 |
5T4_0108 (MEDI0641 antibody) is a human monoclonal antibody (mAb) targeting TPBG. 5T4_0108 can be used in breast and prostate cancer research.
Species: Human |
|
/
|
| HY-14771S | Imeglimin-d3 |
Imeglimin-d3 (EMD 387008-d3) is deuterium labeled Imeglimin. Imeglimin (EMD 387008) is an oral glucose-lowering agent. Imeglimin improves insulin sensitivity. Imeglimin also reduces reactive oxygen species (ROS) production, increases mitochondrial DNA and improves mitochondrial function.
|
|
/
|
| HY-117160S1 | 4-trans-Hydroxy glibenclamide-d5 |
4-trans-Hydroxy glibenclamide-d5 is deuterated labeled 4-trans-Hydroxy glibenclamide.
|
|
/
|
| HY-120657S1 | 9-PAHSA-d31 |
9-PAHSA-d31 is the deuterium labeled 9-PAHSA. 9-PAHSA is an orally active endogenous GPR120 agonist (EC50=18 μM). 9-PAHSA significantly inhibits LPS-induced inflammatory responses by blocking the NF-κB pathway. 9-PAHSA induces adipocyte browning, enhances glucose uptake and reduces lipid accumulation, while improving mitochondrial function and the survival rate of steatotic hepatocytes. In terms of neuroprotection, 9-PAHSA regulates the expression of REST and BDNF in the prefrontal cortex of diabetic mice, and effectively prevents spatial working memory deficits and abnormal social behaviors. 9-PAHSA does not directly regulate insulin secretion or improve systemic insulin sensitivity, and possesses specific anti-inflammatory, metabolic regulatory and neuroprotective properties. 9-PAHSA can be used in the research of diabetes-related cognitive impairment, obesity and non-alcoholic fatty liver disease.
|
|
/
|
| HY-107333S | Cinoxate-d3 |
|
/
|
|
| HY-113440R | 5-Methoxytryptophol (Standard) |
5-Methoxytryptophol (Standard) is the analytical standard of 5-Methoxytryptophol. This product is intended for research and analytical applications. 5-Methoxytryptophol is a 5-methoxyindole alcohol structurally homologous to Melatonin (HY-B0075). It is secreted by the mammalian pineal gland and exhibits an inverse circadian rhythm. 5-Methoxytryptophol regulates bone metabolism by activating the ERK1/2 pathway. It reduces the levels of pro-inflammatory cytokines TNF-α and IL-1β, as well as proteolytic enzymes MMP-1 and MMP-2, in serum and dental pulp tissues, thereby ameliorating acute pulpitis. 5-Methoxytryptophol induces rapid sleep in mice, while high doses cause respiratory depression and death. 5-Methoxytryptophol. 5-Methoxytryptophol can be used in studies related to acute pulpitis, hypnosis, and bone metabolism.
|
Reference Standards
Melatonin Receptor
MMP
Endogenous Metabolite
ERK
Interleukin Related
TNF Receptor
Neurological, Eye or Ear Disease
Inflammation or Immune System Disease
Metabolic or Endocrine Disease
|
/
|
| HY-10585AS1 | Valproic acid-d14 sodium |
Valproic acid-d14 (sodium) is deuterium labeled Valproic acid (sodium). Valproic acid sodium salt (Sodium Valproate) is an HDAC inhibitor, with IC50 in the range of 0.5 and 2 mM, also inhibits HDAC1 (IC50, 400 μM), and induces proteasomal degradation of HDAC2. Valproic acid sodium salt activates Notch1 signaling and inhibits proliferation in small cell lung cancer (SCLC) cells. Valproic acid sodium salt is used in the treatment of epilepsy, bipolar disorder and prevention of migraine headaches.
|
|
/
|
| HY-101064S1 | Fmoc-leucine-13C6,15N |
Fmoc-leucine-13C6,15N is a 15N-labeled and 13C-labled Fmoc-leucine. Fmoc-leucine is a selective PPARγ modulator. Fmoc-leucine activates PPARγ with a lower potency but a similar maximal efficacy than rosiglitazone. Fmoc-leucine improves insulin sensitivity
|
|
/
|
| HY-108692S | Enterolactone-d6 |
Enterolactone-d6 is the deuterium labeled Enterolactone. Enterolactone is a bioactive phenolic metabolite known as a mammalian lignan derived from dietary lignans. Enterolactone has estrogenic properties and anti-breast cancer activity. Enterolactone is a radiosensitizer for human breast cancer cell lines through impaired DNA repair and increased apoptosis.
|
|
/
|
| HY-170473 | Wheat germ oil |
Wheat germ oil is an oil with nutritional value, especially its high Vitamin E content. Wheat germ oil is rich in health- beneficial bioactive compounds, such as phytosterols, tocopherols, carotenoids, and omega-3 fatty acids.
|
|
/
|
| HY-Z9022 | Iso cephalomannine |
Iso cephalomannine is a tubulin-targeting cytotoxic agent. Iso cephalomannine induces cytotoxicity in breast cancer cells. Iso cephalomannine can be used in breast cancer-related research.
|
|
/
|
| HY-B1812S | Veratrole-d4 |
Veratrole-d4 is the deuterium labeled Veratrole. Veratrole (1,2-Dimethoxybenzene) is a key compound that widely exists in plants and attracts pollinators. The release of Veratrole has a circadian rhythm and plays an important role in plant reproduction, species differentiation, and interactions with pollinators. In addition, Veratrole can be demethylated by cytochrome P-450 in Streptomyces setonii.
|
|
/
|
| HY-B1647 | Ferric phosphate |
Ferric phosphate is used as food and feed supplement, particularly in bread enrichment. Ferric phosphate is also used as a fertilizer and as a molluscicide for a variety of slugs and snails including Deroceras reticulatum, D.laeve, Arion subfuscus.
|
|
/
|
| HY-P3176 | Motilin, human, porcine |
Motilin, human, porcine is a gastrointestinal hormone, which is released during fasting and after eating, or by drinking water. Motilin, human, porcine promotes enteric cholinergic activity in human stomach with an EC50 of 33 nM, and thus modulates gastrointestinal motility function.
|
|
/
|
| HY-B1812S1 | Veratrole-d2 |
Veratrole-d2 is the deuterium labeled Veratrole. Veratrole (1,2-Dimethoxybenzene) is a key compound that widely exists in plants and attracts pollinators. The release of Veratrole has a circadian rhythm and plays an important role in plant reproduction, species differentiation, and interactions with pollinators. In addition, Veratrole can be demethylated by cytochrome P-450 in Streptomyces setonii.
|
|
/
|
| HY-151704 | ICG-alkyne |
ICG-alkyne is a short-wave infrared (SWIR)-emitting cyanine fluorescent probe based on alkyne-derivatized indocyanine green. ICG-alkyne can undergo click chemistry reaction to conjugate with antibody molecules via binding to the azide groups introduced into antibodies. ICG-alkyne enables SWIR fluorescent molecular imaging of breast tumors in living mice. ICG-alkyne can be used in breast cancer-related research.
|
|
/
|
| HY-P2166A | MMP3 inhibitor 3 TFA |
MMP3 inhibitor 3 (TFA) is an inhibitor of MMP3. MMP3 inhibitor 3 (TFA) can used to study breast cancer.
|
|
/
|
| HY-W014989 | Thioglucose |
Thioglucose is a thiosugar with antioxidant properties. Thioglucose acts as an H2S/polysulfide donor to elevate intracellular sulfane sulfur levels and promote hydropersulfide formation. Thioglucose reduces the endocytosis of gold nanoparticles by phagocytes, enhances cytotoxicity and improves biocompatibility by increasing their adsorption on the surface of cancer cells. Thioglucose can be engineered into a stimulus-responsive prodrug or functional reagent for the development of targeted nanocarriers, and is used in studies related to human breast adenocarcinoma and cervical cancer.
|
|
/
|
| HY-W587468 | all-trans-3,4-Didehydro retinoic acid |
All-trans-3,4-Didehydro retinoic acid (3,4-DHRA) is a compound with gene-regulating activity that binds to retinoic acid receptors (RARs) and triggers receptor activation. All-trans-3,4-Didehydro retinoic acid plays an important role in skin development and differentiation and has potential anti-tumor and anti-inflammatory properties. All-trans-3,4-Didehydro retinoic acid is also being studied for the inhibition of a variety of diseases, including skin diseases and certain types of cancer.
|
|
/
|
| HY-P991641 | IMC-EB10 |
IMC-EB10 (LY3012218) is an anti-FLT3 monoclonal antibody. IMC-EB10 binds to FLT3 with high affinity (Kd = 158 pM) and blocks the binding of FLT3 ligand to FLT3 (IC50 ≈ 10 nM), thereby inhibiting MAPK, STAT5, and PI3K/Akt signaling in leukemia cells. IMC-EB10 can enhance the anti-leukemic effect of Methotrexate (HY-14519) and inhibit leukemias expressing wild-type or ITD-mutated FLT3 receptors. IMC-EB10 prolongs the survival of acute lymphoblastic leukemia (ALL) cells and primary leukemia samples and reduces engraftment in non-obese diabetic/severe combined immunodeficiency patients. IMC-EB10 is indicated for leukemia research.
Species: Human |
|
/
|
| HY-N6802 | Tigloylgomisin H |
Tigloylgomisin H is a lignan isolated from the fruits of S. chinensis, can induce quinone reductase (QR) activity in Hepa1c1c7 mouse hepatocarcinoma cells. Tigloylgomisin H functions as a monofunctional inducer that specifically upregulates phase II detoxification enzyme NQO1 through the NF-E2-related factor 2 (Nrf2)-ARE pathway, thus represents a potential liver cancer prevention agent.
|
|
/
|
| HY-P992201 | Anti-CD160 Antibody (MAT 302) |
Anti-CD160 Antibody (MAT 302) (CL1-R2) is a human monoclonal antibody targeting CD160. Anti-CD160 Antibody (MAT 302) blocks the CD160-HVEM protein interaction, inhibits FGF2-mediated renal tubular vascular growth, and induces endothelial cell apoptosis. Anti-CD160 Antibody (MAT 302) targets CD160 on neovascularization to exert anti-angiogenic and vascular normalization effects, trigger the production of IFN-γ, TNF and IL-6 by NK cells, and enhance glucose metabolism of NK cells through the AKT/mTOR/s6k signaling pathway. Anti-CD160 Antibody (MAT 302) reduces vascular density, normalizes remaining tumor blood vessels, and inhibits tumor growth in melanoma-bearing mice. Anti-CD160 Antibody (MAT 302) can be used in research related to neovascularization, proliferative diabetic retinopathy, and melanoma.
Species: Human |
|
/
|
| HY-W770410 | 9-PAHSA-13C4 |
9-PAHSA-13C4 is 13C-labeled 9-PAHSA. 9-PAHSAis an orally active endogenous GPR120 agonist (EC50=18 μM). 9-PAHSAsignificantly inhibits LPS-induced inflammatory responses by blocking the NF-κB pathway. 9-PAHSAinduces adipocyte browning, enhances glucose uptake and reduces lipid accumulation, while improving mitochondrial function and the survival rate of steatotic hepatocytes. In terms of neuroprotection, 9-PAHSAregulates the expression of REST and BDNF in the prefrontal cortex of diabetic mice, and effectively prevents spatial working memory deficits and abnormal social behaviors. 9-PAHSAdoes not directly regulate insulin secretion or improve systemic insulin sensitivity, and possesses specific anti-inflammatory, metabolic regulatory and neuroprotective properties. 9-PAHSAcan be used in the research of diabetes-related cognitive impairment, obesity and non-alcoholic fatty liver disease.
|
|
/
|
| HY-123115 | Leucrose |
Leucrose (5-O-α-D-Glucopyranosyl-D-fructose) is an orally active Sucrose (HY-B1779) isomer naturally found in pollen and honey. Leucrose promotes phosphorylation of JAK1 and STAT6, reduces pro-inflammatory mediators and cytokinesas (TNFα, and IL-1β), increases M2 macrophage polarization and suppresses DSS (HY-116282C)-induced colitis. Leucrose suppresses hepatic triglyceride accumulation, improves fasting blood glucose levels, and regulates hepatic lipogenesis and fatty acid β-oxidation in high-fat diet-induced obese mice. Leucrose is slowly hydrolyzed into glucose and fructose by α-glucosidase and acts as as a sugar substitute in diet.
|
|
/
|
| HY-P11097 | Pep-20 |
Pep-20 is a CD47 binder with a human Kd of 2.91 µM and a murine Kd of 3.63 µM. Pep-20 blocks the interaction between CD47 and SIRPα, with an IC50 of 24.56 µM for human targets and 12.03 µM for murine targets. Pep-20 also acts as a phagocytosis enhancer and an inducer of anti-tumor immune responses. By blocking the CD47/SIRPα interaction, Pep-20 reduces the tyrosine phosphorylation level of SIRPα, disrupts the inhibitory "don't eat me" signaling pathway, enhances macrophage-mediated phagocytosis of solid tumor cells and hematologic tumor cells, and promotes macrophage mobilization of anti-tumor T-cell responses. Pep-20 can be used in research related to solid tumors, hematologic malignancies, breast cancer, and pancreatic cancer.
|
|
/
|
| HY-W1048555A | Mal-PEG2000-SCM |
Mal-PEG2000-SCM is a heterobifunctional PEG crosslinker bearing maleimide and succinimidyl carboxymethyl ester functional groups. MMal-PEG2000-SCM conjugates the F3 peptide to nanoparticles: the SCM group reacts with amino groups on the nanoparticle surface to form amide groups, while the MAL group reacts with thiol groups of the F3 peptide to form carbon-sulfur bonds. Mal-PEG-SCM enables unidirectional addition of linkers, ensuring that appropriate functional groups are available for RGD incorporation. Mal-PEG2000-SCM can be used in the development of nanoparticles targeting specific tumor cells.
|
|
/
|
| HY-10585S4 | Valproic acid-d4-1 |
Valproic acid-d4-1 is the deuterium labeled Valproic acid. Valproic acid (VPA; 2-Propylpentanoic Acid) is an HDAC inhibitor, with IC50 in the range of 0.5 and 2 mM, also inhibits HDAC1 (IC50, 400 μM), and induces proteasomal degradation of HDAC2. Valproic acid activates Notch1 signaling and inhibits proliferation in small cell lung cancer (SCLC) cells. Valproic acid sodium salt is used in the treatment of epilepsy, bipolar disorder and prevention of migraine headaches.
|
|
/
|
| HY-P11290 | MC4-NN2-0453 |
|
/
|
|
| HY-157346 | LB Nutrient Agar |
LB Nutrient Agar is a nutritionally rich medium originally developed for growth and maintenance of E. coli strains. LB Nutrient Agar is the most widely used medium for the growth of bacteria. The composition of 1 liter of LB Nutrient Agar contains:10.0 g tryptone, 5.0 g yeast, 10.0 g sodium chloride, and 15.0 g agar.
|
|
/
|
| HY-101064S3 | Fmoc-leucine-d10 |
Fmoc-leucine-d10 is the deuterium labeled Fmoc-leucine. Fmoc-leucine is a selective PPARγ modulator. Fmoc-leucine activates PPARγ with a lower potency but a similar maximal efficacy than rosiglitazone. Fmoc-leucine improves insulin sensitivity in normal, diet-induced glucose-intolerant, and in diabetic db/db mice. Fmoc-leucine has a lower adipogenic activity.
|
|
/
|
| HY-101064S2 | Fmoc-leucine-d3 |
Fmoc-leucine-d3 is the deuterium labeled Fmoc-leucine. Fmoc-leucine is a selective PPARγ modulator. Fmoc-leucine activates PPARγ with a lower potency but a similar maximal efficacy than rosiglitazone. Fmoc-leucine improves insulin sensitivity in normal, diet-induced glucose-intolerant, and in diabetic db/db mice. Fmoc-leucine has a lower adipogenic activity.
|
|
/
|
| HY-113081S | 1-Methyladenosine-d3 |
1-Methyl Adenosine-d3 is the deuterium labeled 1-Methyladenosine. 1-Methyladenosine is an RNA modification that can serve as a tumor marker, with elevated levels in the body associated with cancer development. Following 1-methyladenosine methylation, upregulation of PPARδ expression regulates cholesterol metabolism and activates Hedgehog signaling pathway, driving liver tumorigenesis.
|
|
/
|
| HY-107542S | Oleoylethanolamide-d4 |
Oleoylethanolamide-d4 is the deuterium labeled Oleoylethanolamide. Oleoylethanolamide is a high affinity endogenous PPAR-α agonist, which plays an important role in the treatment of obesity and arteriosclerosis.
|
|
/
|
| HY-10585AR | Valproic acid sodium (Standard) |
Valproic acid (sodium) (Standard) is the analytical standard of Valproic acid (sodium). This product is intended for research and analytical applications. Valproic acid (Sodium Valproate) sodium is an orally active HDAC inhibitor, with IC50 in the range of 0.5 and 2 mM, also inhibits HDAC1 (IC50, 400 μM), and induces proteasomal degradation of HDAC2. Valproic acid sodium activates Notch1 signaling and inhibits proliferation in small cell lung cancer (SCLC) cells. Valproic acid sodium is used in the treatment of epilepsy, bipolar disorder, metabolic disease, HIV infection and prevention of migraine headaches.
|
Infection
Neurological, Eye or Ear Disease
Metabolic or Endocrine Disease
Respiratory Disease
Small Cell Lung Cancer
|
/
|
| HY-W115607 | PEG4000-bis-amine |
PEG4000-bis-amine (Poly(ethylene glycol)-bis-amine 4000) is a diamine-terminated polyethylene glycol that acts as a linker for conjugate synthesis. PEG4000-bis-amine facilitates the development of MUC1 aptamer-based near-infrared fluorescent probes, and also conjugates folic acid with the near-infrared dye ICG-Der-01 to form a tumor-targeting probe. PEG4000-bis-amine supports the synthesis of folic acid-PEG-DSPE conjugates for the preparation of folic acid-targeted biliposomes. PEG4000-bis-amine is widely used in studies related to breast cancer, non-small cell lung cancer, hepatocellular carcinoma, rheumatoid arthritis, and tumors with high folate receptor expression.
|
|
/
|
| HY-128400 | 4'-Methoxychalcone |
|
/
|
|
| HY-P10032A | NN1177 TFA |
NN1177 (NNC9204-1177) TFA is a long-acting GLP-1/glucagon receptor co-agonist. NN1177 TFA can induce a dose-dependent body weight loss in diet-induced obese (DIO) mice.
|
|
/
|
| HY-P991023 | Safimestomig |
Safimestomig (6MW3211) is an CD47/PD-L1-targeting bispecific antibody. Safimestomig blocks CD47-mediated 'don't eat me' signaling and selectively binds to CD47 on tumor cells. Safimestomig blocks PD-L1-mediated immune checkpoint signaling. Safimestomig can be used for the research of cancer.
Species: Human |
|
/
|
| HY-113081AS | 1-Methyladenosine-d3 hydrochloride |
1-Methyladenosine-d3 hydrochloride is the hydrochloride salt form of deuterium labeled 1-Methyladenosine (HY-113081). 1-Methyladenosine is an RNA modification that can serve as a tumor marker, with elevated levels in the body associated with cancer development. Following 1-methyladenosine methylation, upregulation of PPARδ expression regulates cholesterol metabolism and activates Hedgehog signaling pathway, driving liver tumorigenesis.
|
|
/
|
| HY-W012382S | N-Acetyl-L-tyrosine-d3 |
N-Acetyl-L-tyrosine-d3 is the deuterated form of N-Acetyl-L-tyrosine (HY-W012382). N-Acetyl-L-tyrosine is an orally active endogenous mitochondrial stress response regulator that can permeate the cell membrane by passive diffusion. N-Acetyl-L-tyrosine induces low-level reactive oxygen species (ROS) generation by transiently perturbing mitochondrial membrane potential, triggering reverse signaling to activate FoxO and Keap1 pathways. As a result, N-Acetyl-L-tyrosine enhances the expression of antioxidant enzyme genes, exerting anti-stress and cytoprotective effects. N-Acetyl-L-tyrosine can improve heat stress tolerance, inhibit tumor growth, and regulate energy metabolism. N-Acetyl-L-tyrosine can be used in the research of aging, metabolic diseases (such as diabetes), and cancer.
|
|
/
|
| HY-N7592 | Arjunetin |
Arjunetin, isolated from Terminalia arjuna, is an insect feeding-deterrent and growth inhibitor.
|
|
/
|
| HY-N0658S | L-Threonine-15N |
L-Threonine-15N is the 15N-labeled L-Threonine. L-Threonine is a natural amino acid, can be produced by microbial fermentation, and is used in food, medicine, or feed.
|
|
/
|
| HY-P4102 | Cyclic PSAP peptide |
Cyclic PSAP peptide is a cyclic pentapeptide (DWLPK). Cyclic PSAP peptide exhibits agent-like properties and could inhibit metastatic spread and restrain tumor development in general in vivo.
|
|
/
|
| HY-B1779S3 | Sucrose-d14 |
Sucrose-d14 is the deuterium labeled Sucrose. Sucrose (D-(+)-Saccharose) is a disaccharide which is composed of two monosaccharides, glucose and fructose. Sucrose can be applied in some animal models, including metabolic disease, obesity, diet on preferen
|
|
/
|
| HY-W015273AR | trans-3-Indoleacrylic acid (Standard) |
trans-3-Indoleacrylic acid (Standard) is the analytical standard of trans-3-Indoleacrylic acid. This product is intended for research and analytical applications. Trans-3-Indoleacrylic acid is a tryptophan metabolite, which promotes tumor development through inhibition of RSL3 (HY-100218A) induced ferroptosis via AHR-ALDH1A3-FSP1-CoQ10 axis, and facilitates colorectal carcinogenesis[1]
|
|
/
|
| HY-W768340 | Sucrose-13C6-1 |
Sucrose-13C6-1 is 13C labeled Sucrose. Sucrose (D-(+)-Saccharose) is a disaccharide which is composed of two monosaccharides, glucose and fructose. Sucrose can be applied in some animal models, including metabolic disease, obesity, diet on preference, and diabetes, et al.
|
|
/
|
| HY-10585S1 | Valproic acid-d6 |
Valproic acid-d6 is the deuterium labeled Valproic acid. Valproic acid (VPA; 2-Propylpentanoic Acid) is an HDAC inhibitor, with IC50 in the range of 0.5 and 2 mM, also inhibits HDAC1 (IC50, 400 μM), and induces proteasomal degradation of HDAC2. Valproic acid activates Notch1 signaling and inhibits proliferation in small cell lung cancer (SCLC) cells. Valproic acid sodium salt is used in the treatment of epilepsy, bipolar disorder and prevention of migraine headaches.
|
|
/
|
| HY-139058 | 23-epi-26-Deoxyactein |
23-epi-26-Deoxyactein is a natural and orally active anti-obesity and anti-cancer compound.
|
|
/
|
| HY-W105734 | 15-Hydroxypentadecanoic acid |
15-Hydroxypentadecanoic acid is a long-chain fatty acid found in various plant and animal sources and also produced by bacteria and fungi. It has potential health benefits and is used as an intermediate in the synthesis of other organic compounds, including pharmaceuticals, agrochemicals and surfactants. Its unique chemical properties make it an essential ingredient in several industrial processes, especially in the fields of food science and nutrition.
|
|
/
|
| HY-P1437 | Neuropeptide S (mouse) |
Neuropeptide S (mouse) is a bioactive peptide. Neuropeptide S (mouse), as a neurotransmitter/neuromodulator of 20 amino acids, can be used for the research of arousal, anxiety, locomotion, feeding behaviors, memory and agent addiction.
|
|
/
|
| HY-P0237A | KKI-5 TFA |
KKI-5 (TFA) is a specific inhibitor of tissue kallikrein. KKI-5 (TFA) can attenuate breast cancer cell invasion.
|
|
/
|
| HY-N0658S5 | L-Threonine-d2 |
L-Threonine-d2 is the deuterium labeled L-Threonine. L-Threonine is a natural amino acid, can be produced by microbial fermentation, and is used in food, medicine, or feed.
|
|
/
|
| HY-W012499S | N-Acetyl-L-methionine-d3 |
N-Acetyl-L-methionine-d3 is the deuterium labeled N-Acetyl-L-methionine. N-Acetyl-L-methionine, a human metabolite, is nutritionally and metabolically equivalent to L-methionine. L-methionine is an indispensable amino acid required for normal growth and development.
|
|
/
|
| HY-W039939 | 2-Azido-2-deoxy-D-glucose, 98% |
2-Azido-2-deoxy-D-glucose, 98% (2-ADG, 98%) is a substrate of O-GlcNAc transferase (OGT). 2-Azido-2-deoxy-D-glucose, 98% can be transferred from UDP-GlcAz to proteins in vitro via OGT mediation. When delivered as AcGlcAz, 2-Azido-2-deoxy-D-glucose, 98% enables the labeling and investigation of O-GlcNAc-modified nuclear and cytoplasmic proteins in cells. 2-Azido-2-deoxy-D-glucose, 98% undergoes strain-promoted [3+2] azide-alkyne cycloaddition (SPAAC) with technetium-99m-labeled dibenzocyclooctyne derivatives in vivo. 2-Azido-2-deoxy-D-glucose, 98% can be used in sarcoma-related research.
|
|
/
|
| HY-W654002 | (3R)-3-Hydroxybutyric acid-1-13C |
(3R)-3-Hydroxybutyric acid-1-13C is 13C labeled (R)-3-Hydroxybutanoic acid. (R)-3-Hydroxybutanoic acid is a metabolite, and converted from acetoacetic acid catalyzed by 3-hydroxybutyrate dehydrogenase. (R)-3-Hydroxybutanoic acid has applications as a nutrition source and as a precursor for vitamins, antibiotics and pheromones.
|
|
/
|
| HY-76632 | 4-Hydroxyisophthalic acid |
4-Hydroxyisophthalic acid activates antioxidant enzymes (such as catalase CAT and superoxide dismutase SOD), scavenges free radicals, and exhibits antioxidant property. 4-Hydroxyisophthalic acid activates AChE and BChE, enhances neuronal function and improves Tau-induced neurobehavioral defects. 4-Hydroxyisophthalic acid improves the cognitive defects, and ameliorates circadian rhythm disorders of fruit flies.
|
|
/
|
| HY-N7364R | (E)-β-Farnesene (Standard) |
(E)-β-Farnesene (Standard) is the analytical standard of (E)-β-Farnesene. This product is intended for research and analytical applications. (E)-β-Farnesene (trans-β-Farnesene) is a volatile sesquiterpene hydrocarbon which can be found in Phlomis aurea Decne essential oil. (E)-β-Farnesene can be used as a feeding stimulant for the sand fly Lutzomyia longipalpis.
|
|
/
|
| HY-113270AS | Actinine-d9 chloride |
Actinine-d9 chloride is the deuterium labeled Actinine chloride. Actinine chloride is angiopathic substance produced as an intermediary metabolite by gut microbiota that feed on carnitine in dietary red meat.
|
|
/
|
| HY-P1765 | Galanin (1-19), human |
|
/
|
|
| HY-P99687 | Latikafusp |
Latikafusp (AMG 256) is a bifunctional fusion protein comprising a PD-1-targeting antibody and IL-21 mutein designed to deliver IL-21 pathway stimulation to PD-1+ cells. Latikafusp is designed to prime and extend the activity of cytotoxic and memory T cells and induce anti-tumor immunity. Latikafusp has the potential for solid tumors research.Latikafusp may lead to the development of immunogenicity-mediated responses.
|
|
/
|
| HY-P10026 | Nisotirostide |
Nisotirotide (LY-3457263) is a subcutaneous injectable NPY2 receptor agonist. By mimicking peptide YY (PYY), Nisotirotide inhibits appetite and can be used in the research of diseases such as obesity and diabetes.
|
|
/
|
| HY-P5244 | Tripeptide-32 |
Tripeptide-32 is a bioactive peptide that targets the PER1 gene. Tripeptide-32 can regulate circadian rhythms and stimulate the synthesis of cellular repair proteins, with anti-aging activity.
|
|
/
|
| HY-113081S1 | 1-Methyladenosine-d3 hydriodide |
1-Methyladenosine-d3 hydriodide is the deuterium labeled 1-Methyladenosine (HY-113081). 1-Methyladenosine is an RNA modification that can serve as a tumor marker, with elevated levels in the body associated with cancer development. Following 1-methyladenosine methylation, upregulation of PPARδ expression regulates cholesterol metabolism and activates Hedgehog signaling pathway, driving liver tumorigenesis.
|
|
/
|
| HY-10585S2 | Valproic acid-d15 |
Valproic acid-d15 is the deuterium labeled Valproic acid. Valproic acid (VPA; 2-Propylpentanoic Acid) is an HDAC inhibitor, with IC50 in the range of 0.5 and 2 mM, also inhibits HDAC1 (IC50, 400 μM), and induces proteasomal degradation of HDAC2. Valproic acid activates Notch1 signaling and inhibits proliferation in small cell lung cancer (SCLC) cells. Valproic acid sodium salt is used in the treatment of epilepsy, bipolar disorder and prevention of migraine headaches.
|
|
/
|
| HY-P10959A | Macupatide acetate |
Macupatide acetate is a glucose-dependent insulinotropic polypeptide (GIP) receptor agonist. Macupatide acetate improves insulin secretion responses and insulin sensitivity.Macupatide acetate can be used for the research of type 2 diabetes.
|
|
/
|
| HY-B1812 | Veratrole |
Veratrole (1,2-Dimethoxybenzene) is a key compound that widely exists in plants and attracts pollinators. The release of Veratrole has a circadian rhythm and plays an important role in plant reproduction, species differentiation, and interactions with pollinators. In addition, Veratrole can be demethylated by cytochrome P-450 in Streptomyces setonii.
|
|
/
|
| HY-N0658S1 | L-Threonine-d5 |
L-Threonine-d5 is the deuterium labeled L-Threonine. L-Threonine is a natural amino acid, can be produced by microbial fermentation, and is used in food, medicine, or feed.
|
|
/
|
| HY-137840 | Hippuryl-L-phenylalanine |
Hippuryl-L-phenylalanine is a substrate of carboxypeptidase. Carboxypeptidase is a protease enzyme that related with obesity, epilepsy and neurodegeneration. Hippuryl-L-phenylalanine can be used for the determination of carboxypeptidase activity.
|
|
/
|
| HY-N0658S3 | L-Threonine-13C4,15N |
L-Threonine-13C4,15N is the 13C- and 15N-labeled L-Threonine. L-Threonine is a natural amino acid, can be produced by microbial fermentation, and is used in food, medicine, or feed.
|
|
/
|
| HY-B0228S10 | (R)-3-Hydroxybutanoic acid-13C2 sodium |
(R)-3-Hydroxybutanoic acid-13C2 sodium is the 13C labeled (R)-3-Hydroxybutanoic acid sodium (HY-W015851). (R)-3-Hydroxybutanoic acid sodium is a metabolite converted from acetoacetic acid catalyzed by 3-hydroxybutyrate dehydrogenase. (R)-3-Hydroxybutanoic acid sodium can function as a nutrition source, and as a precursor for vitamins, antibiotics and pheromones.
|
|
/
|
| HY-P2378 | Neuromedin U-25 (human) |
|
/
|
|
| HY-W002116 | Methyl syringate |
Methyl syringate is a selective TRPA1 agonist. Methyl syringate regulates food intake and gastric emptying through a TRPA1-mediated pathway. Methyl syringate is an efficient phenolic mediator for bacterial and fungal laccases. Methyl syringate is a chemical marker of Asphodel monofloral honey. Methyl syringate contributes to the antibacterial activity of honey. Methyl syringate inhibits aflatoxin production. Methyl syringate can contribute to weight suppression. Methyl syringate can be studies for cancer prevention (e.g. lung cancer), suppression of hypoxia-induced inflammatory response and tumorigenesis.
Source: honey |
Metabolic or Endocrine Disease
Lung Cancer
Gastric Cancer
Bacterial Infection
Pain
Rheumatoid Arthritis
|
/
|
| HY-15206S1 | Glyburide-d3 |
Glyburide-d3 is the deuterium labeled Glibenclamide. Glibenclamide (Glyburide) is an orally active ATP-sensitive K+ channel (KATP) inhibitor and can be used for the research of diabetes and obesity[1]. Glibenclamide inhibits P-glycoprotein. Glibenclamide directly binds and blocks the SUR1 subunits of KATP and inhibits the cystic fibrosis transmembrane conductance regulator protein (CFTR)[3]. Glibenclamide interferes with mitochondrial bioenergetics by inducing changes on membrane ion permeability[4]. Glibenclamide can induce autophagy[5].
|
|
/
|
| HY-P2612A | WP9QY TFA |
WP9QY, TNF-a Antagonist, TNF-a Antagonist is a biological active peptide. (This cyclic peptide is designed to mimic the most critical tumor necrosis factor (TNF) recognition loop on TNF receptor I. It prevents interactions of TNF with its receptor. This TNF antagonist is a useful template for the development of small molecular inhibitors to prevent both inflammatory bone destruction and systemic bone loss in rheumatoid arthritis.)
|
|
/
|
| HY-N4294 | Arjungenin |
Arjungenin, a pentacyclic triterpenoid compound, is a FXR agonist. Arjungenin can improve insulin sensitivity by regulating the function of fat cells. Arjungenin exhibits moderate free radical scavenging activity. Arjungenin has growth inhibitory activity against the insect Spilarctia obliqua. Arjungenin has significant antiviral activity against a series of viruses such as chikungunya Virus (CHIKV).
|
|
/
|
| HY-W768338 | Sucrose-13C |
Sucrose-13C is 13C labeled Sucrose. Sucrose (D-(+)-Saccharose) is a disaccharide which is composed of two monosaccharides, glucose and fructose. Sucrose can be applied in some animal models, including metabolic disease, obesity, diet on preference, and diabetes, et al.
|
|
/
|
| HY-Y1220J | Potassium carbonate, 99% |
Potassium carbonate, with a purity of 99%, is an inorganic compound. At low concentrations, potassium carbonate can be used as an alkaline treatment agent and feed buffer in pork processing, as well as to inhibit the synthesis of milk fat in dairy cows.
|
|
/
|
| HY-78216 | 2-Thiooxamic acid ethyl ester |
|
/
|
|
| HY-W010934 | 3β,5α,6β-Trihydroxycholestane |
3β,5α,6β-Trihydroxycholestane is a steroid that occurs naturally in the body and is also found in certain foods. It belongs to a class of compounds known as cholestanes, which are closely related to the better known cholesterol. This particular compound is formed from cholesterol through a series of enzymatic reactions in the liver and other organs. It has been studied for its potential health benefits, including its ability to reduce inflammation and oxidative stress in the body. Some research suggests that it may also play a role in regulating blood sugar levels and improving insulin sensitivity. Despite these potential benefits, 3β,5α,6β-Trihydroxycholestane is not widely used as a supplement or medicine due to its relatively low content, focus on natural resources and limited research. However, researchers continue to investigate its potential uses and effects on human health.
|
|
/
|
| HY-W250120 | Konjac glucomannan (Viscosity≥15000mPa.s) |
Konjac glucomannan (Viscosity≥15000mPa.s) is an orally active acetylated (1-4)-β-D-glucomannan with multiple biological activities including anti-diabetic, anti-obesity, anti-inflammatory effects, as well as film-forming and gelling properties. Konjac glucomannan (Viscosity≥15000mPa.s) forms a defensive coating on the intestinal surface, reducing levels of blood glucose, cholesterol, triglycerides and blood pressure; it is specifically degraded by colonic β-mannanase produced by human colonic bacteria. Konjac glucomannan (Viscosity≥15000mPa.s) can be used as a food additive, dietary supplement and excipient for oral colon-targeted drug delivery systems. Konjac glucomannan (Viscosity≥15000mPa.s) is applicable to research related to various diseases such as type 2 diabetes, obesity, atopic dermatitis and metabolic syndrome, as well as research in fields including biotechnology, pharmaceuticals and tissue engineering.
|
|
/
|
| HY-W015851S2 | (R)-3-Hydroxybutanoic acid-13C4 sodium |
(R)-3-Hydroxybutanoic acid-13C4 sodium is a 13C labeled (R)-3-Hydroxybutanoic acid (HY-W051723). (R)-3-Hydroxybutanoic acid is a metabolite converted from acetoacetic acid catalyzed by 3-hydroxybutyrate dehydrogenase. (R)-3-Hydroxybutanoic acid can function as a nutrition source, and as a precursor for vitamins, antibiotics and pheromones.
|
|
/
|
| HY-N2122 | Neoisoliquiritin |
Neoisoliquiritin (Neoisoliquiritigenin) is an androgen receptor (AR) inhibitor. Neoisoliquiritin inhibits the ATPase activity of GRP78. Neoisoliquiritin induces G0/G1 cell cycle arrest and inhibits proliferation in cancer cells, while it also induces cell apoptosis (apoptosis). Neoisoliquiritin suppresses tumor growth in mouse models of prostate cancer and breast cancer. Neoisoliquiritin can be used in studies related to prostate cancer and breast cancer.
|
|
/
|
| HY-P990667 | STX-100 |
STX-100 (BG00011) is a humanized monoclonal antibody targeting αVβ6 integrin. STX-100 specifically binds αVβ6 integrin, blocks latent TGF-β activation via latency-associated peptide (LAP) interaction prevention, and reduces profibrotic responses. STX-100 can be used for the research of idiopathic pulmonary fibrosis, and cancer.
Species: Human |
|
/
|
| HY-P10131 | 3BP-3940 |
3BP-3940 is a highly potent and selective peptide inhibitor of FAP that targets cancer-associated fibroblasts (CAFs) in the tumor microenvironment. 3BP-3940 can be labeled with radionuclides (such as Ga-68) for precise tumor imaging or Lu-177 for the development of targeted anticancer technologies. 3BP-3940 accumulates in tumor lesions and can be used to diagnose and inhibit various solid cancers and CAFs-related diseases.
|
|
/
|
| HY-77813 | Benzyl isothiocyanate |
Benzyl isothiocyanate is an orally available isothiocyanate with bactericidal, anticancer, antiangiogenic and anthelmintic activities. Benzyl isothiocyanate exerts anticancer functions by regulating multiple signaling pathways, including apoptosis, cell proliferation, cell cycle arrest, metastasis, angiogenesis, and autophagy. In addition, Benzyl isothiocyanate can enhance muscle insulin sensitivity to improve obesity-induced hyperglycemia.
|
Metabolic or Endocrine Disease
Digestive System Disease
Leukemia/Lymphoma/Myeloma
Bacterial Infection
Parasitic Infection
Digestive System Inflammation
|
/
|
| HY-129297 | CMPF |
CMPF can be found in trace constituent of urine and blood. CMPF is a biomarker of type 2 diabetes. CMPF can act on the β cell and induces impaired mitochondrial function. CMPF decreases glucose-induced ATP accumulation, and induces oxidative stress. CMPF reverses hepatic lipid accumulation and improves insulin sensitivity in obese mice.
|
|
/
|
| HY-Y0520S | Itaconic acid-13C5 |
|
/
|
|
| HY-P11285A | LAGIPRA peptide TFA |
LAGIPRA peptide TFA is a long-acting GIP1R agonist. LAGIPRA peptide TFA enhances insulin sensitivity by augmenting glucose disposal and reduces branched-chain amino acids (BCAAs) and ketoacids. LAGIPRA peptide TFA has the potential for the research of type 2 diabetes.
|
|
/
|
| HY-N0140R | Ursolic acid (Standard) |
Ursolic acid (Standard) is the analytical standard of Ursolic acid. This product is intended for research and analytical applications. Ursolic acid (Prunol) is a natural pentacyclic triterpenoid carboxylic acid, exerts anti-tumor effects and is an effective compound for cancer prevention and therapy.
|
|
/
|
| HY-113334 | Turanose |
Turanose is an isomer of Sucrose that naturally exists in honey. Turanose has anti-inflammatory and regulates adipogenesis effect. Turanose has potential for obesity and related chronic diseases research.
Source: honey |
|
/
|
| HY-N1440 | Koumine |
Koumine is an alkaloid separated from Gelsemium elegans, shows potent anti-tumor activity. Koumine up-regulates the Bax/Bcl-2 ratio and caspase-3 expression in human breast cancer cells. Koumine has anxiolytic, antistress, antipsoriatic, and analgesic activities, protects against the development of arthritis in Rheumatoid arthritis (RA) animal models.
|
|
/
|
| HY-P990964 | Efimosfermin alfa |
Efimosfermin alfa is a genetically engineered FGF21 variant. Efimosfermin alfa exerts its function by activating the FGFR1c/β-Klotho complex. Efimosfermin alfa is applicable to researches on metabolic dysfunction-associated steatohepatitis, obesity and mild hypertriglyceridemia.
Species: Human |
|
/
|
| HY-W007664 | (R)-4-Benzyl-2-oxazolidinone |
(R)-4-Benzyl-2-oxazolidinone is an oxazolidinone-type auxiliary that enables highly stereoselective asymmetric alkylation reactions. (R)-4-Benzyl-2-oxazolidinone is applied in the total synthesis of natural products and pharmaceutical preparations. Especially in pharmaceutical research and development, (R)-4-Benzyl-2-oxazolidinone not only serves as a key precursor for the synthesis of aromatase inhibitors, but also can be used in studies related to estrogen-dependent breast cancer.
|
|
/
|
| HY-75102 | 4-Boronobenzoic acid |
4-Boronobenzoic acid is an organic compound. 4-Boronobenzoic acid forms reversible cyclic boronate esters with molecules containing cis-vicinal diol structures (such as sialic acid) through the boron atom, achieving molecular recognition and binding. 4-Boronobenzoic acid can be used in research of breast cancer .
|
|
/
|
| HY-110228 | Metformin-d6 hydrochloride |
Metformin-d6 hydrochloride is a deuterium labeled Metformin hydrochloride. Metformin hydrochloride inhibits the mitochondrial respiratory chain in the liver, leading to AMPK activation and enhancing insulin sensitivity, and can be used in the study of type 2 diabetes. Metformin hydrochloride also inhibits liver oxidative stress, nitrosative stress, inflammation, and apoptosis caused by liver ischemia/reperfusion injury. In addition, metformin hydrochloride regulates the expression of autophagy-related proteins by activating AMPK and inhibiting the mTOR signaling pathway, thereby inducing tumor cell autophagy and inhibiting the growth of renal cell carcinoma in vitro and in vivo.
|
|
/
|
| HY-N8522 | 9,10-Dihydroxystearic acid |
9,10-Dihydroxystearic acid is an oxidation product of oleic acid. 9,10-Dihydroxystearic acid can improve glucose tolerance and insulin sensitivity in KKAy mice.
|
|
/
|
| HY-D0203 | Basic green 4 |
Basic green 4 (Malachite green) is a cationic dye that is widely used as a bactericide in aquaculture and is also commonly used in laboratories for the determination of phosphates. Basic green 4 exhibits high cytotoxicity and carcinogenicity to mammalian cells, specifically shown by its IC50 values of 2.03 µM for HEp-2 human laryngeal cells and 13.8 µM for Caco-2 human colorectal adenocarcinoma cells, and it can promote the development of liver tumors. The maximum absorbance wavelength is 621 nm.
|
|
/
|
| HY-P10959 | Macupatide |
Macupatide is a glucose-dependent insulinotropic polypeptide (GIP) receptor agonist. Macupatide improves insulin secretion responses and insulin sensitivity.Macupatide can be used for the research of type 2 diabetes.
|
|
/
|
| HY-P3366 | Ecnoglutide |
|
/
|
|
| HY-NP132 | Recombinant Humanized Type III Collagen 28.6kDa |
Recombinant Humanized Type III Collagen 28.6kDa is a 28.6 kDa recombinant humanized type III collagen. Recombinant Humanized Type III Collagen possesses a variety of biological functions, such as promoting the regeneration of the skin extracellular matrix and improving the cellular microenvironment. Recombinant Humanized Type III Collagen can also inhibit the proliferation, migration and invasion of breast cancer cells. Recombinant Humanized Type III Collagen plays a role in cell adhesion, migration, proliferation and differentiation by interacting with Integrin.
|
|
/
|
| HY-P1434 | [Pro3]-GIP (mouse) |
[Pro3]-GIP (mouse) is a GIP receptor antagonist (IC50: 2.6 μM). [Pro3]-GIP (mouse) improves glucose tolerance and insulin sensitivity in ob/ob mice. [Pro3]-GIP (mouse) can be used for research of type 2 diabetes.
|
|
/
|
| HY-P991504 | LAE-102 |
|
/
|
|
| HY-W250308A | ε-Poly-L-lysine hydrochloride (MV 2000-5000) |
ε-Poly-L-lysine (Epsilon-polylysine; ε-Polylysine) hydrochloride (MV 2000-5000) is a polycationic antibacterial agent with broad-spectrum activity against Gram-positive bacteria, Gram-negative bacteria, fungi, yeasts and specific bacteriophages. ε-Poly-L-lysine hydrochloride (MV 2000-5000) exerts bactericidal effects through mechanisms such as disrupting microbial membranes, inducing ROS production, inhibiting metabolism and spore germination. ε-Poly-L-lysine hydrochloride (MV 2000-5000) also regulates the expression of multiple key genes including sodA, oxyR and recA. ε-Poly-L-lysine hydrochloride (MV 2000-5000) exhibits properties such as low eukaryotic cytotoxicity, thermal stability and pH stability, and supports tissue regeneration and anti-tumor applications. ε-Poly-L-lysine hydrochloride (MV 2000-5000) can be applied in research fields including bacterial and fungal infections, diabetic ulcers, and methicillin-resistant Staphylococcus aureus infections.
|
|
/
|
| HY-120657 | 9-PAHSA |
9-PAHSA is an orally active endogenous GPR120 agonist (EC50=18 μM). 9-PAHSA significantly inhibits LPS-induced inflammatory responses by blocking the NF-κB pathway. 9-PAHSA induces adipocyte browning, enhances glucose uptake and reduces lipid accumulation, while improving mitochondrial function and the survival rate of steatotic hepatocytes. In terms of neuroprotection, 9-PAHSA regulates the expression of REST and BDNF in the prefrontal cortex of diabetic mice, and effectively prevents spatial working memory deficits and abnormal social behaviors. 9-PAHSA does not directly regulate insulin secretion or improve systemic insulin sensitivity, and possesses specific anti-inflammatory, metabolic regulatory and neuroprotective properties. 9-PAHSA can be used in the research of diabetes-related cognitive impairment, obesity and non-alcoholic fatty liver disease.
|
Neurological, Eye or Ear Disease
Digestive System Disease
Digestive System Inflammation
Glucose Metabolism
Obesity
|
/
|
| HY-42680 | D-Tagatose |
D-Tagatose (D-(-)-Tagatose) is a natural low-calorie rare sugar. D-Tagatose inhibits the activities of sucrase, maltase and intestinal disaccharidases, reduces the digestion of sucrose and starch, and blocks the absorption of sucrose, maltose and glucose. D-Tagatose promotes glucokinase activity and inhibits glycogen phosphorylase activity via tagatose-1-phosphate, regulates the synthesis and decomposition of hepatic glycogen, reduces postprandial and fasting blood glucose levels, and improves hyperinsulinemia. D-Tagatose regulates lipid profiles, stimulates GLP-1 secretion, and exhibits prebiotic effects. D-Tagatose is a bulking sweetener. D-Tagatose can be used in research related to diabetes, hyperlipidemia, dental caries, atherosclerosis and type 2 diabetes.
|
|
/
|
| HY-P10091 | CD24/Siglec-10 blocking peptide, CSBP |
CD24/Siglec-10 blocking peptide, CSBP can not only block the interaction of CD24/Siglec-10 but also PD-1/PD-L1. CD24/Siglec-10 blocking peptide, CSBP can induce the phagocytosis of tumor cell.
|
Lung Cancer
Breast Cancer
Colorectal Cancer
Gastric Cancer
Liver Cancer
Leukemia/Lymphoma/Myeloma
Ovarian Cancer
|
/
|
| HY-W133982 | Corn steep liquor |
Corn steep liquor, a food industrial by-product, is a nutritional additive in the liquid culture medium of fungus. Corn steep liquor can increase the production of fairy chemicals and mycelia.
|
|
/
|
| HY-P1928 | Humanin |
Humanin, an anti-apoptotic peptide of 24 amino acids, is a Bax inhibitor. Humanin prevents the translocation of Bax from cytosol to mitochondria, blocks Bax from the inactive to active conformation. Humanin is a mitochondria-associated peptide with a neuroprotective effect against AD-related neurotoxicity. Humanin also improves overall insulin sensitivity in animal. Humanin are related to aging.
Humanin analogue, in which the serine at position 14 is replaced by glycine, names HNG. |
|
/
|
| HY-113270A | Actinine chloride |
Actinine (γ-Butyrobetaine) chloride is angiopathic substance produced as an intermediary metabolite by gut microbiota that feed on carnitine in dietary red meat.
|
|
/
|
| HY-13012G | RepSox (GMP) |
|
/
|
|
| HY-NP163A | Wheat germ agglutinin-AF488 |
Wheat germ agglutinin-AF488 (WGA-AF488) is a cell membrane-specific staining agent prepared by conjugating wheat germ agglutinin with the Alexa Fluor 488 (HY-D1304) fluorescent dye, and it binds to cell surface glycoproteins with high affinity. Wheat germ agglutinin-AF488 is applied in fluorescence microscopy and confocal imaging techniques, and it can clearly label the membrane structures of various cells including breast cancer cells, enabling high-resolution visual observation. Wheat germ agglutinin-AF488 is used in studies of breast cancer and triple-negative breast cancer to observe cell morphology and membrane dynamic changes.
|
|
/
|
| HY-128748 | DL-Glyceraldehyde |
DL-Glyceraldehyde is a bioactive substance involved in cellular energy metabolism and a key intermediate in sugar metabolism pathways (such as glycolysis and gluconeogenesis). During glycolysis, DL-Glyceraldehyde is converted by enzymes into other metabolites to provide energy for cells; during gluconeogenesis, DL-Glyceraldehyde participates in the synthesis of glucose as a precursor. In the field of medical research, DL-Glyceraldehyde can be used to study diseases related to sugar metabolism, such as diabetes, tumors, etc
|
|
/
|
| HY-P990047 | Maridebart |
Maridebart (AMG133 antibody) is a human immunoglobulin G1-kappa, anti-GIPR (gastric inhibitory polypeptide receptor) monoclonal antibody. Maridebart is the antibody portion of Maridebart cafraglutide (HY-164535) and can be used for the synthesis of antibody-drug conjugates (ADC). Maridebart can be used for the reserrch of obesity and type 2 diabetes .
Species: Human |
|
/
|
| HY-153126 | Yeast extract |
Yeast extract is a concentrate of the soluble components of yeast, especially Saccharomyces cerevisiae. Yeast extract is rich in nutritional components such as partially hydrolyzed proteins, free amino acids, B vitamins, and minerals. As a food ingredient, Yeast extract has both nutritional and flavoring properties. Yeast extract can also promote wound healing.
|
|
/
|
| HY-A0103 | Xanthan gum |
Xanthan gum interacts with gelatin (HY-Y1365) via hydrogen bonds, thereby increasing the viscosity and stability of the hydrogel while promoting cell growth and creating a microenvironment conducive to cell differentiation. Xanthan gum induces pro-inflammatory responses by increasing the levels of TNF-α, IL-6, and IL-10. Xanthan gum can be used for inflammation and immunology research.
|
|
/
|
| HY-P1120 | WKYMVm |
WKYMVm is a selective formylpeptide receptor 2 (FPR2) agonist. WKYMVm has a powerful anti-inflammatory effect that can reduce lung injury and spinal cord injury. WKYMVm ameliorates obesity by regulating lipid metabolism and leptin signaling. WKYMVm is involved in the regulation of immune cells by activating FPRs. WKYMVm can promote the chemotactic migration of immune cells and inhibit the apoptosis of phagocytes. In addition, WKYMVm may play a favorable or unfavorable role in tumors, depending on the type of tumor.
|
Cancer
Neurological, Eye or Ear Disease
Metabolic or Endocrine Disease
Digestive System Disease
Digestive System Inflammation
|
/
|
| HY-N7364 | (E)-β-Farnesene |
(E)-β-Farnesene (trans-β-Farnesene) is an aphid alarm pheromone, which can be found in Phlomis aurea Decne essential oil. (E)-β-Farnesene shows good binding score with a value of -30.64 kcal/mol to the CDK2 receptor. (E)-β-Farnesene also exhibits good affinity to odorant-binding protein 3 (OBP3). (E)-β-Farnesene can be used as a feeding stimulant for the sand fly Lutzomyia longipalpis.
|
|
/
|
| HY-P11274A | Zenagamtide sodium |
Zenagamtide (Amycretin; NN 9487) sodium is an orally active, blood-brain barrier permeable triple agonist that targets GLP-1, amylin (Amylin Receptor) and calcitonin receptor (Calcitonin Receptor). Zenagamtide sodium is a single peptide consisting of 68 amino acids that can target brain regions regulating food intake, significantly suppress appetite and reduce energy intake. Therefore, Zenagamtide sodium improves body weight, waist circumference, glycated hemoglobin and lipid profile, and also alleviates the histological features of metabolic dysfunction-associated steatotic liver disease (MASLD) and enhances insulin sensitivity. Zenagamtide sodium may cause transient increases in heart rate and fluctuations in serum calcium levels, but it is an important compound for the study of overweight, obesity, insulin resistance and related metabolic diseases.
|
|
/
|
| HY-P10746 | EB1002 |
EB1002 is a highly selective, long-acting NK2R agonist. EB1002 exerts central appetite suppression, increases peripheral energy expenditure and enhances insulin sensitivity, which effectively reduces body weight, improves glucose and lipid metabolism, with favorable safety profiles. EB1002 can be used for research on diseases such as obesity and type 2 diabetes.
|
|
/
|
| HY-134816 | D-Glucan |
D-Glucan is an orally effective Dectin-1 receptor immune activator with antioxidant properties (reducing TNF-α). D-Glucan activates macrophages and neutrophils to scavenge free radicals, inhibit oxidative stress and inflammatory responses, and improve insulin sensitivity. D-Glucan promotes glycolysis by enhancing the activity of the antioxidant enzyme glutathione, inhibiting gluconeogenesis and activating GK. D-Glucan can be used in the research of liver damage protection (antagonizing Acetaminophen (HY-66005) toxicity), radiation protection (synergistic with vitamin E) and diabetes (improving glucose metabolism).
|
|
/
|
| HY-P71043 | SNCG Protein, Human |
SNCG proteins help maintain the integrity of neurofilament networks and may influence axonal structure during development and adulthood. In vitro, it enhances the sensitivity of neurofilament-H to calcium-dependent proteases. SNCG Protein, Human is the recombinant human-derived SNCG protein, expressed by E. coli , with tag free.
Species: Human; Source: E. coli |
|
/
|
| HY-P7232A | Leptin Protein, Human (His) |
Leptin is a cytokine-like sugar secretory protein secreted by adipocytes that helps regulate energy balance by inhibiting food intake and increasing thermogenesis. Leptin can activate the JAK2-STAT3 and PI3K-AKT/mTOR pathways to regulate energy metabolism, prolong the QT interval via MAPK in the myocardium, and play a protective role in the gastric mucosa by inducing NO/CGRP release via the vagus nerve. Circulating CRP protein binds to leptin and blocks signal transduction, leading to obesity resistance. Leptin Protein, Human (His) is a recombinant human Leptin protein expressed by E. coli with N-6*His tag.
Species: Human; Source: E. coli |
|
/
|
| HY-P72470 | Siglec-F Protein, Mouse (HEK293, His) |
Siglec-F Protein, a putative adhesion molecule, crucially mediates sialic-acid dependent binding to cells with a preferential affinity for alpha-2,3-linked sialic acid. Notably, its sialic acid recognition site may be concealed through cis interactions with sialic acids on the same cell surface. Siglec-F Protein, Mouse (HEK293, His) is the recombinant mouse-derived Siglec-F protein, expressed by HEK293 , with C-6*His labeled tag.
Species: Mouse; Source: HEK293 |
|
/
|
| HY-P70511 | TFF1 Protein, Mouse (HEK293, His) |
TFF1 protein functions as a mucous gel stabilizer, vital for fortifying the gastrointestinal mucosa against noxious agents. It contributes to the mucous layer's integrity, providing a crucial physical barrier for the gastrointestinal tract, safeguarding it from potential harm. TFF1's stabilizing role emphasizes its significance in preserving the mucosal barrier, essential for overall gastrointestinal health and protection. TFF1 Protein, Mouse (HEK293, His) is the recombinant mouse-derived TFF1 protein, expressed by HEK293 , with C-6*His labeled tag.
Species: Mouse; Source: HEK293 |
|
/
|
| HY-P71072 | TFF1 Protein, Human (HEK293, His) |
TFF1 protein functions as a mucous gel stabilizer, vital for fortifying the gastrointestinal mucosa against noxious agents. It contributes to the mucous layer's integrity, providing a crucial physical barrier for the gastrointestinal tract, safeguarding it from potential harm. TFF1's stabilizing role emphasizes its significance in preserving the mucosal barrier, essential for overall gastrointestinal health and protection. TFF1 Protein, Human (HEK293, His) is the recombinant human-derived TFF1 protein, expressed by HEK293 , with C-6*His labeled tag.
Species: Human; Source: HEK293 |
|
/
|
| HY-P701888 | FTO Protein, Human (His) |
FTO protein is an RNA demethylase that regulates fat mass, lipogenesis, and energy homeostasis by targeting N(6)-methyladenosine in mRNA. It also demethylates m6A in U6 snRNA and m6A(m) in 5'-cap, affecting mRNA stability. FTO Protein, Human (His) is the recombinant human-derived FTO protein, expressed by E. coli , with N-6*His labeled tag.
Species: Human; Source: E. coli |
|
/
|
| HY-P71928 | TFF1 Protein, Human |
TFF1 protein functions as a mucous gel stabilizer, vital for fortifying the gastrointestinal mucosa against noxious agents. It contributes to the mucous layer's integrity, providing a crucial physical barrier for the gastrointestinal tract, safeguarding it from potential harm. TFF1's stabilizing role emphasizes its significance in preserving the mucosal barrier, essential for overall gastrointestinal health and protection. TFF1 Protein, Human is the recombinant human-derived TFF1 protein, expressed by E. coli , with tag free.
Species: Human; Source: E. coli |
|
/
|
| HY-P703091 | BRCA1 Protein, Human |
BRCA1 Protein, Human is the recombinant human-derived BRCA1, expressed by E. coli, with tag free labeled tag.
Species: Human; Source: E. coli |
|
/
|
| HY-P7233A | Leptin Protein, Rat (His) |
Leptin Protein, Rat is a hormone secreted by fat cells that helps to regulate energy balance by inhibiting feeding and increase thermogenesis.
Species: Rat; Source: E. coli |
|
/
|
| HY-P70181 | Leptin Protein, Carassius auratus (P.pastoris, His) |
Leptin protein plays a pivotal role in regulating energy balance and body weight. It binds to its receptor, LEPR, in various tissues, activating signaling pathways that regulate energy homeostasis. Leptin Protein, Carassius auratus (P.pastoris, His) is the recombinant Leptin protein, expressed by P. pastoris , with N-8*His labeled tag.
Species: Others; Source: P. pastoris |
|
/
|
| HY-P7649 | BCAS2 Protein, Human (His, T7) |
BCAS2 Protein, Human (His, T7) plays crucial roles in pre-mRNA splicing and androgen receptor transcription. BCAS2 helps repair radiation-induced DSBs efficiently in both human PCa cells and Drosophila.
Species: Human; Source: E. coli |
|
/
|
| HY-P7677 | BIN2 Protein, Human (His) |
BIN2 Protein, Human (His) is a recombinant human bridging integrator 2 (BIN2) with a His tag.
Species: Human; Source: E. coli |
|
/
|
| HY-P78359 | TFF1 Protein, Mouse (HEK293, Fc) |
TFF1 protein functions as a mucous gel stabilizer, vital for fortifying the gastrointestinal mucosa against noxious agents. It contributes to the mucous layer's integrity, providing a crucial physical barrier for the gastrointestinal tract, safeguarding it from potential harm. TFF1's stabilizing role emphasizes its significance in preserving the mucosal barrier, essential for overall gastrointestinal health and protection. TFF1 Protein, Mouse (HEK293, Fc) is the recombinant mouse-derived TFF1 protein, expressed by HEK293 , with C-hFc labeled tag.
Species: Mouse; Source: HEK293 |
|
/
|
| HY-P70960 | Siglec-5 Protein, Cynomolgus (HEK293, His) |
Siglec-5 Protein is a member of the sialic acid-binding immunoglobulin-like lectin (Siglec) family. Siglec-5 is a member of the CD33-related subset of Siglecs and is expressed on myeloid cells of the hemopoietic system. Siglec-5 inhibits the response of innate immune cells, such as monocytes and neutrophils against pathogens. Siglec-5 Protein, Cynomolgus (HEK293, His) is the recombinant cynomolgus-derived Siglec-5 protein, expressed by HEK293 , with C-6*His labeled tag.
Species: Cynomolgus; Source: HEK293 |
|
/
|
| HY-P700509 | TFF1 Protein, Human (P. pastoris, N-His) |
TFF1 protein functions as a mucous gel stabilizer, vital for fortifying the gastrointestinal mucosa against noxious agents. It contributes to the mucous layer's integrity, providing a crucial physical barrier for the gastrointestinal tract, safeguarding it from potential harm. TFF1's stabilizing role emphasizes its significance in preserving the mucosal barrier, essential for overall gastrointestinal health and protection. TFF1 Protein, Human (P. pastoris, N-His) is the recombinant human-derived TFF1 protein, expressed by P. pastoris , with N-6*His labeled tag.
Species: Human; Source: P. pastoris |
|
/
|
| HY-P703092 | BRCA2 Protein, Human (HEK293, His, Strep, Flag) |
BRCA2 Protein, Human (HEK293, His, Strep, Flag) is the recombinant human-derived BRCA2, expressed by HEK293, with Strep, His, Flag labeled tag.
Species: Human; Source: HEK293 |
|
/
|
| HY-P80573 | BRCA1 Antibody |
BRCA1 Antibody is a Rabbit-derived and non-conjugated IgG polyclonal antibody, targeting to BRCA1.
Host: Rabbit; Reactivity: Human, Rat |
|
/
|
| HY-P80489 | BRCA1 Antibody (YA819) |
BRCA1 Antibody (YA819) is a Mouse-derived and non-conjugated IgG1 monoclonal antibody, targeting to BRCA1.
Host: Mouse; Reactivity: Human, Mouse |
|
/
|
| HY-P80680 | FTO Antibody (YA424) |
FTO Antibody (YA424) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to FTO.
Host: Rabbit; Reactivity: Human |
|
/
|
| HY-P81241 | Leptin Antibody |
|
/
|
|
| HY-P86790 | BRCA2 Antibody (YA6483) |
BRCA2 Antibody (YA6483) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to BRCA2.
Host: Rabbit; Reactivity: Human |
|
/
|
| HY-P85618 | Leptin Antibody (YA5310) |
|
/
|
|
| HY-P80680A | FTO Antibody (YA424)(PBS only) |
FTO Antibody (YA424) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to FTO.
Host: Rabbit; Reactivity: Human |
|
/
|
| HY-P811317 | Shugoshin 1 Antibody |
Shugoshin 1 Antibody is a Rabbit-derived and non-conjugated IgG Polyclonal antibody, targeting to Shugoshin 1.
Host: Rabbit; Reactivity: Human, Mouse, Rat |
|
/
|
| HY-P81612 | gamma Synuclein/SNCG Antibody (YA1357) |
gamma Synuclein/SNCG Antibody (YA1357) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to gamma Synuclein/SNCG.
Host: Rabbit; Reactivity: Human, Rat |
|
/
|
| HY-P85381 | gamma Synuclein/SNCG Antibody (YA5073) |
gamma Synuclein/SNCG Antibody (YA5073) is a Rabbit-derived and non-conjugated monoclonal antibody, targeting to gamma Synuclein/SNCG.
Host: Rabbit; Reactivity: Human, Rat |
|
/
|
| HY-P85618A | Leptin Antibody (YA5310)(PBS only) |
|
/
|
|
| HY-P85936 | Estrogen Inducible Protein pS2 Antibody (YA5628) |
Estrogen Inducible Protein pS2 Antibody (YA5628) is a Mouse-derived and non-conjugated IgG1 monoclonal antibody, targeting to Estrogen Inducible Protein pS2.
Host: Mouse; Reactivity: Human |
|
/
|
| HY-P86046 | Estrogen Inducible Protein pS2 Antibody (YA5738) |
Estrogen Inducible Protein pS2 Antibody (YA5738) is a Mouse-derived and non-conjugated IgG1 monoclonal antibody, targeting to Estrogen Inducible Protein pS2.
Host: Mouse; Reactivity: Human |
|
/
|
| HY-P86253 | NABC1 Antibody (YA5945) |
NABC1 Antibody (YA5945) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to NABC1.
Host: Rabbit; Reactivity: Human |
|
/
|
| HY-P86495 | FTO Antibody (YA6187) |
FTO Antibody (YA6187) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to FTO.
Host: Rabbit; Reactivity: Human, Mouse, Rat |
|
/
|
| HY-P87282 | BRMS1 Antibody (YA6965) |
BRMS1 Antibody (YA6965) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to BRMS1.
Host: Rabbit; Reactivity: Human, Mouse, Rat |
|
/
|
| HY-P87423A | SIGLEC5/CD170 Antibody (YA7111)(PBS only) |
SIGLEC5/CD170 Antibody (YA7111) is a Mouse-derived and non-conjugated IgG2a monoclonal antibody, targeting to SIGLEC5/CD170.
Host: Mouse; Reactivity: Human |
|
/
|
| HY-K3036 | IMDM (Iscove's Modified Dulbecco's Medium) |
MCE IMDM (Iscove's Modified Dulbecco's Medium) is an enriched formulation modified from DMEM, containing high concentrations of glucose, sodium pyruvate, amino acids, vitamins, HEPES buffer, selenium, and other essential nutrients. It is designed to meet the nutritional requirements for rapid cell proliferation and high-density culture, supporting a variety of cell types, including Jurkat cells, COS-7 cells, and macrophages. The product specifications are based on the 500 mL format, and larger volume packages are provided as multiples of this standard specification. |
|
/
|
| HY-K3114 | Exosome-Specific 293 Cell Medium Supplement |
MCE Exosome-Specific 293 Cell Medium Supplement is designed as a feed supplement for use with the Exosome-Specific 293 Cell Medium (Serum-Free) (MCE Cat. No.: HY-K3113). |
|
/
|
| HY-K6101 | Human Breast Cancer Organoid Kit |
MCE Human Breast Cancer Organoid Kit contains Breast Cancer Organoid Basal Medium A, Breast Cancer Organoid Supplement B (50×), Breast Cancer Organoid Supplement C (250×). This product can be used to efficiently construct human breast cancer organoid. |
|
/
|
| HY-K6101A | Human Breast Cancer Organoid Complete Culture Medium |
MCE Human Breast Cancer Organoid Complete Culture Medium is a pre-mixed, ready-to-use formulation composed of a basal breast cancer organoid medium and multiple key culture supplements at optimized ratios. This medium requires no additional preparation and enables the efficient and stable establishment of human breast cancer organoid models. |
|
/
|
Targets/Pathways










































































































































































































































